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1. LIST OF ABBREVIATIONS 
        
∆
9
 THC                ∆9 Tetrahydrocannabinol 
2AG                     2-Arachidonoyl glycerol 
5HT                     5-Hydroxytryptamine 
ABHD6               Serine hydrolase α-β-hydrolase domain 6 
ABHD12             Serine hydrolase α-β-hydrolase domain 12 
AEA                    Anandamide 
APV                    Aminophosphonovalerate 
ASIA                   American Spinal Injury Association 
ASIC                   Acid sensing ion channel 
CaMKII               Calcium/calmodulin-dependent protein kinase II 
cAMP                  Cyclic adenosine monophosphate 
CB1R                   Cannabinoid 1 receptor 
CB2R                   Cannabinoid 2 receptor 
cDNA                   Complementary DNA 
CNS                     Central nervous system 
CNQX                  6-Cyano-7-nitroquinoxaline-2, 3-dione 
CPG                     Central pattern generator 
CSF                      Cerebrospinal fluid 
DR                        Dorsal root 
EAE                      Experimental autoimmune encephalomyelitis 
ECB                      Endocannabinoids 
FAAH                   Fatty acid amide hydrolase 
FL                         Fictive locomotion 
GABA                  Gamma-aminobutyric acid 
GPCR                   G-protein coupled receptor 
KA                        Kainate 
LTD                      Long term synaptic depression 
LTP                       Long term synaptic potentiation 
MAGL                  Monacylglycerol lipase 
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MAP                    Mitogen-activated protein  
MCAO                 Middle cerebral artery occlusion 
MS                       Multiple sclerosis 
mGluR1               Metabotropic glutamate receptor-1 
MPG                    Motor pattern generator  
mRNA                 Messenger RNA 
NADA                  N-arachidonoyldopamine  
NAT                     N-acyltransferase 
NMDA                 N-methyl D-aspartate 
NO                       Nitric oxide 
NTSCI                  Non-traumatic spinal cord injury 
NAc                      Nucleus accumbens 
PARP1                  Poly ADP-ribose polymerase enzyme 1  
PcTx1                   Psalmotoxin 
PD                        Parkinson's disease 
PE                        Phosphatidylethanolamine 
PFC                     Prefrontal cortex  
PLC                     Phospholipase C 
PLD                     Phopholipase D  
PM                       Pathological medium 
PKA                     Protein kinase A 
PKD2L1               Polycystin 2 like 1, transient receptor potential cation channel 
PNS                     Peripheral nervous system 
ROI                     Region of interest 
SAMHSA            Substance abuse and mental health services administration  
SCI                      Spinal cord injury 
SEM                    Standard error mean 
SN                       Sensory neurons 
TRPV1                Transient receptor potential cation channel subfamily V member 1 
TSCI                    Traumatic spinal cord injury 
VR                       Ventral root 
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2. ABSTRACT 
 
Background: Mammalian spinal cord can generate well-coordinated locomotor activity 
called fictive locomotion in the absence of any higher brain center input or of rhythmic 
sensory feedback. This activity clearly provides evidence for the central pattern generator 
(CPG) that produces the locomotor rhythm. Such CPG consists of glutamatergic 
excitatory and glycinergic and GABAergic inhibitory interneuronal connections that 
finally excite or inhibit the motoneuronal pools. Many factors including fast (ion 
channels) and slow (modulatory G-protein coupled receptors; GPCRs) processes control 
these neuronal pools to act rhythmically. These factors are perturbed following spinal 
cord injury (SCI) in the early and late phases. The present study addresses the role of a 
few modulatory processes, namely acid sensing ion channels (ASICs) and cannabinoid 1 
receptors (CB1Rs) at both initial and the late phases of injury.  
Objectives: Recent evidence has shown that the deletion of ASICs slows down the 
progression of disease in ischemic conditions, whereas the same protocol increases 
seizure severity. CB1R activation or deletion also results in neuroprotective or toxic 
mechanisms. In order to understand the importance of ASICs and CB1Rs in the spinal 
locomotor circuits, it is crucial to analyze them in physiological and pathological 
conditions. To investigate this issue, both organotypic slice culture and an in vitro rat 
spinal cord model were used. With the latter, fictive locomotion can be recorded from the 
ventral roots of the lumbar region for a time window of 24 h. Network parameters like 
synaptic transmission, fictive locomotion and disinhibited bursting provide information to 
explain the physiological modifications and pathological severity after excitotoxicity 
caused by transient kainate (KA; glutamate analog) application. Drugs that modulate 
CB1Rs and ASICs may supply evidence for the role of these processes in fictive 
locomotion.  
Results and conclusion: Our results show that the CB1R activation or block for 24 h 
diminished the locomotor rhythm. In particular, CB1R pharmacological block completely 
depressed both dorsal root (DR) and chemically evoked fictive locomotion. This 
depression was amplified following KA treatment. Furthermore, a limited 
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neuroprotection was observed after CB1R agonists (anandamide; AEA or 2-arachidanoyl 
glycerol; 2AG) and an endogenous cannabinoid uptake inhibitor. These results allow us 
to propose the innate activity of CB1R (that is well preserved) to be important after KA 
mediated excitotoxicity, while any neuroprotective role might come in later phases after 
injury.  
A low concentration of KA that can induce a borderline injury elicited rapid glutamate 
release combined with proton discharge (acidification) in the organotypic SCI model. In 
response to this challenge, the ASIC subtypes (1a, 1b, 2a and 3) mRNA levels were 
found to be elevated after 24 h. Both neuronal numbers and network activity were highly 
depressed after application of ASIC pharmacological blockers that intensified the 
consequences of KA treatment. These results indicate that moderate acidification might 
be beneficial for the recovery (or limitation) of KA mediated excitotoxicity. Hence, this 
study demonstrates that both ASICs and CB1Rs activity are important in the early phase 
of experimental SCI in vitro. Their pharmacological modulation can outline future 
strategies for neuroprotection.   
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3. MAMMALIAN SPINAL LOCOMOTOR NETWORK  
 
Locomotion is an inherent and coordinated motor activity that is the result of coupling 
between the neural dynamics (sensory feedback and rhythm control) and the body 
dynamics (musculoskeletal function). It is neither a simple reflex activity which is 
stereotypically driven by sensory stimulation in a repeated manner, nor a skilled activity, 
like playing any sport, that requires learning and complex coordination of muscles in a 
non-repeated fashion (Grillner and Wallen, 1985; Marder and Bucher, 2001; McLean and 
Dougherty, 2015). 
Locomotion is a fundamental skill that includes gait transition, control of speed and 
direction by the nervous and musculoskeletal systems. Animal locomotion is 
characterized by rhythmic activity that includes various forms such as swimming, 
crawling, walking, flight, hopping, brachiation and burrowing (Ijspeert, 2002). Despite 
the diversity in types, the general organization of vertebrate locomotor circuit is well 
conserved. The basic rhythmic activity is controlled by the interaction of three 
components, sometimes called the motor pattern generator (MPG): (1) spinal central 
pattern generators (CPGs), (2) sensory feedback and (3) descending supraspinal control 
(Frigon, 2012; McLean and Dougherty, 2015).  
Simplest movements are involuntary reflexes (knee jerk, pupil dilation), that are 
stereotyped and graded responses to sensory input, and have no threshold except that the 
stimulus must be large enough to activate the relevant sensory input pathway. Fixed 
action patterns are also involuntary and stereotyped, but they typically have a stimulus 
threshold that must be reached before the action could be triggered, and are less graded 
and more complex than reflexes. Rhythmic motor patterns like walking, scratching, or 
breathing are stereotyped and complex, but these rhythms are subjected to continuous 
voluntary control by higher and lower locomotor centers. Directed movements like 
reaching are voluntary and complex, but generally they are neither stereotyped nor 
repetitive. Rhythmic motor patterns which are complex (unlike reflexes) yet stereotyped 
(unlike directed movements) and, by definition, repetitive (unlike fixed action patterns) 
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comprise a large part of basic animal behavior. Due to its behavioral importance and 
experimental advantage, rhythmic motor pattern generation has been studied extensively 
in a wide range of animals (Hooper, 2001).  
3.1. Anatomical view – a general outline 
Spinal cord is a long and relatively thin neural structure. It is enclosed in the vertebral 
column (a protective bone structure). It is comprised of the white (ascending and 
descending myelinated fibers) and the butterfly-shaped gray matter (unmyelinated cells 
that are involved in reflex and network activity) tissues. In the mid, there is a central 
canal that contains cerebrospinal fluid (CSF) circulating to and from the ventricles in 
brain. In the periphery, three layers (dura, arachnoid, and pia) surround the entire cord for 
protection (Kandel et al., 2000). 
In humans, the length of spinal cord varies between 43 and 45 cm comprising 31 different 
segments (differing between species) that are grouped as 8 cervical, 12 thoracic, 5 
lumbar, 5 sacral, and 1 coccygeal segments (Netter, 2006). In rats there are 8 cervical, 13 
thoracic, 6 lumbar, 4 sacral, and 3 coccygeal segments (Molander et al., 1984; Molander 
et al., 1989). From every segment a pair (right and left) of spinal nerves are projected. 
And it is supplied by a single ventral spinal artery and two dorsal spinal arteries. Spinal 
nerves comprise two different types: 1. sensory nerve roots (a group of afferent 6–8 
rootlets), and 2. motor roots (a group of efferent 6–8 rootlets; Netter, 2006; Nógrádi and 
Vrbová, 2006). 
As mentioned before, each spinal cord segment sends out a pair of nerves that innervates 
different skin areas and sets of muscles. In brief, cervical segments provide innervations 
to and from muscles involved in respiration, head, neck, and arm movements. Thoracic 
segments provide motor control of the paws, chest, back, and abdominal muscles whereas 
the lumbar and sacral segments are generally associated with the control of muscles 
involved in locomotion, micturition, bowel, and reproductive functions (Guertin, 2013). 
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3.1.1. Afferent and efferent pathways 
Afferent pathways carry information from sensory receptors to the brain regions. The 
primary afferent neurons synapse on projection neurons (located in spinal gray matter) 
which join the ascending tracts to the brain. The function of a particular pathway is 
determined by the type of primary afferent neurons and the type of projection neurons 
that synapse in the brain. In general, these pathways can be categorized into three broad 
functional types: 1. Conscious discrimination/localization (e.g. pain, temperature, 
discriminative touch) requires a specific ascending spinal pathway to the contralateral 
thalamus which, in turn, sends an axonal projection to the cerebral cortex, 2. Affective 
related (emotional & alerting behavior) information involves ascending spinal pathways 
directed to the brainstem, 3. Subconscious sensory feedback for posture/movement 
control involves ascending spinal pathways principally to the cerebellum or brainstem 
nuclei that project to the cerebellum (Drake et al., 2009).  
  
Fig 1: Spinal afferent and efferent tracts (modified from Fletcher, 2006) 
Brain axons travel in descending tracts of the spinal white matter. They arise from 
various locations in the brain and synapse primarily on interneurons. By synapsing on 
interneurons, descending tracts regulate spinal reflexes, excitability of efferent neurons 
(for posture and movement) and spinal projection neurons (Knierim, 1999). In certain 
conditions, they also affect axon terminals of primary afferent neurons, blocking release 
of neurotransmitter (presynaptic inhibition; Johnson, 2006). 
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3.1.2. Cytoarchitecture of rat spinal cord  
The structural organization of rat spinal cord is similar to the feline one. There is no 
much difference between adult and newborn rats except less distinct borders of laminar 
regions. The distribution of cells and fibers within the gray matter of the spinal cord 
exhibits a pattern of lamination. The cellular pattern of each lamina is composed of 
various sizes or shapes of neurons classified into 10 layers by Rexed. Laminae I to IV is 
in the dorsal horn and are concerned with exteroceptive, whereas laminae V and VI are 
concerned primarily with proprioceptive sensations and act as a relay between the 
periphery to the midbrain and the cerebellum. Lamina VII is an intermediate zone and 
acts as a relay between muscle spindles to midbrain and cerebellum which innervate 
neurons in autonomic ganglia and laminae VIII-IX comprise the ventral horn and contain 
mainly motor neurons. The axons of these neurons innervate mainly skeletal muscle. 
Lamina X surrounds the central canal and contains preganglionic neurons and neuroglia 
(Dafny, 1999). 
 
Fig 2: Cross sectional view of lumbar 5 region (modified from Ostroumov, 2006) 
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3.2. Functional organization  
As mentioned before, white matter tracts essentially serve as 'relay region' for signals that 
carry descending motor control and ascending sensory-related information between the 
brain and spinal cord. The gray matter, however is an 'action execution' region, where 
neurons for local reflex arcs and complex circuits are present (Guertin and Steuer, 2009). 
3.2.1. Spinal reflex   
Classical reflexes involve simple reflex arcs or pathways. A simple reflex typically leads 
to a rapid, predictable, repeatable, stereotyped, and involuntary motor reaction in 
response to the given stimulus. Mostly, reflexes are mediated within one or two spinal 
segments, by relatively minimal neural pathways (interneurons and motoneurons) that 
generally involve either one (monosynaptic), two (disynaptic), or more (polysynaptic) 
synapses according to the stimulus threshold. These reflexes are either autonomic (related 
with internal organs) or somatic (related with skeletal muscle responses) origin. 
 
Fig 3: A simple illustration of reflex activity (modified from 
http://www.easynotecards.com/notecard_set/21865) 
Monosynaptic reflex arc (Ia) is one of the somatic reflex pathways. This is a simple and 
fast reflex mediated by primary afferent (Ia) inputs from muscle spindles typically 
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activated by muscle stretch (for example: patellar reflex). The Ia afferent input enters the 
dorsal spinal cord and establishes monosynaptic connections with homonymous alpha-
motoneurons in the ventral horn area. A polysynaptic reflex has more than one synapse 
and one or more interneurons in its reflex arc. All reflexes except stretch reflex are 
polysynaptic (for example: flexor and plantar reflex; Lloyd and McIntyre, 1955; Perl, 
1962).    
3.2.2. Central pattern generator     
Extensive work by Sherrington and Graham Brown initiated the idea of potential 
existence of a spinal neuronal network for locomotion. Then many studies have emerged 
proposing various model of network operation. Table 1 lists the major models of CPG 
(data extracted from Guertin, 2009). 
Table 1: Different conceptual models of CPG  
Model Highlights 
Half center model 
(Brown, 1911, 1914) 
                                         
Rhythm is generated by reciprocal activation and inhibition of 
motoneurons. 
Miller and Scott 
model (Miller and 
Scott, 1977) 
Renshaw cells rather than fatigue are responsible for the alternation 
between flexion and extension. 
Ring model (Székely 
et al., 1969; 
Gurfinkel and Shik, 
1973) 
CPG contains a closed chain of at least five groups of neurons (2 pure 
extensors, 2 pure flexors and 1 bifunctional) that project to the 
motoneurons either directly or through specific interneurons to produce 
rhythms. 
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Flexor burst 
generator model 
(Pearson and 
Duysens, 1976) 
It is a asymmetrical model proposing that the rhythmic excitatory drive is 
from the flexor burst generator to populations of flexor motoneurons. 
Then the burst generator would inhibit, via an inhibitory interneuron, 
resulting in the extensor movement.  
Unit burst generator 
model (Grillner and 
Zangger, 1974; 
1979) 
                                         
A symmetrically organized generator in the spinal cord that can produce 
basic pattern of motor commands in the absence of any peripheral input. 
Two-level (multi 
level) half center 
model (Perret and 
Cabelguen, 1980; 
McCrea and Rybak, 
2008) 
                     
Two half-centers (extensor and flexor ones) would send motor commands 
to bifunctional motoneurons. A rhythm generator and a pattern generator 
are functionally separated since they are two distinct entities that can be 
independently and spontaneously changing. Later the model has evolved 
by adding more such half centers throughout the spinal segments.  
Initially there were two hypotheses for the generation of rhythmic and alternating 
movements: 1. The reflex chain model which explains that sensory neurons excite 
interneurons that activate motor neurons to the muscle, 2. The CPG model which 
explains that a central circuit generates rhythmic patterns of activity in the motor neurons 
to antagonist muscles. Later, the CPG model was proved by different groups showing 
that completely isolated and deafferented spinal cords could generate patterns that are 
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very similar to those recorded during intact locomotion (Grillner and Zangger, 1974; 
Wilson, 1966).  
 
Fig 4: Hypotheses of rhythmic movements. (a) Reflex model (b) CPG model (Marder and 
Bucher, 2001) 
The cellular organization of neural circuits that results in flexor–extensor and left–right 
coordination remains incompletely understood even at the present time (Kiehn 2016). 
Detailed studies using neuronal pool specific deletions and computational modeling of 
circuits indicate the plausible wiring diagram of the neurons including interneurons that 
contribute to rhythm generation (Grillner 2006; McCrea and Rybak, 2008). Fig 5 shows a 
currently-popular model of integrated pattern formation that is compatible with 
experimental data and computational simulations (Rybak et al., 2015; Zhang et al., 
2014a).  
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Fig 5: Schematic representation of bilaterally interacting rhythm generators in the spinal cord 
illustrating the role of interneurons (Rybak et al., 2015). 
Based on these animal CPG models, some studies have developed a simple mathematical 
model to prototype that can control human motor system and generates periodic motions 
in a musculoskeletal arm based on the CPG network (Nandi et al., 2008; Razavian et al., 
2015). This computational model generates a motion similar to real human based on a 
simple descending command (i.e. the desired frequency of motion; Razavian et al., 2015). 
This provides the evidence that using animal locomotion inputs and electromyography 
data from humans, human motion prosthetics can be developed.  
 
Fig 6: The layered structure of the CPG controller that can generate a motion similar to human 
limb movement (Razavian et al., 2015) 
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4. SPINAL CORD INJURY 
 
Acute spinal cord injury (SCI) is an insult that results in temporary or permanent sensory, 
motor, or autonomic function disturbances. Traumatic SCI can be divided into 
penetrative (damage to the spinal cord by any sharp object or even the vertebra) and non-
penetrative injuries (contusion or compression developed by any kind of accident). SCI 
can be complete or incomplete. With a complete SCI, the cord can't send signals below or 
above the level of the injury which leads to paralysis. With an incomplete injury, there is 
some movement and sensation below the injury (Kalsi-Ryan et al., 2014). 
Upon various radiological evaluation and diagnostic tests (for muscle contraction and 
sensation), the extent of injury is graded by the American Spinal Injury Association 
(ASIA) Impairment Scale, using the following categories (ASIA, 2000; Ditunno et al., 
1994): 
1. A (Complete) - No sensory or motor function is preserved in below the injury 
(including sacral segments S4-S5; Waters et al., 1991) 
2. B (Motor complete and sensory incomplete) - Sensory, but not motor, function is 
partially preserved below the neurologic level and extends through sacral segments S4-S5 
3. C (Motor and sensory incomplete) - Motor and sensory functions are partially  
preserved below the neurologic level, and most key muscles below the neurologic level 
have a muscle grade of less than 3 
4. D (Motor and sensory incomplete) - Motor and sensory functions are partially  
preserved below the neurologic level, and most key muscles below the neurologic level 
have a muscle grade that is greater than or equal to 3 
5. E (Normal) - Sensory and motor functions are normal 
Respiratory dysfunction following SCI at various level of spinal segments can result in 
loss of ventilatory muscle function, pneumothorax, hemothorax, pulmonary contusion or 
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decreased central ventilatory drive. A direct relationship exists between the level of 
injury and the degree of respiratory dysfunction (Zimmer et al., 2007): 
1. Lesions at C1 or C2 - Vital capacity is only 5-10% of normal 
2. Lesions at C3 through C6 - Vital capacity is 20% of normal, and cough is weak and 
ineffective 
3. High thoracic cord injuries (T2 through T4) - Vital capacity is 30-50% of normal, and 
cough is weak 
4. Lower cord injuries - Respiratory function improves 
5. Injuries at T11 - Respiratory dysfunction is minimal; vital capacity is essentially 
normal, and cough is strong. 
There are no established ways to reverse damage to the spinal cord. But there are new 
treatments, including prostheses and medications that may promote nerve cell 
regeneration or improve the function that remains after a SCI. First, SCI treatment 
focuses on preventing any further damage to the spinal cord. This includes emergency 
actions such as immobilization of the spine (to reduce any further trauma), maintenance 
of breathing ability, shock prevention and avoidance of possible complications, such as 
stool or urine retention, respiratory or cardiovascular distress and formation of deep vein 
blood clots in the extremities. Intravenous administration of methylprednisolone is one 
treatment option for an acute SCI. If methylprednisolone is given within eight hours of 
injury, some people experience mild improvement. Often surgery is necessary to remove 
fragments of bones, foreign objects, herniated disks or fractured vertebrae to avoid any 
further deformity. Once the initial injury or disease stabilizes, secondary problems such 
as deconditioning, muscle contractures, pressure ulcers, bowel and bladder issues, 
respiratory infections and blood clots may arise. Once the initial injury and the secondary 
phase is stabilized by surgery and medications, rehabilitation is required for recovery. 
Drugs can be administered to control pain, muscle spasticity, and bladder and bowel 
functions. There are many pilot studies for recovering the locomotor (and standing) 
function back such as stem cell therapy, computer devices (for someone with limited 
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hand function), electronic aids to daily living, electrical stimulation devices, robotic gait 
training (for retraining walking ability after SCI) (Evaniew et al., 2015; Zimmer et al., 
2007). However, none of these treatments and recovery processes completely restores the 
function of spinal cord. 
4.1. Epidemiology 
SCI occurs with an annual incidence of 12.1–57.8 cases per million (van den Berg et al., 
2010a) with lower survival of non-traumatic SCI compared with traumatic SCI (van den 
Berg et al., 2010b). In most developing countries, the majority of patients are young 
adults (20–40 years of age), thereby causing a high burden to these countries (Ackery et 
al., 2004). The rates of SCIs vary across countries, regions, and cities. SCI can occur 
accidentally (traumatic) or due to any disease (non traumatic). Studies show a high male-
to-female ratio of traumatic SCI (TSCI) and peak incidence is seen in younger than 30 
years old. It has been reported that 40 cases per million in United States suffer from TSCI 
(0.4% of the total population), in Germany it is 66 cases per million population, in France 
12.7 cases per million population and in Canada 46 cases per million population (Guertin, 
2013). Majority (40-50%) of SCI cases is due to motor vehicle accidents and then to 
sports related injuries (24%), violence (7-23%) followed by falls in the elderly population 
(12-20%; Norenberg et al., 2004; Sekhon and Fehlings, 2001). Non-traumatic SCI 
(NTSCI) is mainly due to cancer, infection, vascular problems and nerological diseases. 
Higher risks of TSCI are reported during adolescence and older adults. NTSCI again can 
be complete or incomplete. In Canada, no complete SCI was seen in NTSCI patients, 
whereas in India 36% of NTSCI were complete (Agarwal et al., 2007)  
4.2. Pathophysiology 
Shortly after SCI many clinical changes occur including airway block, hemorrhage, 
neurogenic shock, ileus etc. Despite injury level, spinal or neurogenic shock generally 
occurs immediately after trauma. The injury can be divided into primary lesion and 
secondary lesion. The primary lesion is further classified into concussion (transitory 
spinal cord dysfunction in the absence of structural damage), contusion (like 
craniocerebral injuries, the damage is due to any vertebral disc displacement), laceration 
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(injury due to vertebral facture) and compression (is again like a contusion but the 
continuity of the columns are immediately restored completely without any intervention; 
Bailey 1971; Jellinger, 1976). This primary injury can cause numerous changes in 
morphology and physiology of the cord. 
 
Fig 7: Progression of spinal cord injury after initial trauma 
After the initial injury the presence of any pericapillary extravasation of erythrocytes and 
serum constituents are clinically observed (Kakulas, 1984). At cellular level, the initial 
injury can cause spinal cord deformation, laceration, crush and compression shortly after 
any trauma. And this leads to immediate cell death, axonal disruption and retraction, 
vascular and metabolic changes, which leads to secondary injury processes that can occur 
hours and days after injury. They are mainly associated with glutamate excitotoxicity, 
higher release of inflammatory mediators, free radical generation which results in local 
hypoxic condition and finally leads to scar formation (Park et al., 2004).   
4.3. Kainate-induced neonatal rat SCI model 
Because there is no curative treatment for SCI, establishing an ideal animal model is 
important to identify injury mechanisms and develop therapies for individuals suffering 
from spinal injuries. Some animal models are used for investigating pathophysiological 
mechanisms and others for investigating the mechanisms underlying tissue engineering 
and spinal cord regeneration (treatment). Over the past three decades, there has been 
substantial research for establishing animal models, and a large number of therapeutic 
strategies have been developed (Kwon et al., 2011; Tetzlaff et al., 2011).  
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The pathology of human SCI is not greatly different from that of experimental animal 
models, except for some specific differences. Allen (1911) first created SCI models using 
a weight drop technique and this was later considered as a standard experimental spinal 
cord contusion injury model (Koozekanani et al., 1976). Experimental animal models for 
SCI include the spinal cord ischemia-reperfusion injury model (Cheriyan et al., 2014, 
Lafci et al., 2013), spinal cord traumatic injury model (Koozekanani et al., 1976), 
photochemical-induced SCI model (Piao et al., 2009), spinal cord transection model (Min 
et al., 2011), and bidirectional distraction SCI model (Seifert et al., 2011; Zhang et al., 
2014b).  
There are many limitations in experimental animal models including complex pathology 
(surrounding the injury site), difficulty in studying specific injury processes, restriction in 
identifying affected cells without anesthesia (which can cause interference in results; 
Bajrektarevic and Nistri, 2016; Kaur et al., 2016; Shabbir et al., 2015a). Hence, to 
provide a more complete understanding of the mechanisms (biochemical or physiological 
parameters) of SCI, numerous in vitro systems may be used. These comprise primary 
neuronal cultures for studying cellular changes (Kehl et al., 1997), co-cultures of neurons 
and glia to study scar formation (Skaper and Facci, 2012), organotypic and isolated spinal 
cord preparations to study the entire network changes after injury (Cifra et al., 2012; 
Taccola et al., 2008).  
Isolated spinal preparations from rodents are widely used to study the integrated sensory 
and motor pathways since their functional circuitry remains undamaged (Smith and 
Feldman, 1987; Cazalets et al., 1995). The neonatal rat in vitro preparation (which is used 
in our entire study) contains all the network components for rhythmic locomotion which 
can be recorded through ventral roots (VRs) (Cazalets et al., 1995). Excitatory chemicals 
can be directly applied to the preparation to evoke the CPG and the output which is 
similar to the real locomotion (fictive locomotion) can be recorded from VRs in both 
flexor and extensor pools of lumbar region (L2 and L5 respectively). Electrical 
stimulation can be given to the dorsal root (DR) and either reflex or rhythm can be 
recorded from VRs. This provides a clear ground to study entire locomotor network 
including sensory pathways. A fictive locomotion through DR stimuli can only be evoked 
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if the dorsal sensory neurons, interneurons and the motoneurons are integrated well. 
These phenomena provide a better understanding of entire system. To study any injury 
process, a wide time window is required and this is feasible with the neonatal (P0-P2 rats) 
preparations. Their survival up to 24 h in physiological solution is a greater advantage. In 
our lab we use kainic acid (KA, glutamate analog) for 1 h to evoke the primary injury and 
the preparation is kept for 24 h to study the secondary injury events. Despite the KA 
washout, the secondary damage progresses and peaks within the first few hours 
(Kuzhandaivel et al., 2011). During this time frame, the present model enables repeated 
testing of locomotor network activity and of pharmacological treatments on injury.  
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5. ENDOCANNABINOID SYSTEM   
For at least 8000 years, humans have used Cannabis sativa for recreational and 
therapeutic purposes. The prevalence estimates of cannabis use are in the range of 10-
30% of the adult population. In 2010, the Substance Abuse and Mental Health Services 
Administration (SAMHSA) estimated a lifetime prevalence of cannabis use of 52.1%. 
Marijuana and many of its constituents influence the CNS in a complex and dose-
dependent manner (Zuardi, 2006). The chief psychoactive component, ∆9-
tetrahydrocannabinol (∆9-THC) was successfully isolated and chemically characterized 
by Mechoulam and Gaoni in 1965 (Mechoulam and Gaoni, 1965 a, b). The 
endocannabinoid (ECB) system includes endogenous ligands, their receptors and the 
enzymes that are responsible for their synthesis and degradation (Pertwee, 2009). The 
entire ECB system regulates pain, memory, learning and synaptic plasticity, appetite, 
immune function, lipid metabolism and many other physiological mechanisms (Hohmann 
et al., 1995; Di Marzo et al., 1998; Kishimoto and Kano, 2006).  
5.1. Cannabinoid receptors  
Howlett (1984) have first shown the existence of THC-sensitive CB receptors that 
decreased cAMP production in neuroblastoma cell cultures mediated by a Gi/o-coupled 
pathway and it was then characterized by Devane et al (1988) from brain using 
immunohistochemical and radioligand binding methods (Howlett, 1985; Howlett and 
Fleming, 1984; Howlett et al., 1986; Devane et al., 1988). 
5.1.1. Receptor types and distribution 
The dominant types of cannabinoid receptors are CB1R, CB2R and non CB1/CB2R 
(GPR18, GPR55, GPR119 and TRPV1) (Devane et al., 1988; Howlett, 1995; Howlett et 
al., 2002a, b; Pertwee 2007a, b, 2008; Pertwee et al., 2007; Ross, 2003). Most of the 
endogenous cannabinoid signals are mediated through guanine-nucleotide binding 
proteins-coupled heptahelical CB1 and CB2 receptors (receptor nomenclature follows 
Alexander et al., 2013; Console-Bram et al., 2012).  
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CB1Rs are widely distributed in the nervous system and in peripheral tissues. A dense 
staining of CB1R is seen in mammalian hippocampus, cerebral cortex, brainstem, 
cerebellum and in the areas that are involved in pain modulation, including the 
periaqueductal gray and the dorsal horn of the spinal cord (Svìzenskà et al., 2008). In 
spinal cord, CB1Rs are densely located in the regions that processes pain signals. 
Superficial dorsal horn and the dorsolateral funiculus are highly stained structures for 
CB1R (Farquhar-Smith et al., 2000; Herkenham et al., 1991; Sañudo-Peña et al., 1999). 
Immunoreactivity of CB1R in dorsal horn is predominantly found in interneurons, 
particularly in laminae I, II, and inner II/III transition, and in lamina X (Farquhar-Smith 
et al., 2000; Tsou et al., 1998). The majority of CB1Rs are found on axons of larger 
diameter neurons with myelinated A fibres (Bridges et al., 2003). The peripheral system 
that expresses CB1Rs includes skeletal muscle, liver, pancreas and adipose tissue that are 
involved in energy and cellular metabolism (Herkenham, 1990; Kaur et al., 2016; 
Piomelli, 2005). CB2Rs are widely distributed in peripheral tissues, and in immune 
tissues. Expression of CB2R gene transcripts are found in the spleen, tonsils, thymus, 
mast cells and blood cells (Atwood and Mackie K, 2010; Cabral and Griffin-Thomas, 
2009). Their expression is also found in microglia, retina and cerebellar granule cells 
(Svíženská et al., 2008). 
The intensity of CBRs decreases in neurodegenerative diseases, such as Parkinson's and 
Huntington's disease (Svìzenskà et al., 2008). Callen et al have shown that even at lower 
expression levels, CB1R and CB2R forms heteromers in the following brain regions: 
pineal gland, nucleus accumbens and globus pallidus. CB1R-CB2R heteromers exhibited 
bidirectional cross-antagonism and agonist co-activation (Callen et al., 2012).     
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Fig 8: Expression CB1R and CB2Rs and its function in CNS and in peripheral organs. 
5.1.2. Structure of cannabinoid receptors 
The CB1R gene is polymorphic, signifying its various role in the biological system. 
Using an oligonucleotide probe derived from a member of GPCRs, cDNA of CB1R was 
first isolated from a rat cerebral cortex library (Matsuda et al., 1990). The human CB1R 
gene locus is on chromosome 6, position: 6q14–q15 (Caenazzo et al., 1991; Hoehe et al., 
1991). The human CB2R gene is located in chromosome 1 p36 (Onaivi et al., 2006). 
Both CB1 and CB2 receptors share 44% amino acid sequence identity throughout the 
total protein (Munro et al., 1993). 
 
Fig 9: Structure of CB1R and CB2R (Ramos et al., 2011) 
25 
 
The CB1R gene is intronless and its structure is similar in rodents and human. The CB2R 
gene is intronless only in its coding region (Onaivi et al., 2002). The CB1R gene is highly 
conserved across humans and rodents, whereas the CB2R gene is more divergent across 
different species (Griffin et al., 2000). Like other GPCRs, cannabinoid receptors contain 
C-terminal intracellular domain coupled to G protein subunits, an N-terminal 
extracellular domain that possesses glycosylation site and seven hydrophobic stretches of 
20–25 amino acids that form transmembrane α helices, connected by alternating 
extracellular and intracellular loops. CB1 and CB2 receptor three-dimensional models 
have been constructed and compared between human, rat and mouse (Bramblett et al., 
1995; Ramos et al., 2011). Unlike most GPCRs where the cysteines occur in the second 
and third extracellular domains, both CB1R and CB2Rs have no cysteines within the 
second extracellular domain, but the third contains two or more cysteines residues. 
Cysteines stabilize the tertiary structure of the receptor by forming intra-molecular 
disulfide bridges. One other variation from most other GPCRs is that the CB1R and 
CB2Rs lack a highly conserved proline residue in fifth hydrophobic domain. The clusters 
for cAMP-dependent protein kinase and Ca2+-calmodulin-dependent protein kinase sites 
are conserved across the human, rat, and mouse receptor proteins. There is a single 
potential protein kinase C site which is also conserved in CB1Rs (Matsuda, 1997). Hua et 
al. have recently shown the crystal structure of human CB1R in complex with a tight 
binding antagonist AM6538 and also the same group have provided information about 
binding modes of cannabinoid agonists using molecular docking experiments (Hua et al., 
2016) 
5.2. Endogenous and synthetic ligands 
Cannabinoids are diverse chemical compounds that acts on CBRs in brains and in other 
peripheral tissues. These compounds include, the endocannabinoids (endogenous ligands 
from body), the phytocannabinoids (like ∆9-THC and cannabidiol from plant sources), 
and synthetic cannabinoids (cannabimimetics including the aminoalkylindoles, 1,5-
diarylpyrazoles, quinolines, and arylsulfonamides, as well as eicosanoids related to 
endocannabinoids). At least five different endogenous compounds in human brain are 
known to have affinity towards cannabinoid receptors, namely, N-
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arachidonoylethanolamide (anandamide; AEA), 2-arachidonoylglycerol (2-AG), noladin 
ether, virodhamine and N-arachidonoyldopamine (NADA).   
AEA was the first endogenous cannabinoid receptor agonist to be identified and well 
documented (Devane et al., 1992). The second major ECB, 2-AG was primarily isolated 
from canine intestine (Mechoulam et al., 1995) and rat brain (Sugiura et al., 1995). This 
lipid messenger has been reported in inflammatory responses, immune function, cell 
proliferation, embryo development and long-term potentiation in the hippocampus 
(Sugiura and Waku, 2000). 2-AG is present in the brain at higher levels than AEA. 
Therefore, 2-AG is considered the dominant endogenous cannabinoid in the brain 
(Childers and Breivogel, 1998). Another endocannabinoid, Noladin ether was in the 
thalamus and hippocampus and at much lower amounts in the spinal cord (Fezza et al., 
2002). AEA and 2-AG were found in areas of the brain with high densities of CBRs 
(Devane et al., 1992; Egertova and Elphick, 2000; Piomelli, 2005; Pertwee, 2009). AEA 
binds to both CB1 and CB2 receptors (Glass and Northup, 1999), but its affinity for the 
CB2 receptor is approximately four-fold less than for CB1 receptors (Felder et al., 1995). 
2-AG exhibits a lower affinity for CB1 than anandamide and it is also a natural ligand for 
CB2R (Suigiura and Waku, 2000).  
The first selective CB1 receptor antagonist synthesized was, the diarylpyrazole 
SR141716A (Rimonabant; Rinaldi-Carmona et al., 1994). In vitro and in vivo studies 
have shown the reversal effects of rimonabant on actions induced by cannabinoids at 
CB1Rs (Howlett et al., 2002a; Pertwee, 1997). Although rimonabant is CB1R-selective, 
it is not CB1R-specific as it also binds with CB2Rs but with lower affinity (Hirst et al., 
1996). Other studied CB1R-selective antagonists are LY320135, AM251 and AM281 
that also produce inverse cannabimimetic effects (Pertwee, 2006).  
5.2.1. Structure of ligands 
Cannabinoid term is used  for  the  typical  C-21 compounds  present in Cannabis  saliva 
and  includes  their  analogs  and  transformation  products and they often possess chiral 
centers.  Two different  numbering  systems depending upon the structure namely, 
dibenzopyran  and  monoterpenoid,  are  generally used  for  identifying  the  cannabinoid 
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related compounds. The  most  important  pharmacologically  active  member  of  the 
phytocannabinoids family is (-) delta-9-THC,6a,10a-trans-tetrahydrocannabinol (THC; 
Gaoni and Mechoulam, 1964a). The three-dimensional shape of AEA strongly resembles 
THC. AEA has a long hydrocarbon tail which makes it soluble in fat and allows it to 
easily slip across the blood-brain barrier (Pertwee, 2005). 2-AG is a unique molecular 
species of monoacylglycerol having arachidonic acid at the second position of the 
glycerol backbone (Sugiura et al., 2002) 
 
   
Fig 10: Chemical structures of cannabinoid receptor agonists (Freund et al., 2003; Rodríguez et 
al., 2005) 
The first synthesized, CB1R inverse agonist rimonabant was in the market for anti-
obesity treatment. The structure of this diarylpyrazole derivative is shown in the Fig 9. 
AM251 is a close analogue of rimonabant, only differing by replacing an I-atom for a Cl-
atom on the 5-phenyl ring (Gatley et al., 1996; Lan et al., 1999; Rinaldi-Carmona et al., 
1994 and 1995).  
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Fig 11: Chemical structures of cannabinoid receptor antagonists / inverses agonists (Pertwee, 
2005) 
5.3. Endogenous cannabinoid synthesis and degradation 
Synthesis: 
Both the eicosanoids, AEA and 2-AG are synthesized 'on demand' from the hydrolysis of 
a pre-formed membrane phospholipid precursor through a common two-step pathway, 
termed ‘the transacylation-phosphodiesterase pathway’. They are produced following the 
enhancement of intracellular Ca2+ concentrations, either by cell depolarization, or by 
mobilization of intracellular Ca2+ stores subsequent to stimulation of Gq/11 protein-
coupled receptors. The enzymes catalyzing the final step of both AEA and 2-AG 
biosynthesis are all Ca2+-sensitive (Childers and Breivogel, 1998; Di Marzo, 2006). AEA 
is formed from phosphatidylethanolamine (PE) in which an acyl group is transferred from 
the glycerophospholipid molecule to the amino group of PE by the enzyme Ca2+-
dependent N-acyltransferase (NAT). The second reaction is phopholipase D (PLD)-type 
mediated hydrolysis leading to the formation of N-arachidonoylethanolamide 
(Anandamide, AEA) and phosphatidic acid (Wang and Ueda, 2009). 2-AG is formed 
from arachidonic acid-enriched membrane phospholipids such as inositol phospholipids 
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through phospholipase C and diacylglycerol lipase or through actions of phospholipase 
A1 and phospholipase C (Sugiura et al., 1995).  
 
 
Fig 12: Synthesis and degradation of AEA and 2-AG (El Manira and Kyriakatos, 2010) 
Degradation: 
AEA is a highly unstable compound, and get rapidly hydrolysed by amidase like fatty 
acid amide hydrolase (FAAH) yielding ethanolamine and arachidonic acid (Deutsch and 
Chin, 1993). AEA inactivation mainly involves two mechanisms: 1. Intracellular 
hydrolysis by the membrane associated enzyme FAAH (Di Marzo et al., 1999); 2. Uptake 
by rapid, saturable, presynaptic transmembrane transporter which delivers the compound 
to FAAH (Beltramo et al., 1997; Piomelli et al., 1999). Monoacylglycerol lipase (MAGL) 
is the main 2-AG degrading enzyme; three other serine hydrolases also contribute, 
namely FAAH, serine hydrolase α-β-hydrolase domain 6 (ABHD6), and serine hydrolase 
α-β-hydrolase domain (ABHD12) (Blankman et al., 2007). These pathways lead to two 
major 2-AG breakdown products: arachidonic acid and glycerol (Freund et al., 2003). 
There are many synthetic inhibitors of these degrading enzymes that are used to 
pharmacologically elevate the levels of endogenous cannabinoid levels, for ex. FAAH 
inhibitors like LY 2183240 and URB 597, and MAGL inhibitors like JZL 195 and 
Pristimerin (Blankman and Cravatt, 2013).  
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5.4. Signaling 
Endocannabinoids act retrogradly to modulate neurotransmitter release from CBR-
expressing presynaptic terminals (Egertovà and Elphick, 2000). CB1 and CB2 receptors 
in presynaptic nerve terminals are coupled with Gi/o subunits that lead to negative 
regulation of adenylyl cyclase (attenuating the production of cAMP) and positive 
regulation of mitogen-activated protein (MAP) kinase. Decrease in cAMP accumulation 
inhibits cAMP-dependent protein kinases (PKA). In the absence of cannabinoids, PKA 
phosphorylates the potassium channel protein, thereby decreasing outward potassium 
current. In the presence of cannabinoids, the phosphorylation of the channel by PKA is 
reduced, which leads to an enhanced outward potassium current. CB1Rs are also coupled 
positively to A-type and inwardly rectifying potassium channels, and negatively to N-
type and P/Q-type calcium channels and to D-type potassium channels (Howlett and 
Mukhopadhyay, 2000; Howlett et al., 2002a; Pertwee, 1997). Hence, in CB1R expressing 
presynaptic terminals, cannabinoids are able to inhibit glutamate (Shen et al., 1996), 
acetylcholine (Gifford et al., 1997a) and noradrenaline release (Schlicker et al., 1997) by 
inhibiting presynaptic calcium channels. These transduction pathways mediate long term 
synaptic depression (LTD) in homoneuronal synapses. Studies have also shown that 
endocannabinoid-CB1R mediated signaling leads to long term potentiation (LTP) 
through stimulation of astrocyte-neuron signaling in heteroneuronal synapses (Gómez-
Gonzalo et al., 2015)   
CB2Rs are primarily located on immune cells (among them leucocytes and lymphocytes 
of the spleen and tonsils) and modulate cytokine release (Pertwee, 2001). Activation of 
B- and T-cell CB2Rs by cannabinoids leads to inhibition of adenylyl cyclase activity in 
these cells and to a reduced response for any immune challenge (Condie et al., 1996). 
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Fig 13: CB1R signaling pathways: CB1Rs inhibit N-, P/Q- and L-type Ca2+ channels and 
adenylyl cyclase by the α subunits of the G-protein. Adenylyl cyclase inhibition subsequently 
reduces cAMP production that decreases activation of cAMP-dependent protein kinase A (PKA), 
which finally leads to decreased phosphorylation of K+ channels. Action on GIRK and PI3K are 
through αβ subunits. Inducing responses of CB1Rs are shown by a (→) sign and inhibitory 
effects by a (⊥) sign (Basavarajappa, 2007). 
5.5. Cannabinoids in locomotor networks 
Cannabinoids have been shown to increase dopamine in the prefrontal cortex (PFC; Pistis 
et al., 2002). In vivo studies have demonstrated the increase in extracellular dopamine in 
nucleus accumbens (NAc) after ∆9-THC administration (Chen et al., 1990a; 1991; Tanda 
et al., 1997). In addition, dose-dependent increase in dopamine release has been observed 
in striatum and PFC (Chen et al., 1990a, b; Malone & Taylor, 1999). In this context, there 
is a strong correlation between cannabinoid-induced behavioral effects and dopamine 
alterations in higher brain centers (Polissidis et al. 2009, 2010). However, CB1Rs are not 
reported to be located at dopaminergic terminals of these main regions; thus, the effects 
of cannabinoids on dopaminergic neurotransmission are mainly indirect and modulated 
via other neurotransmitter activity such as glutamate (Fernandez-Ruiz et al., 2010).  
A few studies have shown that ∆9-THC and other cannabinoid synthetic agonists, such as 
WIN55 212-2, induce a decrease in glutamatergic neurotransmission in the hippocampus, 
striatum and NAc (Adermark et al., 2009; Cannizzaro et al., 2006; Fujiwara and Egashira, 
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2004; Pintor et al., 2006; Sano et al., 2008). On the other hand, other studies have shown 
that CB1R activation with ∆9-THC or WIN55,212-2 increases extracellular glutamate 
levels in the cortex (Ferraro et al., 2001; Pistis et al., 2002). The biphasic cannabinoid-
induced actions on glutamatergic neurotransmission in multiple higher brain centers 
cause effects on motor cognition, activity, reward function and neuroprotection or 
neurotoxicity. Pharmacological treatments with CB1R agonists exert biphasic effects also 
in a dose-dependent manner on motor activity, with low doses inducing motor activation 
and high doses producing suppressed motor activity or catalepsy (Drews et al., 2005; 
Polissidis et al., 2010; Rodvelt et al., 2007; Sanudo-Pena et al., 2000; Sulcova et al., 
1998). 
 
 
Fig 14: Locomotor rhythm induced by NMDA in the lamprey spinal cord in vitro. Subsequent 
application of (a) antagonist SR141716 (5 µM) decreased burst frequency (b) agonist 
WIN55,212-2 (5 µM) increased the burst frequency (El Manira et al., 2008) 
In lower vertebrate locomotor networks, experiments on the isolated lamprey spinal cord 
show that endocannabinoids are released during ongoing rhythmic activity in spinal cord 
and participate in setting the baseline rhythm (See Fig 13). Endocannabinoids are found 
to be released in response to metabotropic glutamate receptor-1 (mGluR1) activation. 
This conditional release of endocannabinoids allow motoneurons and midline crossing 
interneurons to be modulatory neurons by enabling them to regulate their inhibitory 
synaptic inputs and, thus, to contribute to the locomotor burst frequency. These results 
provide evidence that endocannabinoid signaling in the lower vertebrate locomotor 
circuit contributes to motor pattern generation and regulation (El Manira et al., 2008). 
Thus, understanding endocannabinoid signaling is pivotal to understanding the complex 
networks that are regulating the basic locomotion. 
 
33 
 
5.6. Endocannabinoid system in neuroprotection 
CB1R activation influences intra-cellular  homeostasis, intercellular communication,  and  
the  modulation  of  neuro-transmitter   release. Cannabinoids are anti-excitotoxic 
substances as they are able to maintain the glutamate homeostasis (Grundy et al., 2001; 
Romero et al., 2002; Van der stelt et al., 2001). Studies both in vitro (Shen et al., 1996; 
Shen and Thayer, 1999) and in vivo (Schlicker and Kathman, 2001) experimental models 
have demonstrated that cannabinoid agonists inhibit glutamate release via binding to 
CB1Rs located presynaptically on glutamatergic terminals, an effect was reversed by 
selective CB1 antagonists (Grundy et al., 2001; Van der stelt et al., 2001). Cannabinoids  
have  also  been  shown to  inhibit  GABAergic  transmission  in  several brain areas  
(Katona et al., 1999; Szabo et al., 1998). Release of nitric oxide (NO), which plays a key 
role in neurodegenerative processes, is controlled by the cannabinoid  system,  that 
inhibits  the production  of  NO  by  microglia (Waksman et al., 1999), astrocytes 
(Molina-Holgado et al., 1997), neurones (Hillard et al., 1999), and macrophages (Coffey 
et al., 1996). In addition, CB1R activation influences dopaminergic signal transmission in  
striatal   slices (Cadogan et al., 1997) and in vivo (Gessa et al., 1998), inhibits 
noradrenaline release in isolated rat atria and vasa deferentia (Ishac et al., 1996), inhibits   
acetylcholine   release   in   vivo (Carta et al., 1998) and  inhibits  serotonin  release  from  
mouse brain cortical slices (Nakazi et al., 2000). Besides their role in controlling 
neurotransmitter release, it has been shown that CB1R knockouts are more susceptible to 
experimental autoimmune encephalomyelitis (EAE), neurodegeneration and show 
increase in caspase 3 activation (Pryce and Baker, 2007). Likewise, in conditional mutant 
mice that lack expression of the CB1R in principal forebrain neurons, the excitotoxic 
agent kainic acid induces stronger seizures in vivo (Marsicano et al., 2003). 
It  should  be  noted,  that  in  some  experimental models, endocannabinoids  do  not  
provide  any protection to neurons or produce neurotoxic effects. AEA was shown to be 
ineffective against prolonged exposure to toxic levels of glutamate (Andersson  et  al.,  
2000; Skaper  et  al.,  1996). The CB1R antagonist rimonabant evokes a neuroprotective 
response in unilateral intrastriatal NMDA microinjected neonatal rats by reducing the 
ipsilateral infarct area and the number of degenerating cortical neurons. This protective 
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effect is abolished by co-injection of the cannabinoid agonist WIN55,212-2, indicating 
that block of cannabinoid receptor activity inhibits caudal propagation of the excitotoxic 
response (Hansen et al., 2002). Furthermore, genetically engineered mice lacking FAAH 
(in which brain AEA levels are permanently elevated) appear to be more susceptible 
toward kainate-induced seizures (Clement  et  al., 2003). In summary, studies so far show 
a mixed view of cannabinoid agonists and CB1R on neuroprotection. The protective or 
toxic role is also further dependent on dose and time of application on the system. Hence, 
it is very important to precisely study the role of these ligands in any experimental model.   
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6. ACID SENSING ION CHANNELS 
Under physiological conditions, intra- and extra-cellular pH is maintained between 7.0 
and 7.4. Increased neuronal excitability alters pH to activate a wide range of receptors 
and ion channels in cell membranes, including a variety of voltage- and ligand-gated ion 
channels. Waldmann and his colleagues have first cloned acid-sensing ion channels 
(ASICs) that are activated in response to diminished extracellular pH (Waldmann et al., 
1997). Acid sensing ion channels (ASICs) are members of Na+ channel superfamily that 
are permeable to cations and are activated by extracellular acidosis. They are modulated 
by extracellular alkalosis (Benson et al., 1999; Delaunay et al., 2012), intracellular pH 
(Wang et al., 2006) and various other factors like neuropeptides, arachidonic acid,  nitric 
oxide, ATP, serotonin and polyamines (Wemmie et al., 2013). In mammals, there are 
four genes (ASIC 1-4) encoding at least six subunits of these channels (ASIC1a, ASIC1b, 
ASIC2a, ASIC2b, ASIC3, and ASIC4; Wemmie et al., 2006). Each subunit has two 
hydrophobic transmembrane regions flanking with a large extracellular loop and short 
intracellular N- and C-termini (Gonzales et al., 2009; Jasti et al., 2007). The subunit 
composition of ASIC channel determines its properties like pH sensitivity, ion selectivity, 
activation kinetics and desensitization kinetics. Each subunit possesses unique property. 
For example, ASIC1a and ASIC3 channels are activated only if the extracellular pH 
decreases to ≤ 7 (Benson et al., 2002; Hesselager et al., 2004), whereas ASIC2a channels 
are not activated until the pH is less than 6 (Askwith et al., 2004; Benson et al., 2002). 
Table 2: pH sensitivity data of homomeric and heteromeric channels (adapted from Huang et al., 
2015) 
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ASIC subunits can assemble in homo or hetero-tetrameric forms. The heteromers have 
distinct activation and desensitization characteristics, pharmacological properties, and 
different abilities to interact with intra and extracellular factors. For example, the 
desensitization rate of ASIC1a/ASIC2a heteromeric channels is more rapid than that of 
ASIC1a or ASIC2a homomeric channels (Askwith et al., 2004).  
Table 3: Characteristics of ASIC channels. SN - sensory neurons. (Table modified from 
Bronstein-Sitton, 2004) 
 
ASIC isoforms in the rat have amino acid sequence similarity of 45-80%. The primary 
structure of ASIC channels is quite conserved for a variety of mammalian species (rats, 
mice, and humans). For example, the mouse ASIC1a and the human ASIC1a share over 
99% of their amino acid sequence identity. ASIC1a, ASIC2a and ASIC2b are widely 
expressed in the CNS, while almost all subunits (except ASIC4) are present in sensory 
neurons of the PNS (Deval and Lingueglia, 2015; Lin et al., 2015). Activation of ASICs 
induce depolarization, associated with direct and indirect Ca2+ entry that will finally 
modulate the number of downstream signaling cascades. ASICs have been involved in 
several physiological and pathological processes such as nociception and pain, neuronal 
acidotoxicity, synaptic function and plasticity, and other conditions. 
6.1. Expression and role of ASIC channels in spinal cord 
ASICs are widely expressed throughout the central and peripheral nervous systems and 
play a role in nociception, learning and memory, and fear conditioning. ASIC1a is a key 
subunit in the modulation of nociceptive signals in the CNS as it is broadly expressed in 
all the laminas of the adult spinal cord (Duan et al., 2007; Mazzuca et al., 2007). The 
homomeric ASIC1a is the major channel underlying ASIC currents in rat spinal dorsal 
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horn neurons (Duan et al., 2007). Significant expression of ASIC2a and ASIC2b is also 
seen in the dorsal region of spinal cord (Wu et al., 2004). ASIC2a is broadly expressed in 
all the laminae of the adult spinal cord, where it is often co-localized with ASIC1a and 
plays a significant modulatory role (Baron et al., 2008; Jasti et al., 2007). The role of 
ASICs in the spinal cord is probably complex, because these channels could be involved 
at different levels of nociception. ASIC1a homomeric channels in the CNS are involved 
in the control of the endogenous opioid system, thereby having analgesic role (Mazzuca 
et al., 2007).  
A recent study by Jalalvand and colleagues (2016) has demonstrated that increase or 
decrease in pH reduces the locomotor burst rate in the lamprey isolated spinal cord. They 
have confirmed that this suppressive effect is caused by central canal neurons (CSF-c). 
Furthermore, it is also shown that the CSF-c neurons possess a novel innate homeostatic 
mechanism to sense any change in pH (regardless of acidic or alkaline condition) and to 
respond by causing a depression of the motor activity. The CSF-c neurons express acid-
sensing (ASIC3) and alkaline-sensing (PKD2L1) channels. Since CSF-c neurons are 
found in all vertebrates, their pH-sensing and locomotor modulatory function is most 
likely to be conserved (Jalalvand et al., 2016). However, there are very sporadic studies 
of the expression of ASICs in the spinal cord and its role in reflex and complex rhythmic 
activities.   
6.2. Role of ASICs in synaptic plasticity, neurotoxicity and protection 
Synaptic plasticity 
H+ activated inward current results in excitatory post synaptic potentials (EPSCs) that are 
15-20 times lower than the current generated from glutamate receptors (Du et al., 2014; 
Highstein et al., 2014; Kreple et al., 2014) which makes it very hard to detect any specific 
proton-activated component during neurotransmission (Alvarez de la Rosa et al., 2003). 
However, it is now shown that this small component is one of the boosting mechanisms 
for neurotransmission, and is important for the generation of long-term potentiation 
(LTP) in amygdala (Du et al., 2014) and in hippocampal slices (Wemmie et al., 2002). 
Protons inhibit NMDA receptors directly. However, the LTP effect is due to the fact that 
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activation of ASIC1a results in membrane depolarization which helps relieving voltage-
dependent blockade of NMDA receptors by Mg2+, thus facilitating the activation of 
NMDA receptors and the expression of LTP (Huang et al., 2015). In contrast, one study 
using ASIC1a knockout have shown no difference in hippocampal LTP compared to 
wildtype (Wu et al., 2013) suggesting that ASICs can mediate proton signaling at 
synaptic sites, but the exact contribution to synaptic plasticity may vary, depending on 
the system and condition. 
Neurotoxicity and protection 
Following brain ischemia, there is a large increase in reactive oxygen species 
accompanied by a large reduction in brain pH down to 6.0 in severe conditions (Hertz, 
2008; Xiong et al., 2007). This pH reduction is large enough for robust activation of 
ASIC1a channels. Studies have shown that ASIC1a gene deletion protects mice from 
brain injury induced by middle cerebral artery occlusion (MCAO) (Pignataro et al., 2007; 
Xiong et al., 2007). Amiloride, a non-specific ASIC inhibitor, has a similar protective 
effect on MCAO (Pignataro et al., 2007). Activation of NMDA receptors, through the 
recruitment of calcium/calmodulin-dependent protein kinase II (CaMKII) signaling, 
increased ASIC1a current and potentiates ischemia-induced neuronal injury (Gao et al., 
2005). Consistent with these studies, an additive protection was observed when ASIC 
channels are inhibited along with NMDA receptors inhibition (Mishra et al., 2011; 
Pignataro et al., 2007).  
In normal conditions, ASIC1a expression in axons is relatively low (Vergo et al., 2011; 
Zha et al., 2006; Zha et al., 2009). However, in the animal EAE model (where pH was 
about 6.0-6.5; Friese et al., 2007) and human multiple sclerosis (MS) patients, an increase 
in ASIC1a expression or trafficking to axons, as well as an upregulation of ASIC1a in 
oligodendrocytes (Arun et al., 2013; Vergo et al., 2011) is observed. ASIC1a gene 
deletion or inhibition reduces EAE-induced axonal injury and improves the clinical score 
(Friese et al., 2007). In the same way, amiloride alleviates the severity of the disease 
(Vergo et al., 2011). In a recent clinical study, where MS patients were orally treated with 
amiloride for a period of one year, has shown significant reduction in brain atrophy rate, 
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axonal damage and myelin loss (Arun et al., 2013). Studies have demonstrated that 
substantia nigra neurons express ASICs and typical ASIC-type currents (Arias et al., 
2008; Pidoplichko and Dani, 2006). In a mouse Parkinson's disease (PD) model, ASIC 
inhibition with amiloride or Psalmotoxin (PcTx1) attenuates the reduction of 
immunoreactivity to tyrosine hydroxylase and dopamine transporters (markers for 
dopaminergic neurons; Arias et al., 2008). 
Extracellular pH decreases after spinal cord or traumatic brain injury (TBI; Gupta et al., 
2004; Vink et al., 1987; Yin et al., 2013). In TBI patients, the degree of pH reduction is 
correlated with the injury condition, with lower pH associated with higher lethality 
(Gupta et al., 2004; Timofeev et al., 2011). In rodents, inhibiting ASIC1a with amiloride 
or PcTx1 alleviates the severity of TBI (Hu et al., 2011; Yin et al., 2013). Thus, targeting 
ASICs, especially when combined with other therapeutic interventions, may be an 
effective therapeutic strategy for alleviating neuronal injuries. 
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7. IMPORTANCE OF TREATMENT DURING EARLY PHASE OF SCI 
Subsequent to an initial insult, there is a cascade of downstream events termed 'secondary 
injury', which culminate in degenerative events in the structure and function of the spinal 
cord (Borgens and Liu-Snyder, 2012; Hilton et al., 2016; Oyinbo, 2011; Park et al., 
2004). These secondary injury mechanisms include, but are not limited to, ischemia, 
inflammation, free radical-induced cell death, glutamate excitotoxicity, cytoskeletal 
degradation, and induction of extrinsic and intrinsic apoptotic pathways (Borgens and 
Liu-Snyder, 2012; Hilton et al., 2016). Research from our group has shown both positive 
and negative effects of drugs in early stages of SCI (see Table 3). Our previous study on 
methoxyflurane (a volatile anesthetic) showed complete recovery of structure and 
function of the KA treated spinal cord after 24 h (Shabbir et al., 2015a). Furthermore, the 
anesthetic propofol protected from KA mediated injury organotypic cultures 
(Bajrektarevic and Nistri, 2016). These data strongly support that excitotoxicity (a main 
secondary injury mechanism; Park et al., 2004) can be reversed within a time window of 
24 h from the initial insult.  
Table 4: List of studies from our group on SCI models (      Protection;      Toxic) 
Compounds and study Protection Toxicity 
6-Cyano-7-nitroquinoxaline-2, 3-dione (CNQX) 
and aminophosphonovalerate (APV), glutamate 
antagonists on KA or pathological medium (PM) 
treated in vitro rat spinal cord injury (SCI) model 
(Margaryan et al., 2010) 
      Partial recovery 
after CNQX and APV 
treatment in both KA 
and PM treated 
preparations 
 
PJ 34 (poly ADP-ribose polymerase enzyme 1; 
PARP1 inhibitor) on excitoxic damage evoked by 
KA on rat organotypic cultures (Mazzone and 
Nistri, 2011) and on in vitro rat SCI model 
(Nasrabady et al., 2011)   
      Protection in 
histology of both 
organotypic and in vitro 
SCI model. Limited 
functional recovery in 
the in vitro model   
 
Riluzole, an inhibitor of glutamate release, on KA 
mediated in vitro SCI model (Samano et al., 2012) 
No functional and 
histological protection 
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Methoxyflurane (volatile anesthetic) on KA in 
vitro SCI (Shabbir et al., 2015a) 
      Complete protection 
of neurons and function 
 
VER155008 (HSP 70 inhibitor) on KA induced in 
vitro SCI model (Shabbir et al., 2015b) 
  
Methylprednisolone sodium succinate (MPSS; 
glucocorticosteroid) on either KA or PM treated 
in vitro rat SCI model (Samano et al., 2016) 
     Partial (white matter 
recovery) 
 
Propofol (anesthetic) on KA treated organotypic 
culture SCI model (Bajrektarevic and Nistri, 
2016) 
     Complete  
Propofol (anesthetic) on in vitro KA mediated 
SCI model (Kaur et al., 2016) 
       Partial (no 
functional recovery) 
 
 
An abnormal acid-base balance is encountered in many traumatic brain injury (TBI) 
patients on the first day of injury (Clausen et al., 2005; Taha and Ammar, 2015), among 
them acidosis is the commonest factor (Taha and Ammar, 2015). This change persists for 
four days post injury in patients (Clausen et al., 2005; Taha and Ammar, 2015). 
Similarly, Arevalo-Martin et al. have shown that endogenous cannabinoids are modulated 
within few hours post-SCI (Arevalo-Martin et al., 2012). These studies prompted our 
interest in the potential role of ASICs and CB1R s in KA mediated SCI during the first 24 
h and to investigate further their impact on the locomotor rhythm.   
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8. THESIS AIMS 
To understand how spinal CPGs produce locomotor movements and to assist the recovery 
of function after SCI, it is necessary to functionally dissect out the network connectivity, 
the intrinsic properties of the constituent neurons and their neuromodulatory mechanisms. 
It is well known that in spinal locomotor networks concerted operation of ion channels 
and transmitter receptors is required for initiating, setting and fine-tuning the frequency 
and amplitude of ongoing locomotor activity (El Manira et al., 2002; Grillner et al., 2001; 
Katz and Clemens, 2001; Harris-Warrick, 2002). 
Hence, this thesis focuses on: 
 How endocannabinoid system modulation can contribute to set the baseline 
locomotor activity in mammalian spinal cord 
• Importance of CB1R in the fictive locomotion 
• CB1R activity in the isolated neonatal rat spinal cord 
• Cannabinoid ligands and uptake inhibitors mediated modulation in the 
rhythm 
 How endocannabinoid system can modulate the impaired rhythmicity very early 
after SCI  
• Expression and activity of CB1R after experimental SCI 
• Importance of CB1R after SCI 
 How ASICs can modulate the locomotor rhythm after SCI 
• pH modulation after KA mediated injury and changes in ASIC 
expression 
• Blockade of ASIC channels and its importance to SCI 
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MODULATORY EFFECTS BY CB1 RECEPTORS ON RAT SPINAL
LOCOMOTOR NETWORKS AFTER SUSTAINED APPLICATION OF
AGONISTS OR ANTAGONISTS
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Advanced Studies (SISSA), Via Bonomea 265, 34136 Trieste, Italy
Abstract—Sustained administration of cannabinoid agonists
acting on neuronal CB1 receptors (CB1Rs) are proposed for
treating spasticity and chronic pain. The impact of CB1Rs
on mammalian locomotor networks remains, however,
incompletely understood. To clarify how CB1Rs may control
synaptic activity and locomotor network function, we used
the rat spinal cord in vitro which is an advantageous model
to investigate locomotor circuit mechanisms produced by
the local central pattern generator. Neither the CB1 agonist
anandamide (AEA) nor the CB1R antagonist AM-251 evoked
early (<3 h) changes in mono or polysynaptic reﬂexes or in
locomotor rhythms. Application of AEA (24 h) signiﬁcantly
decreased the ability of dorsal root (DR) aﬀerents to elicit
oscillatory cycles, and left synaptic responses unchanged.
Similar application of LY 2183240, or JZL 184, inhibitors of
endocannabinoid uptake processes, produced analogous
results. Application of the antagonist AM-251 (or rimonabant)
for >3–24 h largely impaired locomotor network activity
inducedbyDRstimuli or neurochemicals, anddepresseddis-
inhibited bursting without changing reﬂex amplitude or
inducing neurotoxicity even if CB1R immunoreactivity was
lowered in the central region. Since CB1R activation usually
inhibits cyclic adenosinemonophosphate (cAMP) synthesis,
we investigated how a 24-h application of AEA or AM-251
aﬀected basal or forskolin-stimulated cAMP levels. While
AEA decreased them in an AM-251-sensitive manner, AM-
251 per se did not change resting or stimulated cAMP. Our
data suggest that CB1Rs may control the circuit gateway
regulating the inﬂow of sensory aﬀerent inputs into the
locomotor circuits, indicating a potential site of action for
restricting peripheral signals disruptive for locomotor
activity.  2015 IBRO. Published by Elsevier Ltd. All rights
reserved.
Key words: cannabinoid receptor-1, ﬁctive locomotion,
anandamide, AM-251, cAMP, endocannabinoids.
INTRODUCTION
There is increasing interest in cannabinoid research as
this ﬁeld may yield important therapeutic tools against a
range of diseases. A recent report has summarized the
North American guidelines for the medical use of
cannabinoids, highlighting the principal goals of
decreasing chronic pain and spasticity especially in
multiple sclerosis patients (Koppel et al., 2014).
Conversely, use of endocannabinoid antagonists has
been investigated to treat obesity and food craving
(Poncelet et al., 2003; Howlett et al., 2004; Pagotto
et al., 2005): however, early antagonists have not
received approval by drug regulatory agencies because
of severe central nervous system eﬀects in man (Jones,
2008; Bifulco and Pisanti, 2009). A large body of evidence
supports a critical role of cannabinoid receptors type 1
(CB1Rs; Pertwee et al., 2010) that are physiologically
activated by endocannabinoids like anandamide (AEA)
and 2-arachidonoylglycerol (2 AG), as pharmacological
targets to control aberrant nociceptive transmission in
the spinal cord and the maladaptive processing of aﬀerent
inputs underlying spasticity (Piomelli, 2005; Manzanares
et al., 2006). Nevertheless, the role of CB1Rs in spinal
locomotor networks is incompletely understood. In vivo
observations indicate that activation of CB1Rs usually
produces less locomotor activity, although the precise
mechanisms remain unknown and the site of action
unclear (Lee et al., 2006; Bosier et al., 2010). Previous
studies of the lamprey spinal cord in vitro have shown that
acute CB1R activation by AEA speeds up chemically-
stimulated locomotor network function, while the
antagonist AM-251 depresses locomotor cycles in a
time-dependent fashion (Kettunen et al., 2005). Data on
mammalian locomotor networks are currently unavailable.
Thus, it seems important to investigate how CB1Rs may
modulate mammalian circuits because the pharmacologi-
cal consequences of CB1R activity largely depends on
their coupling to distinct G-proteins, in turn regulating
various intracellular eﬀectors that may be species, tissue
and cell speciﬁc (Hudson et al., 2010).
Most experimental studies have employed short-term
application of CB1R agonists or antagonists.
Nonetheless, these drugs are usually expected to be
administered for a prolonged time, raising the possibility
that they might induce adaptive changes in their
receptors. To explore the functional consequences of
sustained application of such drugs, we used the rat
http://dx.doi.org/10.1016/j.neuroscience.2015.06.045
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spinal cord preparation in vitro as a model. This is an
advantageous system to study locomotor network
activity that is generated by a central pattern generator
(namely a local neuronal circuitry with intrinsic
rhythmicity) located in the lumbar spinal and readily
activated by either neurochemicals (N-methyl-D-
aspartate (NMDA) and serotonin (5-HT); Grillner, 2003,
2006; Kiehn, 2006, 2011) or trains of electrical stimuli
applied to one dorsal root (DR; Marchetti et al., 2001).
This pattern, which comprises alternating ventral root
(VR) discharges among extensor and ﬂexor motoneuron
pools located on both sides of the spinal cord, is termed
ﬁctive locomotion because the rhythm is expressed in
the absence of hind limbs. One important advantage of
the isolated spinal cord is its 24-h survival in vitro with
intact histological proﬁle (Cifra et al., 2012) and fully pre-
served locomotor rhythms (Taccola et al., 2008). This
property enables studies of delayed consequences of
drug action with a timecourse resembling the in vivo
administration protocols as CB1R ligands are not
intended for brief eﬀects only.
The aims of the present study were to clarify the
eﬀects of activation or block of CB1Rs on synaptic
transmission in the rat spinal cord both acutely or after a
24-h application of CB1R ligands, their role in locomotor
networks, any plasticity in the CB1R expression and
potential neurotoxicity, and any preferential modulation
of CB1R eﬀectors.
EXPERIMENTAL PROCEDURES
In vitro spinal cord preparation
Spinal cords were isolated from neonatal Wistar rats
(0–2 days old) in accordance with the guidelines of the
National Institutes of Health and the Italian act D.Lgs.
27/1/92 no.116 116 (implementing the European
Community directives n. 86/609 and 93/88). All eﬀorts
were made to minimize the number of animals used for
the experiments and their suﬀering. Preparations were
continuously superfused (7.5 ml min1) with standard
Kreb’s solution of the following composition (in mM):
113 NaCl, 4.5 KCl, 1 MgCl27H2O, 2 CaCl2, 1 NaH2PO4,
25 NaHCO3, 11 glucose, gassed with 95% O2 and 5%
CO2 (pH 7.4) at room temperature during
electrophysiological recording. All the experimental
procedures were carried out as previously described
(Bracci et al., 1996; Beato and Nistri, 1999; Taccola
et al., 2008) with ethical permission granted by the ethics
committee of our School.
Experimental protocols for early or delayed eﬀects of
CB1R ligands
Reﬂex and locomotor network activity were ﬁrst tested in
all preparations before any ligand application. On the ﬁrst
day of experimentation, preparations were superfused
with cannabinoid ligands (AM-251, AEA), while any
changes in electrophysiological responses were
continuously monitored. Ligands were then washed out
and the preparations were kept in Kreb’s solution (24 h)
for further electrophysiological testing. In a separate
batch of experiments, preparations were treated
continuously for 24 h with ligands (AM-251, rimonabant,
AEA, LY 218324, 2 AG, or JZL 184) that were washed
out before recording on the second day. All experiments
were done in parallel with untreated ‘‘sham’’
preparations kept for 24 h in Kreb’s solution to be used
as control. The same protocol of drug application was
used for quantifying basal cyclic adenosine
monophosphate (cAMP) levels: these experiments also
included an additional experimental group treated with
AM-251 for 24 h, washed out and then treated with AEA
for 30 min to analyze whether any sustained block of
CB1Rs was reversed by short-term application of AEA.
Finally, we measured changes in cAMP levels induced
by forskolin (Frsk) (1 lM; 30-min application; Steﬀens
et al., 2004) in preparations treated for 24 h with
AM-251 or AEA: in this paradigm, CB1R ligands were also
co-applied with Frsk.
Drug concentrations used for the present experiments
were obtained from previously validated studies with the
appropriate references provided for each one of the
chemicals listed below. To detect changes in locomotor
rhythms by blocking CB1Rs, two antagonist/inverse
agonists were employed, namely AM-251 (5 lM;
Kettunen et al., 2005; Gonzalez-Islas et al., 2012) or SR
141716A, (rimonabant; 5 lM; Kettunen et al., 2005).
CB1Rs were activated by exogenously applying AEA
(5–10 lM; Eljaschewitsch et al., 2006) or 2 AG
(2–5 lM; Iannotti et al., 2014). We also used the AEA
uptake inhibitor; LY 218324 (1–5 lM; Gonzalez-Islas
et al., 2012) and the 2 AG uptake inhibitor JZL 184 (1–
5 lM; Pan et al., 2009). All these drugs were dissolved
in dimethyl sulfoxide (DMSO) except AEA (which was dis-
solved in ethanol) to reach a 10 mM stock from which ﬁnal
dilutions were made with Kreb’s. In all cases, the ﬁnal
concentrations of DMSO or ethanol were also added to
the Kreb’s solution for control or sham preparations
without inducing any detectable change in electrophysio-
logical parameters.
Electrophysiology
Full details of these methods were previously reported
(Marchetti et al., 2001; Taccola et al., 2008). In brief,
to study reﬂexes and rhythmicity (ﬂexor and extensor
cyclic discharges) of the spinal cord, VRs of the lumbar
region segments (L2 and L5) were tightly sucked into
monopolar suction electrodes connected to Ag/Ag–Cl
micropellets in glass micropipettes. To evoke VR
responses, electrical square pulses (0.1-ms duration)
were given through a single ipsilateral DR using a bipo-
lar suction electrode. We graded the DR stimulus inten-
sity to evoke either low-threshold monosynaptic
responses when the stimulus was just above threshold
to induce a detectable response (Fulton and Walton,
1986; Marchetti et al., 2001) or polysynaptic responses
when the stimulus was three times higher. Our previous
experiments with intracellular recording from motoneu-
rons have validated the functional identiﬁcation of these
responses as either mono or polysynaptic (Ostroumov
et al., 2007).
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Dorsal-Dorsal root potentials (DR-DRP) were
recorded by stimulating (0.1 ms) a single DR and
recording from the ipsilateral segmental DR. Reﬂex
responses were the average from 3 to 5 events in each
group. To study electrically induced ﬁctive locomotion, a
train of 30 pulses (5–7 V) at 2-Hz frequency was given.
Alternating rhythmic discharges were also recorded by
bath applying NMDA (2–6 lM) and 5-hydroxytryptamine
(5-HT; 10 lM) as amply reviewed by Kiehn (2006). To
analyze the cycle peak amplitude and periodicity, twenty
constitutive oscillations were taken as described in our
previous studies (Taccola et al., 2008). The amplitude of
each locomotor biphasic cycle was measured from peak
to peak, and averaged for at least twenty responses.
Disinhibited bursting was elicited by blocking
c-aminobutyric acid (GABA)-A and glycine receptors
using bicuculline (20 lM) and strychnine (1 lM),
respectively (Bracci et al., 1996). All signals were
acquired, digitized and recorded in pClamp version 9.2
(20-kHz acquisition frequency with high- and low-pass
ﬁlters of 0.1 Hz and 10 kHz, respectively; Molecular
Devices, Sunnyvale, CA, USA) using a DP-304
Diﬀerential ampliﬁer (Warner Instruments LLC, Hamden,
CT, USA) in DC mode.
Responses to exogenously-applied (2 min) transmitter
agonists GABA (10 lM), glycine (100 lM), NMDA
(10 lM) or a-amino-3-hydroxy-5-methyl-4-isoxazolepro
pionic acid (AMPA) (2.5 lM) were recorded from VRs.
Concentrations of these drugs were chosen to produce
approximately equi-amplitude depolarizations, with the
exception of glycine that was a much weaker agent.
After washout and recovery to basal level of VR
polarization, AEA (or the CB1 antagonist AM-251) was
applied for 30 min and responses re-tested on the same
preparation. We also studied whether 24 h in vitro might
have altered the eﬀects of AEA on these drugs. Thus,
after 24 h exposure to AEA (or its antagonist AM-251)
and its washout, we tested these transmitter agonists
diluted in standard Krebs solution and compared the
responses with those from sham spinal cords (24 h) run
alongside the treated ones.
In view of the observed late eﬀects induced by CB1
agonist or antagonist application, we also tested
whether these phenomena might have actually been
due to relatively rapid developmental changes that
occurred during 24 h in vitro rather than delayed actions
due to CB1R modulation. Thus, we studied if spinal
cords removed from older rats (P4) could exhibit
locomotor-like patterns induced by NMDA (5 lM) and
5HT (10 lM), or DR stimuli. Fictive locomotor patterns
are typically studied with spinal cords removed from
very young preparations (Cazalets et al., 1992; Kudo
and Nishimaru, 1998) because those obtained from older
animals are less viable in vitro unless hemisected (Long
et al., 1988), a procedure that abolishes ﬁctive
locomotion. In the present study, stronger DR electrical
pulses (5–7  threshold for monosynaptic reﬂex vs
2–3  threshold in P0–P2 spinal cords) were necessary
to elicit cumulative depolarization with superimposed
oscillations. These older preparations were re-tested after
a 3-h application of AEA or AM-251.
Quantiﬁcation of pyknosis and CB1R
immunohistochemistry
Free-ﬂoating sections (from the thoraco-lumbar region) of
30-lm thickness were cut (with a sliding microtome) from
spinal cords after 4% paraformaldehyde ﬁxation and 30%
sucrose cryoprotection. For cell death quantiﬁcation
based on pyknosis counts, images were taken using a
Zeiss Axioskop2 microscope (Oberkochen, Germany)
and Metavue software (Molecular Devices, Sunnyvale,
CA, USA) after DAPI staining. Standard ROIs of
350  350 lm2 for dorsal and central, 235  235 lm2
for ventral areas were constructed and counted in
ImageJ (NIH) in accordance with our former studies
(Cifra et al., 2012).
For CB1R immunostaining, sections were incubated
in blocking solution (5% normal donkey serum, 5%
bovine serum albumin, 0.3% Triton-X 100) for 2 h at
room temperature. The primary antibody (1:50 dilution;
CB1 (K-15) antibody; Santa Cruz Biotechnology, Inc.) in
antibody solution (1% normal donkey serum, 1% bovine
serum albumin, 0.1% Triton-X 100) was incubated at
4 C overnight. Sections were then washed (in
phosphate buﬀer solution) and incubated with the
secondary anti-rabbit Alexa Fluor 488 antibody (1:500)
in the antibody solution for 2 h. They were ﬁnally stained
with DAPI and imaged using a Confocal-Nikon
microscope with identical capture settings throughout.
Five images were acquired at z axis intervals of 1 lm at
each region. To validate the speciﬁcity of the CB1R
primary antibody, it was neutralized with its blocking
peptide (supplied by the CB1 (K-15) antibody
manufacturer) in 1:10 dilution at room temperature as
instructed by the supplier. Spinal cord sections were
then incubated in the neutralized mixture and processed
as mentioned above. No CB1R staining was
subsequently observed. The following ROIs were used:
Dorsal – 200  300 lm2; Central 250  250 lm2 and
Ventral 200  200 lm2 to quantify the intensity of
CB1R. Images were processed and analyzed in volocity
workstation (Perkin Elmer, London, UK) as previously
described by Bianchetti et al. (2013).
cAMP immunoassay
At the end of the experimental protocol of drug application,
spinal cords were immediately frozen in liquid nitrogen and
processed in accordance with the manufacturers’
instructions (Abnova; http://www.abnova.com/products/
products_detail.asp?catalog_id=KA0886) on the same
day to minimize cAMP degradation. CAMP levels were
normalized with respect to the protein concentration
assayed with the bicinchoninic acid method.
Drugs
AM-251, AEA, rimonabant, 2 AG, LY 218324, JZL 184
and NMDA were purchased from Tocris (Bristol, UK),
while 5-HT and strychnine hydrochloride were from
Sigma (Milan, Italy). Bicuculline methiodide was
purchased from Abcam (Cambridge, UK).
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Statistics
Results are expressed as mean ± SEM, with
n= number of preparations. Statistical analysis was
performed with SigmaStat (SigmaStat 3.1, Systat
Software, Chicago, IL, USA). Data were distinguished
as parametric or non-parametric by performing a
normality test and then analyzed with the t-test or
Mann–Whitney test, respectively, in accordance with the
software choice. The accepted signiﬁcance level was
always P< 0.05.
RESULTS
AEA-mediated changes in responses evoked by
exogenously-applied transmitters
Because of the use of neonatal tissue and its in vitro
condition, we ﬁrst explored whether CB1Rs were
functional and whether their activation by AEA might
change spinal network eﬀects induced by GABA
(10 lM), glycine (100 lM), NMDA (10 lM) or AMPA
(2.5 lM). Fig. 1A shows, in the same preparation,
examples of VR depolarization elicited by superfusing
these transmitter agonists (that evoked responses as
previously reported; Nistri and Constanti, 1979; Watkins
and Evans, 1981), and then repeated 30 min and 24 h
after applying AEA (5 lM). On the ﬁrst day, while no
change was observed in the eﬀects by glycine, NMDA
or AMPA, a small, yet signiﬁcant decrease in GABA-
mediated depolarization was on average detected
(Fig. 1B). This pattern of modulation of GABA-mediated
responses was not preserved after a 24-h application of
AEA and washout followed by recording agonist-elicited
responses in standard Kreb’s solution: in fact, depolariz-
ing eﬀects of these agonists were similar to those
obtained from sham (24 h) preparations (Fig. 1A, B). It
is expected that superfusion of exogenous agonists most
likely activated a broad class of receptors widely dis-
tributed within spinal networks. Thus, we subsequently
investigated whether AEA (or its antagonists) might mod-
ulate more focused, i.e. synaptic, actions of these trans-
mitters and locomotor network-dependent activity.
Fig. 1. Eﬀect of AEA on VR depolarization evoked by exogenously-applied transmitter agonists. (A) Top row illustrates examples of responses
recorded from a lumbar VR of the same preparation following superfusion with GABA (10 lM), glycine (100 lM), NMDA (10 lM), or AMPA (2.5 lM)
in control solution. Bottom row shows that AEA (5 lM) depresses GABA responses after a 30-min application. No signiﬁcant alteration in the
response to the other agonists is observed. (B) Plots show average depression (%) in GABA-mediated depolarization after a 30-min application of
AEA (n= 16 vs n= 9 sham; P< 0.05), whereas no change is observed after a 24-h application of AEA compared to sham; for the 24 h data %
changes refer to the values recorded on the ﬁrst day.
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Changes in spinal reﬂexes and ﬁctive locomotion
evoked by CB1R ligands
We ﬁrst explored the eﬀects of AEA (5–10 lM) or the
CB1R antagonist/inverse agonist AM-251 (5 lM) on
mono or polysynaptic transmission elicited by DR
stimulation as exempliﬁed in Fig. 2A, B. Neither agent
continuously applied for up to 6 h signiﬁcantly changed
monosynaptic reﬂexes in terms of peak or area values
(Fig. 2C, D). Likewise, no signiﬁcant alteration in the
polysynaptic reﬂex amplitude and area was apparent
(Fig. 2E, F). Despite the lack of eﬀect by these ligands
on standard tests for synaptic transmission, a clear
change was observed when the locomotor network was
activated by DR stimulation. This phenomenon is
illustrated in Fig. 3A in which a cluster of oscillatory
cycles emerged with 2-Hz pulse train applied to a single
lumbar DR in control conditions. While AEA did not
aﬀect this response, a 3–6-h application of AM-251
signiﬁcantly depressed such a rhythmic activity
(Fig. 3A, B) without changing the cumulative VR
depolarization arising from the DR stimulus train
(Fig. 3C). Interestingly, no change in cycle amplitude or
periodicity appeared when ﬁctive locomotion was
evoked by NMDA plus 5-HT (Fig. 3D–F) and recorded
for 3–6 h in the presence of AEA or AM-251.
These observations suggested that blocking CB1Rs
inhibited the integration of repeated aﬀerent inputs into
the locomotor networks, yet it did not aﬀect the
locomotor central pattern generator when this was
stimulated with neurochemicals. One possibility was that
AM-251 largely modulated GABA-mediated synaptic
transmission especially at dorsal level. This issue could
be examined in the spinal cord by recording the DR-
DRP, namely the primary aﬀerent depolarization
functionally expressed as presynaptic inhibition for
which GABA receptor activation is one important
contributor (Levy, 1977; Rudomin, 2009). Nonetheless,
DR-DRP amplitude and area (control amplitude =
0.49 ± 0.1 mV; area = 827.89 ± 279.03 mV ms;
n= 3) were not signiﬁcantly diﬀerent after applying
AM-251 for 3 h (amplitude = 0.38 ± 0.1 mV; area =
726.11 ± 292.78 mV ms; n= 3). In keeping with these
observations, there was no change induced by AM-251
on GABA- (10 lM) mediated VR depolarizations
(0.84 ± 0.13 mV vs 0.71 ± 0.10 mV in control solution;
n= 7).
Fictive locomotion is just one of the rhythmic patterns
originated in the isolated rodent spinal cord. To check for
the pattern selectivity of CB1R ligand-mediated changes,
we investigated the intrinsic rhythmicity that emerges
when synaptic inhibition is blocked by strychnine and
bicuculline. Thus, slow and large bursts (disinhibited
bursting) appear through the recurrent excitation
mediated by glutamatergic synapses and modulated by
intrinsic neuronal conductances (Bracci et al., 1996).
Fig. 4A shows examples of disinhibited bursting in control
conditions (3 h in Kreb’s solution), or in the continuous
(3 h) presence of AEA or AM-251. No statistical diﬀerence
in the number of bursts, burst amplitude or duration was
found (Fig. 4B–D), suggesting that the oscillatory cycles
elicited by DR stimulation were the primary functional
target for CB1R block.
Fig. 2. Eﬀects of AEA and AM-251 on reﬂex activity after a 3–6-h application. (A, B) Examples of average monosynaptic (A) or polysynaptic (B)
reﬂex responses recorded from lumbar 5 VR in control, AEA or AM-251 solution. (C, D) Histograms showing the peak amplitude of mono (C) and
polysynaptic (E) responses after AEA or AM-251 treatment compared with time-matched control (n= 14), AEA (n= 5) or AM-251 (n= 14). (D, F)
Histograms representing the area of mono and polysynaptic reﬂex responses following AEA or AM-251 application (same data as shown in C, E).
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Longer (24 h) term changes in reﬂex activity evoked
by CB1R ligands
We wondered if the delayed network depression
observed in the presence of AM-251 might be
intensiﬁed for longer application times (24 h). For this
purpose, experiments were performed on the second
day from the spinal cord dissection and used ‘‘sham’’
preparations (namely maintained in vitro for 24 h in
Kreb’s solution) for comparison. We also explored the
long-term consequences of a 24-h application of other
CB1R ligands (see review by Pertwee et al., 2010) like
AEA, the CB1R antagonist rimonabant, the AEA uptake
inhibitor LY 2183240, the CB1R agonist 2 AG, or the 2
AG uptake inhibitor JZL 184. In all these protocols (see
Experimental procedures), the ligands were washed out
just prior to the recording session on the second day of
each experiment, in order to enable detection of delayed
consequences on network function.
On average sham monosynaptic responses were
0.14 ± 0.02 mV in amplitude (n= 15). There was no
diﬀerence in monosynaptic reﬂexes after overnight
exposure to AEA (0.10 ± 0.01 mV, n= 17), or AM-251
(0.18 ± 0.03 mV, n= 19). Likewise, neither 2 AG
(2–5 lM; 0.21 ± 0.11 mV; n= 8), nor LY 2183240
(1–5 lM; 0.06 ± 0.01 mV; n= 6), nor JZL 184 (5 lM;
0.11 ± 0.02 mV; n= 7) changed the monosynaptic
reﬂex amplitude.
Fig. 5A shows representative records of the
depression of polysynaptic transmission evoked by a
24-h application of AM-251. While the average peak
amplitude was unchanged (0.87 ± 0.13 vs
0.84 ± 0.28 mV for treated, n= 19, and sham, n= 15,
respectively), the area of the response became
signiﬁcantly smaller as indicated in Fig. 5B, C. Thus, the
average reﬂex time course plot demonstrated faster
decay to the baseline (Fig. 5C). In analogy with data
observed on the ﬁrst day of treatment, the DR-DRP
parameters were not changed by a 24-h administration
of AM-251 (amplitude: 0.25 ± 0.02 vs 0.20 ± 0.03 mV;
area: 379.03 ± 52.28 vs 741.04 ± 195.88 mV ms for
Fig. 3. Changes in network responses after AEA or AM-251 treatment. (A) Electrically evoked ﬁctive locomotion in control (left), AEA (middle) or
AM-251 (right) solution. Note depression of rhythmic discharges by AM-251 treatment (3–6 h). (B) Histograms of the number of oscillations induced
by DR stimulation. Note that there is a signiﬁcant decline in the number of oscillations after AM-251 3–6-h application (n= 14). (C) Bar graphs
showing no signiﬁcant change in cumulative depolarization after AEA or AM-251 application. (D) Examples of ﬁctive locomotion induced by NMDA
and 5-HT in control (top left), AEA (top right) or AM-251 (bottom), 3–6-h application. (E) Histograms showing no change in peak amplitude of
chemically evoked oscillations after AEA or AM-251 treatment compared with control (same preparations shown in B). (F) Histograms showing the
periodicity of the rhythm generated by NMDA and 5-HT after AEA or AM-251 application in comparison with time-matched controls. Note that there
is no change in the parameters of chemically evoked ﬁctive locomotion. *P< 0.05.
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sham and AM-251, respectively; n= 5). Table 1
summarizes the eﬀect of the other CB1R ligands on
polysynaptic reﬂexes.
Network rhythmicity after a 24-h exposure to CB1R
ligands
Fig. 6A shows that AEA treatment (24 h) signiﬁcantly
impaired the ability to generate oscillations induced by a
DR stimulus train. This eﬀect was associated with
slightly lower amplitude of cumulative depolarization
(0.60 ± 0.05 vs 0.89 ± 0.09 sham preparations;
n = 17, P < 0.05).This phenomenon was even more
dramatically observed after 24 h AM-251 application as
no (or rare) oscillations were present despite strong
cumulative depolarization and irregular discharges
associated with the DR train. Fig. 6B quantiﬁes these
observations for AEA or AM-251 treatments. Table 1
shows that rimonabant, LY 2183240 or JZL 184 also
decreased the number of rhythmic oscillations, while 2
AG was ineﬀective.
A diﬀerent picture emerged from experiments with
chemically-evoked ﬁctive locomotion. In fact, as shown
in Fig. 6C, while a 24-h treatment with AEA had no
blocking eﬀect (data are summarized in Fig. 6D, E) in
analogy with LY 2183240, 2 AG or JZL 184 (see
Table 1), preparations treated with AM-251 for 24 h
could be split into two groups. The majority of them
(11/19 spinal cords) could not generate any ﬁctive
locomotor cycles (Fig. 6C) despite systematic stepwise
changes in the NMDA concentration (2–6 lM). In the
remaining eight spinal cords, ﬁctive locomotion was
evoked, however the rhythm was very much slower than
the sham one with diminished cycle amplitude (Fig. 6D,
E).To validate this result, we also explored the eﬀect of
a chemically diﬀerent CB1R antagonist, rimonabant
(5 lM; 24 h) that signiﬁcantly prolonged the cycle period
(7.7 ± 2.2 s; n= 6, three further preparations lacked
ﬁctive locomotion; Table 1). The slowly developing
depression of ﬁctive locomotion by AM-251 was
conﬁrmed by examining the outcome after just 3–6 h of
treatment with AM-251 on the ﬁrst experimental day
followed by a 24-h washout with Kreb’s solution. In this
case, on a database of 15 spinal cords, we observed a
lower number of oscillations (3.8 ± 0.3; n= 14,
p< 0.001) induced by standard DR trains, while the
chemically-elicited ﬁctive locomotion showed a
signiﬁcantly smaller cycle amplitude (0.23 ± 0.03 mV;
n= 14, p< 0.05) and slower period (6.4 ± 0.40 s;
n= 14, p< 0.05). These results indicated that any
Fig. 4. Disinhibited bursts after 3–6 h of CB1R ligand application. (A) Sample disinhibited burst recordings obtained from control (top), AEA-treated
(middle) or AM-251-treated (bottom) preparations. Bursts were evoked by strychnine and bicuculline application. (B–D) Histograms showing no
eﬀects by AEA (n= 5) or AM-251 (n= 7) on number of bursts in 20 min (B), burst amplitude (C), and duration (D).
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change induced by AM-251 was actually quite slow, as it
grew over a matter of a few hours and could not be rapidly
arrested by washout. On disinhibited bursting (Fig. 7A, B),
a 24-h application of AM-251 produced a comparatively
lower number of bursts vs sham preparations and no
further change in burst properties. Conversely, AEA
application for 24 h had no eﬀect (see Fig. 7B–D).
Downregulation of CB1R expression by AM-251
We ﬁrst examined whether a 24-h application of AM-251
had any neurotoxic eﬀect. We looked for pyknosis in the
three main ROIs as used in previous reports (Cifra
et al., 2012). Thus, we saw no evidence for pyknosis in
dorsal, central or ventral ROIs as illustrated in
Fig. 8B, C that conﬁrmed full histological viability of the
preparations after 24 h in vitro. We next looked for
immunoﬂuorescence expression of CB1Rs in dorsal, cen-
tral and ventral ROIs as shown in Fig. 9A. The non-
nuclear localization of the CB1R staining made it diﬃcult
to count the number of positive cells. Hence, in analogy
with our previous reports (Bianchetti et al., 2013), we
recorded the average ﬂuorescence intensity (AU) in dor-
sal, central and ventral regions (Fig. 9A, B). A signiﬁcant
fall in immunoﬂuorescence intensity was observed for the
central area after application of AM-251 for 24 h, suggest-
ing that main downregulation of CB1R expression was
topographically-localized to this region.
CB1R signaling following sustained application of
ligands
One principal eﬀector of CB1R activation in the central
nervous system is the depression of cAMP synthesis,
whereas CB1R block may be associated with a rise in
cAMP levels depending on the degree of constitutive
activity of CB1Rs (Howlett et al., 2004). We used this phe-
nomenon as a readout for the ability of AEA or AM-251 to
activate or inhibit cAMP formation either under basal con-
ditions or following Frsk (1 lM)-evoked activation of
adenylyl cyclase (Steﬀens et al., 2004). For this purpose,
we employed an ELISA-based assay with spinal cord
samples collected after 24 h in vitro with (or without) sub-
sequent application of Frsk for 30 min. Fig. 10A shows
that, under basal conditions, the cAMP levels at 24 h were
similar for sham or AM-251-treated spinal cords. A
signiﬁcant reduction was, however, observed after a
24-h application of AEA. Fig. 10A also shows that, on
AM-251-treated preparations, AEA (30 min) did not
depress basal cAMP.
Fig. 5. Changes in polysynaptic reﬂex response after AM-251 24-h treatment. (A) Sample recordings of control (left) and AM-251 24-h-treated
(right) preparations. (B) Bar graph indicating the signiﬁcant reduction in polysynaptic reﬂex response area after AM-251 24-h application, n= 19.
(C) Plot of decay time course of the polysynaptic reﬂex showing signiﬁcant change in AM-251-treated preparations compared with sham (same
spinal cords as in B). *P< 0.05.
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Fig. 10B shows that Frsk-stimulated cAMP to similar
levels in sham or AM-251-treated (24 h) preparations.
The outcome of AEA treatment (24 h) was diﬀerent as
the action of Frsk was signiﬁcantly decreased
(Fig. 10B). Furthermore, co-application (30 min) of AEA
together with Frsk to preparations previously treated for
24 h with AM-251 24 evoked a cAMP rise as much as in
sham preparations (Fig. 10B).
Eﬀects of AEA or AM-251 on network activity in older
spinal cords
The delayed eﬀects observed after a 24-h application of
CB1R ligands might have been actually due to ongoing
developmental maturation of this tissue even in the
in vitro condition. To assess this possibility, we recorded
responses taken acutely from P4 spinal cords in vitro.
As shown in Fig. 11A, ﬁctive locomotion induced by
NMDA and 5HT was observed with periodicity and
alternation similar to the values found at P0–P2. Table 2
summarizes the main characteristics of network eﬀects
at this postnatal age. When AM-251 or AEA was applied
for 3 h, no signiﬁcant alteration in any of these parameters
was observed with the notable exception of the number of
oscillations associated with DR stimulation during AM-251
application (Fig. 11B and Table 2).
DISCUSSION
The principal ﬁnding of the present report is the novel
observation that application of the CB1R antagonist AM-
251 (or the pharmacological analogue rimonabant)
triggered oﬀ a delayed (24 h) strong depression of
locomotor network activity in the rat spinal cord in vitro
despite modest changes in fast synaptic transmission.
Such a modulatory action showed a gradient of
neurodepression that was ﬁrst targeted to the
locomotor-like activity recruited by aﬀerent impulses.
Conversely, CB1R agonists evoked just moderate
depression of locomotor networks. These data have
implications for the prolonged use of CB1 R drugs
in vivo and are the ﬁrst electrophysiological description
of how mammalian locomotor circuits react to their
sustained administration.
CB1Rs in spinal networks
A large body of evidence shows that CB1Rs potently
modulate nociceptive signal processing in the dorsal
horn (Kato et al., 2012; Piomelli et al., 2014) by regulating
synaptic inhibition mediated by GABA and glutamatergic
synaptic excitation (Castillo et al., 2012; Katona and
Freund, 2012). These eﬀects are typically, though not
exclusively, exerted at presynaptic level via control of
neurotransmitter release and are usually observed within
a short time period. In this framework, CB1Rs are known
to inhibit the synthesis of cAMP, an important intracellular
regulator of ligand and voltage-gated channels (Howlett
et al., 2004). On the other hand, CB2 receptors are poorly
expressed by spinal neurons and appear to be mainly
associated to activated microglia after experimental
chronic inﬂammation (Burston et al., 2013).T
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Despite extensive studies carried out on the lamprey
spinal cord (El Manira and Kyriakatos, 2010) indicating
the modulatory role of CB1Rs on locomotor networks
(Kettunen et al., 2005), the involvement of CB1Rs in
mammalian locomotion remains unclear. While CB1R
activation globally reduces in vivo locomotion in mammals
(Lee et al., 2006; Bosier et al., 2010; Chaouloﬀ et al.,
2011; McLaughlin et al., 2013), the mechanisms underly-
ing this phenomenon are not readily resolved with motor
behavior experiments. It is, however, clear that, even after
a single injection of a CB1R agonist, decrease in locomo-
tion occurs rapidly (Di Marzo et al., 2000) and can persist
for many hours with concomitant changes in brain meta-
bolic activity (Whitlow et al., 2002). This issue seems
important because of the increasing focus on the use of
cannabinoid agonists to control chronic pain and spastic-
ity as demonstrated by recent clinical guidelines (Koppel
et al., 2014). Conversely, there is large interest in devel-
oping novel antagonists to suppress food craving or can-
nabis dependence (Borgelt et al., 2013) as the more
traditional CB1R blockers possess major neuropsychiatric
side eﬀects in man (Jones, 2008; Bifulco and Pisanti,
2009). None of these therapeutic targets are achieved
with short-term pharmacological treatments. Thus, the
present study sought to investigate how rat locomotor net-
works may react to sustained application of cannabinoid
agonists and antagonists.
Early eﬀects of cannabinoid drugs
Rather unexpectedly, we found that the CB1R agonist
AEA or the antagonist AM-251 had no signiﬁcant eﬀect
on synaptic transmission and network function despite
the fact that these receptors are widely expressed in the
rat spinal cord (Herkenham et al., 1991; Farquhar-Smith
et al., 2000). It is interesting to note that CB1Rs are devel-
opmentally regulated in so far that neonatal and young
preparations express them at higher level with full func-
tional activity (Kato et al., 2012; Galve-Roperh et al.,
2013). Furthermore, we observed similar results even
when recording from P4 preparations, a ﬁnding that made
unlikely that developmental changes occurring during the
long in vitro experiment were confounding our observa-
tions at P0–P2. Hence, it is not simple to attribute lack
of acute changes in synaptic transmission merely to
immaturity of CB1Rs in the neonatal rat spinal cord: in
fact, their immunohistochemical expression was readily
observed in the present study. Even the very large disin-
hibited bursts were not changed by AEA or AM-251 appli-
cation, suggesting that CB1Rs were not directly
contributing to the control of such events contrary to our
early expectation that they should perhaps be capable
of retrogradely aﬀecting synaptic release (Castillo et al.,
2012; Katona and Freund, 2012). These data led us to
actually query if CB1Rs had any functional activity in the
neonatal spinal cord. Thus, we investigated whether VR
depolarizations induced by transmitter agonists were
aﬀected by AEA and observed that GABA responses
were decreased by approximately 30%. Such VR
responses presumably included a broad contribution by
extrasynaptic and synaptic receptors distributed within
the wide spinal network and could not pinpoint the site
of GABA response modulation. Thus, while these data
could not per se clarify the mechanism of action of
CB1Rs in this preparation, they did show that such recep-
tors were functionally active (as conﬁrmed by studying
changes in cAMP concentrations) and that their acute
impact on glutamatergic receptors was minimal. The
depression of GABA responses by AEA accords with pre-
vious reports of CB1R-mediated inhibition of GABAergic
transmission in the rat dorsal horn (Jennings et al.,
2001; Pernı´a-Andrade et al., 2009).
We, therefore, examined the possibility that CB1Rs
had a subtler action involved in the maintenance and
modulation of important network activities besides any
rapid control over synaptic transmission. Indeed, a
potential role of these receptors was hinted by the fact
that sustained (P3 h) application of AM-251 signiﬁcantly
decreased the number of oscillations elicited by a train
of DR pulses even though the amplitude of mono and
polysynaptic reﬂexes was unchanged. In addition, lack
of changes in DR-DRPs conﬁrmed that DR impulse
conduction and primary aﬀerent depolarization were not
the origin of this depression. When we tried to wash out
this eﬀect and looked for any recovery one day later, we
actually observed further deterioration of locomotor
network function, suggesting that the former application
of AM-251 had set oﬀ a slow depression targeted to
locomotor circuits whose delayed consequences were
apparent 24 h later. There was, however, no neurotoxic
eﬀect. It is noteworthy that clearance of AM-251 from a
single administration in vivo requires just a few hours,
indicating that this drug is not an irreversible CB1R
antagonist (Liu et al., 2008). The present data do not con-
ﬂict with a former study showing reversible depression of
excitatory synaptic currents elicited by rather strong elec-
trical pulses in superﬁcial dorsal horn neurons of the adult
mouse spinal cord (Kato et al., 2012): in fact, our report is
based on responses elicited by weaker DR stimuli through
activation of a complex and extended circuitry that pre-
sumably could compensate any discrete deﬁcit in gluta-
matergic transmission detected by Kato et al. (2012) at
single-cell level in the superﬁcial dorsal horn laminae.
Delayed eﬀects of cannabinoid drugs
It is noteworthy that the present protocols to examine
delayed drug actions comprised full washout of the
previously applied agents. Hence, any observed change
was likely due to formerly developed phenomena. When
AM-251 was applied for 24 h, the locomotor depression
was very intense. Thus, oscillations induced by DR
stimuli were almost completely suppressed together with
a decrease in the area of single polysynaptic responses
(implying impaired synaptic integration at network level),
although the amplitude of the VR cumulative
depolarization was not signiﬁcantly altered. In line with
this ﬁnding, expression of chemically-triggered ﬁctive
locomotion became impossible in the majority of
preparations or very impaired in periodicity and cycle
amplitude in the rest. It was interesting that, when very
slow ﬁctive locomotor cycles remained, they preserved
alternation between ﬂexor and extensor motor pools,
suggestive of a deﬁcit in the operation of the generator
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clock rather than the pattern formation circuitry (McCrea
and Rybak, 2008). These observations were validated
by analogous results obtained with a 24-h application of
another CB1R antagonist, namely rimonabant, indicating
that the network depression was not a peculiar eﬀect by
AM-251, but it was probably a consequence of CB1R
block. Interestingly, a slow depression of locomotor net-
work function was also observed to gradually develop
over the ﬁrst few hours of CB1R antagonist application
to the lamprey spinal cord (Kettunen et al., 2005) even if
the underlying mechanism remains to be fully elucidated.
Close inspection of the eﬀects of AM-251 revealed
that there was a certain gradient of network sensitivity
to this blocker-evoked depression. In fact, oscillatory
cycles triggered by repeated aﬀerent impulses appeared
to be the most sensitive to AM-251, whereas
monosynaptic reﬂexes or DR-DRPs were always
unscathed. The periodicity of disinhibited bursting was
also decreased, yet never eliminated, indicating that
chronic block of CB1Rs decreased network excitability
even when GABAA and glycine receptors were
pharmacologically blocked. Although GABAergic
mechanisms responsible for DR-DRPs were unchanged,
this ﬁnding may simply reﬂect a rather limited role of
CB1Rs in this speciﬁc pathway, while their function
remains prevalent on laminae I-II neurons predominantly
involved in nociceptive processing (Kato et al., 2012).
The delayed eﬀects of CB1R agonism were
qualitatively similar to those arising from chronic block,
although quantitatively much less intense. Thus, only
the number of DR train-evoked oscillations was
diminished by a 24-h AEA, LY 2183240, or JZL 184
application. Interestingly, studies of rat locomotion
in vivo have actually reported that systemic injection of
either agonists or antagonists slowly depresses
locomotion (Ja¨rbe et al., 2006). This apparent paradox
might be explained if antagonists blocked CB1Rs and
agonists partially desensitize them (Howlett et al., 2004;
Martin et al., 2004) with delayed downstream eﬀects on
locomotor networks. Another possibility is that chronic
application of agonist or antagonist led to diﬀerential cou-
pling to G-proteins with distinct impact on neuronal
Fig. 6. Fictive locomotion changes after AEA or AM-251 24-h treatment. (A) Examples of electrically evoked ﬁctive locomotion in control (left), AEA-
treated (middle), or AM-251-treated (right) preparations. Note depression of oscillatory activity which is very intense after AM-251 treatment. (B)
Histograms showing the number of oscillations evoked by electrical stimulation is signiﬁcantly decreased in AEA- or AM-251-treated spinal cords;
n= 17, 19, respectively. (C) Examples of ﬁctive locomotion induced by NMDA and 5-HT in control (top), AEA-treated (middle), or AM-251-treated
(bottom) preparations. The original records depict the onset of ﬁctive locomotion that is also illustrated on a faster time scale taking the traces from
the records in the box. (D, E) Histograms plotting the peak amplitude of locomotor cycles (D) or cycle period (E) for sham (n= 15), AEA-(n= 16) or
AM-251-(n= 8) treated spinal cords. The AM-251 group comprises those preparations (8/19) in which chemically induced oscillations remained
after AM-251 prolonged treatment. In the latter case, a signiﬁcant fall in cycle amplitude and lengthening of period are observed. *P< 0.05,
***P< 0.001.
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activity (Childers and Deadwyler, 1996), or to CB1R
heteromerization with other membrane proteins possess-
ing certain properties (Hudson et al., 2010; Pertwee et al.,
2010). To further explore the canonical biochemical eﬀec-
tors of CB1R ligands, experiments on cAMP levels were
performed.
Assaying cAMP as readout of CB1R activity
The use of a speciﬁc signal transduction assay was
critical for the identiﬁcation of CB1Rs whose activation
was demonstrated to decrease cAMP (Howlett et al.,
2004). When the cAMP synthesis by synaptosomal
preparations is stimulated by the adenylyl cyclase activa-
tor Frsk, the maximal inhibition induced by AEA via native
CB1Rs is observed at 1–10 lM concentration and
amounts to about 25% fall in cAMP levels (Steﬀens
et al., 2005). It has, however, been repeatedly pointed
out that, while the pharmacology of cannabinoid-
inhibited adenylyl cyclase remains an essential property
for signal transduction studies, it is diﬃcult to directly
relate it to changes in integrated functions of neurobiolog-
ical systems and behavior (Childers and Deadwyler,
1996; Howlett et al., 2004). Thus, the present study
sought to employ the cAMP assay simply as a tool to ﬁnd
out if, after sustained application of CB1R agonist/antag-
onist, these receptors could still transduce such a bio-
chemical signal. Basal cAMP was signiﬁcantly lower
after a 24-h AEA application, suggesting that CB1Rs
remained at least partly operational following the agonist
persistent administration and that any desensitization
(Howlett et al., 2004; Martin et al., 2004) was incomplete.
Caution is, however, required to relate this observation to
any actual degree of CB1R desensitization, or downregu-
lation because of the complexity of intermediate pathways
(Katona and Freund, 2012; Piomelli, 2014). After applying
AM-251 for 24 h, there was no signiﬁcant change in basal
cAMP levels, indicating that cAMP synthesis was under
minimal constitutive control by CB1Rs. The Frsk-
stimulated large rise in cAMP was unaﬀected by
Fig. 7. Disinhibited bursts after 24 h of AEA or AM-251 application. (A) Examples of disinhibited burst recordings obtained from sham- (top), AEA-
treated (middle) or AM-251-treated (bottom) preparations. (B–D) Histograms showing the eﬀects by AEA or AM-251 on number of bursts in 20 min
(B), burst amplitude (C), and duration (D). Note the signiﬁcant reduction in number of bursts after AM-251 24-h treatment. n= 9, *P< 0.05.
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chronically-applied AM-251, yet depressed by AEA in an
AM-251-sensitive fashion. Thus, the present results may
suggest that CB1Rs, notwithstanding the agonist-
sustained application, remained at least partly functional
in terms of regulation of cAMP synthesis.
A number of investigations have clearly shown that
the actual concentration of cAMP has little impact on
locomotor activity because inhibitors of adenylyl cyclase
(Barrie`re et al., 2004), of cAMP-dependent protein
kinases (Parker et al., 1998), or of the cAMP-
metabolizing enzyme phosphodiesterase-4 (Heidemann
et al., 2014), have no eﬀect on spinal rhythmicity in vivo
or in vitro. Furthermore, the CB1R antagonism of the pre-
sent observations makes it unlikely that the depressant
eﬀects by exogenous AEA or endocannabinoids were
caused by AEA-mediated activation of TRPV1 spinal
receptors expressed by a subgroup of nociceptive aﬀer-
ents and capable of modulating mouse locomotor net-
works in biphasic fashion (Mandadi et al., 2009).
Furthermore, while the TRPV1 agonist capsaicin rapidly
facilitates ﬁctive locomotion and then depresses it within
minutes (Mandadi et al., 2009), we could never observe
a similar eﬀect with AEA (or related ligands) application.
A HYPOTHESIS ON THE ROLE OF CB1RS IN
THE RAT SPINAL CORD IN VITRO
The focus of the present study was on the action of
CB1Rs on locomotor networks of the rat spinal cord.
The most parsimonious interpretation of our data is that
CB1Rs were functional as demonstrated with their
inhibitory action on GABA VR depolarization and cAMP
synthesis. These experimental approaches are,
however, unsuitable to understand where these
receptors precisely acted because spinal homogenates
or summated network activity are, of course, not the
best tools to answer such a question. CB1
immunohistochemistry indicated their sparse distribution
in line with the minimal changes in synaptic or network
activity observed after short-term CB1
agonist/antagonist application. In fact, AM-251 did not
change basal cAMP levels suggesting that CB1Rs
Fig. 8. Histology of sham and 24-h AM-251-treated spinal cord preparations. (A) Schematic representation of the ROIs used for analysis. Dors,
dorsal horn; Cent, central region; Vent, ventral region. (B) Examples of sham- (top) and AM-251-treated (bottom) spinal cord cross sections stained
with DAPI in dorsal (left), central (middle) and ventral (right) regions. Scale bar = 10 lm. (C) Histograms showing that there is no change in percent
of pyknosis after AM-251 24-h treatment in comparison with sham in all the three regions. n= 9.
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possessed low constitutive activity and their action was
best demonstrated only when cAMP synthesis was
stimulated by Frsk. The role of CB1Rs clearly emerged
when they were pharmacologically manipulated for
many hours. In particular, after a 24- hblock, a
signiﬁcant downregulation appeared at the level of the
spinal central region that is critical for locomotor activity
generation (Grillner, 2003, 2006; Kiehn, 2006, 2011).
This phenomenon was functionally associated to severe
depression of ﬁctive locomotion. Thus, it is hypothesized
that CB1Rs stabilized the operational activity of the loco-
motor central pattern generator, an eﬀect reminiscent of
the slow regulatory role of CB1Rs in tuning neuronal net-
works (Kim and Alger, 2010).
Previous studies have shown that, in the brain and
spinal cord, CB1Rs are particularly important during the
prenatal stage to ensure correct axon guidance to
establish eﬀective synapses (Berghuis et al., 2007).
Furthermore, persistent block of CB1Rs with AM-251
drastically disrupts neuronal maps in the somatosensory
cortex (Li et al., 2009), outlining a distinct function of
CB1Rs in circuit stabilization. We propose that pharmaco-
logical inhibition of CB1Rs destabilized a critical subset of
synapses that are essential contributors to the locomotor
pattern generation. Future studies will be necessary to
identify the molecular pathways responsible for the
delayed loss of locomotor network function after AM-
251. This is likely to be a complex task because of the dif-
fuse multisegmental projections of primary aﬀerents to the
spinal cord (Kremer and Lev-Tov, 1997; Etlin et al., 2010)
and the widespread distribution of the locomotor central
pattern generator that demands at least three intact lum-
bar segments to express the locomotor cycles (Kiehn and
Kjaerulﬀ, 1998). Former evidence has indicated that
CB1Rs strongly control, in a time-dependent fashion,
locomotor activity in vivo by acting on multiple
Fig. 9. Changes in CB1R intensity after AM-251 24-h treatment. (A) Examples of immunostaining for CB1Rs in dorsal (left), central (middle) and
ventral (right) regions of sham (top) and AM-251 24-h-treated (bottom) preparations. Scale bar = 50 lm. (D) Bar diagram showing the diﬀerence in
CB1R immunoreactivity after AM-251 24-h treatment in all the three regions. Note the signiﬁcant reduction in CB1R intensity in central region of AM-
251-treated preparations. n= 12, *P< 0.05.
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Fig. 10. Eﬀects of AEA or AM-251 on basal and forskolin-induced cAMP levels. (A) Histograms showing the changes in basal cAMP levels after
AEA 24 h, AM-251 24 h or AM-251 24 h/AEA 30 min. Note the signiﬁcant reduction in basal cAMP levels after AEA 24-h treatment compared to
sham. (B) Bar graphs showing the eﬀects of AEA 24 h, AM-251 24 h or AM-251 24 h/AEA 30 min on forskolin- (1 lM; 30 min) induced cAMP levels.
Note the signiﬁcant decline of forskolin-induced cAMP levels after AEA 24-h treatment. Data are from duplicate experiments using 18 spinal cords.
*P< 0.05.
Fig. 11. Fictive locomotion changes in P4 spinal cord preparations after AEA or AM-251 3-h treatment. (A) Examples of ﬁctive locomotion induced
by NMDA and 5-HT in control (top left), AEA-treated (top right) or AM-251-treated (bottom) preparations. (B) Representative records of DR-evoked
oscillations in control (left), AEA (middle) and AM-251 (right) preparations. Note the slight depression of oscillations in the AM-251-treated
preparation.
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dopaminergic systems in the basal ganglia (Ginovart
et al., 2012): since in the isolated spinal cord preparation
this site of action was eliminated, the present work
demonstrated a site of action of CB1Rs on the locomotor
central pattern generator rather than on the motor behav-
ior, outlining a target for CB1R modulation on movement
generation in addition to its role in the origin and selection
of motor commands (Grillner et al., 1998).
CONCLUSIONS
The current results on the partial depression of oscillatory
cycles by CB1R agonism do not conﬂict with the
guidelines for using such an approach to treat spasticity
or chronic pain (Koppel et al., 2014). These syndromes
are likely to arise at the spinal level because a discrete
lesion had induced aberrant motor activity with hyper-
responsiveness to aﬀerent inputs (Dietz, 2010; D’Amico
et al., 2014). Our observations that CB1R agonism could
depress DR-evoked oscillations without aﬀecting the
intrinsic activity of the locomotor central pattern generator
or standard synaptic transmission are in line with a selec-
tive decrease in peripherally triggered hyper-reﬂexia and
hyperalgesia especially when supraspinal descending
control is damaged in neurological disease. Conversely,
the motor network depression induced by persistent
CB1R antagonism indicates this phenomenon as a further
potential side-eﬀect of chronic treatment with CB1R
antagonists like rimonabant that caused signiﬁcant
adverse eﬀects in a number of patients who then withdrew
from the clinical trial (Despre´s et al., 2005).
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A STUDY OF CANNABINOID-1 RECEPTORS DURING THE EARLY
PHASE OF EXCITOTOXIC DAMAGE TO RAT SPINAL LOCOMOTOR
NETWORKS IN VITRO
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Abstract—Endocannabinoids acting on cannabinoid-1
receptors (CB1Rs) are proposed to protect brain and spinal
neurons from excitotoxic damage. The ability to recover
from spinal cord injury (SCI), in which excitotoxicity is a
major player, is usually investigated at late times after mod-
ulation of CB1Rs whose role in the early phases of SCI
remains unclear. Using the rat spinal cord in vitro as a model
for studying SCI initial pathophysiology, we investigated if
agonists or antagonists of CB1Rs might aﬀect SCI induced
by the excitotoxic agent kainate (KA) within 24 h from a tran-
sient (1 h) application of this glutamate agonist. The CB1
agonist anandamide (AEA or pharmacological block of its
degradation) did not limit excitotoxic depolarization of
spinal networks: cyclic adenosine monophosphate (cAMP)
assay demonstrated that CB1Rs remained functional 24 h
later and similarly expressed among dead or survived cells.
Locomotor-like network activity recorded from ventral roots
could not recover with such treatments and was associated
with persistent depression of synaptic transmission.
Motoneurons, that are particularly vulnerable to KA,
were not protected by AEA. Application of
2-arachidonoylglycerol also did not attenuate the electro-
physiological and histological damage. The intensiﬁcation
of damage by the CB1 antagonist AM251 suggested that
endocannabinoids were operative after excitotoxic stimula-
tion, yet insuﬃcient to contrast it eﬃciently. The present
data indicate that the early phases of excitotoxic SCI could
not be arrested by pharmacologically exploiting the endo-
cannabinoid system, consistent with the notion that AEA
and its derivatives are more useful to treat late SCI phases.
 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
Key words: CB1, spinal cord injury, endocannabinoids,
kainate, ﬁctive locomotion, neuroprotection.
INTRODUCTION
Spinal cord injury (SCI) is a major health challenge that
currently occurs with an estimated annual incidence of
over 50 cases per million population with uncertain
recovery despite the fact that the primary lesion is often
incomplete (Singh et al., 2014; Jain et al., 2015). The
SCI process has a complex time course starting from
the initial insult and followed by a cascade of prolonged,
secondary injury events. The secondary injury process
includes early increase in the extracellular level of the
excitatory transmitter glutamate, i.e. the principal activator
of excitotoxicity that irreversibly damages spinal neurons
(Park et al., 2004; Oyinbo, 2011; Borgens and
Liu-Snyder, 2012). This death process is brought about
by over activity of glutamate receptors with subsequent
rise in intracellular Ca2+ that triggers formation of reactive
oxygen species, and inﬂammatory mediators which all
contribute to excitotoxicity, mitochondrial damage,
demyelination and neuronal and glial loss (Dumont
et al., 2001; Rowland et al., 2008; Fakhoury, 2015). It
is, therefore, important to identify the most suitable
targets to arrest the progression of the secondary lesion
and provide neuroprotection.
Since many years cannabis and its derivatives have
been used as an (un)conventional tool to treat pain and
spasticity that can appear after chronic SCI (Teasell
et al., 2010; Arevalo-Martin et al., 2016; Boadas-Vaello
et al., 2016). This approach is, however, not supported
by some animal studies indicating that inhibiting endo-
cannabinoids might ameliorate chronic pain (Toniolo
et al., 2014; Ueda et al., 2014). Furthermore, little is
known about any early role of cannabinoids and their
receptors (that in the central nervous system predomi-
nantly belong to the cannabinoid-1 receptor (CB1R) type;
Pertwee, 2005) in controlling the lesion process during the
ﬁrst few hours after acute spinal injury. Exploring this
issue is prompted by the fact that retrograde signaling
by endocannabinoids via downregulation of glutamate
release physiologically contributes to restrain excessive
excitation (Schlicker and Kathmann, 2001; Brown et al.,
2003; Monory et al., 2015) and by endocannabinoid-
modulation of postsynaptic N-methyl-D-aspartate (NMDA)
receptor traﬃcking (Sa´nchez-Bla´zquez et al., 2014).
http://dx.doi.org/10.1016/j.neuroscience.2016.07.021
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The endocannabinoid function is exerted via
activation of CB1Rs widely expressed in the spinal cord
of adult or neonatal rats (Farquhar-Smith et al., 2000;
Veeraraghavan and Nistri, 2015). Using an in vivo rat
SCI model, Garcia-Ovejero et al. (2009) have investi-
gated changes in the major endogenous cannabinoid
agonists anandamide (AEA) and 2-arachidonoylglycerol
(2-AG) and their receptor expression. Thus, levels of
AEA (and 2-AG) are increased a few hours after injury
with gradual return to basal level, while global CB1R
expression remains unchanged for the ﬁrst few days. It
remains, however, to be explored how changes in endo-
cannabinoid levels in this time interval might be related
to locomotor network activity, their neuroprotection, and
any region-speciﬁc damage.
To pursue this issue, we used an in vitro rat spinal
cord model of SCI in which rhythmic patterns (ﬁctive
locomotion) produced from the locomotor pattern
generator intrinsic to the spinal cord (Kiehn, 2006, 2016;
Grillner et al., 1998) can be electrophysiologically
recorded over the ﬁrst 24 h from injury and related to
the extent of tissue damage evoked by the glutamate ana-
log kainate (KA; Taccola et al., 2008; Kuzhandaivel et al.,
2011). One important feature of this paradigm is that tran-
sient application of KA (50 lM) reliably produces a
histologically-moderate lesion that destroys 12.5–23%
neurons in the central and dorsal gray matters plus a
more severe (50%) loss of motoneurons (Mazzone
et al., 2010). The consequence of such lesion is to bring
the locomotor network cells below the threshold for
‘‘minimal membership”, namely the size of the neuronal
circuitry capable of expressing alternating locomotor pat-
terns (Kuzhandaivel et al., 2011). Although it is diﬃcult to
establish the actual neuronal loss after human SCI, the
large majority of SCI cases are incomplete indicating sig-
niﬁcant neuronal and glial preservation (Sekhon and
Fehlings, 2001; Hillen et al., 2013) that, however, does
not enable recovery of locomotion as only <5% of these
patients will walk again (Dobkin and Havton, 2004). Thus,
moderate neuronal losses are translated into major deﬁcit
as observed in our model. In addition, our experimental
protocol replicates the clinical condition whereby intensive
care support is usually provided at the earliest possible
time to arrest lesion progression (Hillen et al., 2013).
In this context, the present study pursued several
aims: (1) To understand if enhancing the endogenous
levels of AEA might inhibit excitotoxicity by applying
LY2183240, a well-known pharmacological blocker of
the endocannabinoid inactivation mechanisms (cell
uptake and degradation by fatty acid amide hydrolase;
Alexander and Cravatt, 2006). (2) To study if the CB1Rs
remain functional to inhibit cAMP synthesis in the rat spinal
cord (Howlett et al., 2004; Veeraraghavan and Nistri,
2015) after the excitotoxic insult and how their cellular
expression might be altered. (3) To ﬁnd out if pharmaco-
logical activation (or block) of CB1Rs might improve the
outcome of KA-evoked neurotoxicity. This possibility was
pursued by applying exogenous AEA as the prototypic
CB1 agonist, its inverse agonist AM251 (Piomelli, 2005),
or 2-AG that possess stronger agonist activity on CB2 than
CB1 receptors (Di Marzo and De Petrocellis, 2012).
EXPERIMENTAL PROCEDURES
Spinal cord in vitro preparations
Isolated spinal cords were removed from neonatal
(0–2- day-old) Wistar rats under urethane anesthesia.
The experimental protocols were approved by the ethics
committee of the Scuola Internazionale Superiore di
Studi Avanzati and are in accordance with the current
European Union guidelines. A total of 119 animals were
used for the entire study. Details of animals in each
group are as follows: Sham= 21; KA = 21; LY = 4;
LY/KA + LY= 9; KA/LY = 10; AEA= 4; AEA/KA +
AEA= 10; KA/AEA = 14; AM/KA + AM= 3; KA/AM=
12; 2-AG/KA + 2-AG= 3; KA/2-AG= 8. All eﬀorts
were made during experiments to minimize the number
of animals and their suﬀering, and to observe the three
Rs objective. Isolated preparations were continuously
superfused at the rate of 7.5 ml min1 with standard
Kreb’s solution of the following composition (in mM):
113 NaCl, 4.5 KCl, 1 MgCl27H2O, 2 CaCl2, 1 NaH2PO4,
25 NaHCO3, 11 glucose, gassed with 95% O2 and 5%
CO2 (pH 7.4) at room temperature (Bracci et al., 1996;
Beato and Nistri, 1999; Taccola et al., 2008).
Experimental spinal injury model
The present study used a model of SCI in vitro based on
excitotoxic stimulation elicited by the potent glutamate
agonist KA (Taccola et al., 2008; Mazzone et al., 2010).
The rationale for this approach stems from the important
role of excitotoxicity in generating neuronal damage dur-
ing SCI (Park et al., 2004). Thus, the goal is trying to iden-
tify neuroprotective mechanisms directly related to the
nervous tissue without the complexity of vascular
changes or immune reactions. Furthermore, advantages
of the present model are the absence of general anesthe-
sia during the lesion in analogy to human clinical lesions
and the transient nature of the excitotoxic stimulation that
lasts for 1 h and is followed by sustained washout with
oxygenated Krebs solution: this procedure intends to
mimic the intensive care approach that aims at stabilizing
patients as soon as possible with correction of intervening
metabolic dysfunctions and any respiratory depression. It
is noteworthy that, despite the washout of KA, the large
decline of glutamate release (Mazzone and Nistri, 2011)
and the dissipation of network depolarization (Taccola
et al., 2008), the secondary damage progresses and
peaks within the ﬁrst few hours (Kuzhandaivel et al.,
2011) because neuronal losses are stabilized by 24 h
in vitro as indicated by long-term slice cultures
(Mazzone et al., 2013). During this early time frame, the
present model enables repeated testing of locomotor net-
work activity, a parameter not often investigated as clini-
cal reports simply indicate ‘‘spinal shock” as a condition
of temporary paralysis of locomotion (Dietz, 2010).
The present model has also some intrinsic limitations
because it relies on neonatal spinal cords that may have
responses somewhat diﬀerent from adult ones, although
it should be borne in mind that pediatric SCI are a
signiﬁcant percentage of all human SCI (Vogel et al.,
2012). Further limitations of this model are its
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time-restricted survival in vitro (usually two days) that pre-
cludes investigating delayed, important components of
SCI like neuroinﬂammation and scar-forming processes
that inﬂuence the lesion outcome. While temporary oxy-
gen/glucose deprivation mainly aﬀects spinal glia
(Taccola et al., 2008), the present excitotoxic model pref-
erentially damages neurons, especially motoneurons that
are rather vulnerable cells (Mazzone et al., 2010). Our
hypothesis is that, if signiﬁcant neuroprotection can be
observed during the early hours after the lesion, the
pathological late consequences can probably be strongly
decreased.
Protocols for experimental SCI and cannabinoid
ligand treatment
After testing normal locomotor patterns, excitotoxicity was
induced by bath applying KA (50 lM) for 1 h, followed by
washout in standard Kreb’s solution for 24 h. This protocol
was suﬃcient to evoke a standard lesion that was
suprathreshold to abolish locomotor function with
moderate histological damage (Mazzone et al., 2010).
Immediately after washout of KA, a group of preparations
were continuously treated with cannabinoid ligands
(LY2183240 3 lM or AEA 5 lM or 2-AG 2 lM or AM251
5 lM) for 24 h after which functional and histological
observations were done. The drug concentrations were
chosen in accordance with previous studies (Kettunen
et al., 2005; Eljaschewitsch et al., 2006; Gonzalez-Islas
et al., 2012; Iannotti et al., 2014). The canonical eﬀector
of CB1 receptor activity is inhibition of forskolin-
stimulated adenylyl cyclase that synthesizes cyclic ade-
nosine monophosphate (cAMP; Steﬀens et al., 2004).
The aforementioned drug application protocols were used
to explore the CB1 receptor activity at the end of the
experiment. In a few tests, we also investigated the out-
come of cannabinoid ligands (pre-applied for 30 min and
then applied together with KA) on KA-induced depolariza-
tion recorded from VRs. For the sake of comparison, all
experiments were run in parallel with sham preparations.
Electrophysiological recordings
DC-coupled recordings were performed in the lumbar
region (ventral L2 and L5) of isolated spinal
preparations as described in our previous studies
(Marchetti et al., 2001; Taccola et al., 2008) using a
DP-304 Diﬀerential ampliﬁer (Warner Instruments LLC,
Hamden, CT, USA). Reﬂex and locomotor-like discharges
(ﬁctive locomotion) were elicited by stimulating a dorsal
root (DR; usually L5) through a bipolar suction electrode
and recorded from ipsilateral and contralateral ventral
roots (VRs) at segmental level L2 and L5. In each prepa-
ration the smallest near threshold response elicited by
0.1 ms DR stimulation at low stimulus intensity was
recorded from the ipsilateral VR and was interpreted as
monosynaptic (Fulton and Walton, 1986; Marchetti
et al., 2001; Ostroumov et al., 2007). Polysynaptic
reﬂexes were evoked by stimulating the same DR with
intensity of three times the threshold. To study ﬁctive
locomotion (FL) consisting of alternated rhythmic VR
discharges (Marchetti et al., 2001; Taccola et al., 2008),
a train of 30 DR pulses (2–3 times the threshold) was
delivered while recording responses characterized by
cumulative depolarization with superimposed alternated
oscillations from at least 3 VRs. FL was also evoked by
bath applying NMDA (2–6 lM) and 5-hydroxytryptamine
(5-HT; 10 lM). Fictive locomotor parameters were the
amplitude of oscillations and their periodicity. Disinhibited
bursting elicited by blocking c-aminobutyric acid
(GABA)-A and glycine receptors by bicuculline (20 lM)
and strychnine (1 lM), respectively (Bracci et al., 1996),
was also monitored to assess the intrinsic network
excitability. Signals were acquired using pClamp version
9.2 at 20-kHz acquisition frequency (Molecular Devices,
Sunnyvale, CA, USA).
cAMP immunoassay
Full details of this assay based on inhibiton of cAMP
synthesis have recently been published (Veeraraghavan
and Nistri, 2015). Because basal cAMP levels are usually
low in the spinal cord and, upon CB1R activation, may go
even below the detection limit, we measured cAMP levels
stimulated by forskolin (Frsk) (1 lM for 30 min) in accor-
dance with standard methods (Howlett et al., 2004;
Steﬀens et al., 2004). All measurements were performed
on the second day in vitro. Brieﬂy, to study changes in
cAMP levels downstream of CB1 receptor activity, at the
end of the experimental protocols preparations were
immediately frozen in liquid nitrogen to block cAMP
degradation and processed in accordance with the manu-
facturers’ instructions (Abnova; http://www.abnova.com/
products/products_detail.asp?catalog_id=KA0886).
Fluorescence immunostaining procedure
After electrophysiological recordings, spinal cords were
ﬁxed in 4% paraformaldehyde, cryopreserved in 30%
sucrose and then sectioned to obtain 30- lm-thick
sections. The free-ﬂoating immuno-ﬂuorescence
procedure used fully validated antibodies and was
previously described by Taccola et al. (2008), Mazzone
et al. (2010) and Veeraraghavan and Nistri (2015). The
tissue staining with primary antibodies, namely, NeuN
(neuron-speciﬁc nuclear marker, 1:50 dilution, Chemicon,
Millipore MAB377), CB1R (1:50 dilution, CB1 (K-15) anti-
body, Santa Cruz Biotechnology, Inc.), or SMI-32 (anti-
neuroﬁlament H non-phosphorylated mouse mAb used
to stain spinal motoneurons; Mazzone et al., 2010;
1:200 dilution, Covance, SMI-32 R) was visualized using
the secondary ﬂuorescent Alexa Fluor 488 or 594 antibod-
ies (1:500 dilution, Invitrogen, Carlsbad, CA, USA). The
CB1R antibody was previously validated by us through
the use of the speciﬁc blocking peptide (Veeraraghavan
and Nistri, 2015). Sections were stained with a solution
(1 lg/ml) of 4,6-diamidino-2-phenylindole (DAPI) for
20 min to label cell nuclei and mounted on Superfrost Plus
slides (Menzel-Glaser, Braunschweig, Germany). The
immunostaining signal was analyzed by either Zeiss
Axioskop2 (Oberkochen, Germany) or confocal-Nikon
microscope. Each treatment group contained at least
three preparations and three lumbar slices were analyzed
for every spinal cord.
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Quantiﬁcation of pyknosis, NeuN positive cells,
motoneurons and CB1R staining
These procedures were recently described (Cifra et al.,
2012). In brief, to analyze the extent of neuronal damage,
the number of NeuN-positive cells was counted using the
ImageJ Cell counter (NIH, USA), while DAPI-positive
nuclei were counted with‘eCELLence’ software (Glance
Vision, Trieste, Italy). The following standard regions of
interest (ROI) were selected: 350  350 lm2 for dorsal
and central, 235  235 lm2 for ventral areas (Cifra
et al., 2012). The average percent values of nuclei with
condensed chromatin (taken as index of pyknosis) were
normalized with respect to the total number of nuclei
and compared between diﬀerent ROI and treatments.
Additionally, the number of SMI-32-positive cells located
in the ventral ROI and with somatic diameter >25 lm
were considered as motoneurons (Cifra et al., 2012)
and counted using ImageJ Cell counter. CB1R intensity
(AU) was quantiﬁed in a ‘‘volocity” workstation (Perkin
Elmer, London, UK) as previously described by
Veeraraghavan and Nistri (2015) using a manual ROI
constructed every time according to the size of the cell
in diﬀerent regions. From each experimental preparation
three slices were taken and from each slice three cells
were quantiﬁed and averaged.
Drugs
AEA, AM251, LY2183240, 2-AG, KA and NMDA were
obtained from Tocris (Bristol, UK), while bicuculline
methiodide was purchased from Abcam (Cambridge,
UK). 5-HT (5-hydroxytryptamine or serotonin) and
strychnine hydrochloride were purchased from Sigma
(Milan, Italy).
Data analysis
All parametric data are expressed as mean ± SEM, while
non parametric data are shown as median with whole
distribution. Statistical analysis was carried out with
SigmaStat 3.5 (Systat Software, Chicago, IL, USA) and
plotted in Sigmaplot 10. Depending on the parametric or
non-parametric distribution of the data indicated by the
software, the analysis was performed using either the
Student t-test or the one-way analysis of variance
followed by the Tukey test or the Kruskal–Wallis One-
Way Analysis of Variance on Ranks accompanied with
the Dunn’s method.
RESULTS
Eﬀect of cannabinoid ligands on KA induced
depolarization
Our previous studies show that 50 lM KA (1 h) evokes a
very large VR depolarization followed by irreversible
excitotoxic damage to the in vitro neonatal spinal
preparation (Mazzone et al., 2010; Nasrabady et al.,
2011). Furthermore, we have previously demonstrated
that acute application of the CB1R agonist AEA does
not change network depolarization evoked by AMPA or
NMDA (Veeraraghavan and Nistri, 2015). In the present
study we ﬁrst examined if CB1R pharmacological modula-
tion might change VR depolarization evoked by sustained
(1 h) KA superfusion: for this purpose we pre-applied
ligands for 30 min (to allow for drug equilibration within
the tissue) that were then continuously superfused
together with KA for 1 h. Fig. 1A shows examples of VR
depolarization induced by KA (see arrows) that was not
prevented by LY2183240 (3 lM), AEA (5 lM), 2-AG
(2 lM), or AM251 (5 lM). The bar graph of Fig. 1B indi-
cates that, on average, the mean KA depolarization pla-
teau was not changed by anyone of such treatments
(n= 9, n= 10, n= 3, or n= 3, respectively vs. KA;
n= 17).
Since CB1R activity did not appear to regulate the KA
depolarization from which spinal networks are known to
recover regardless the onset of later damage (Taccola
et al., 2008), we queried whether CB1R activity might
actually contrast the slowly developing evolution of sec-
ondary damage over the subsequent 24 h.
CB1R activity after KA treatment
In order to ﬁnd out if CB1Rs could modulate the
progression of excitotoxic lesions, it was ﬁrst necessary
to ﬁnd out if the spinal cord would still express
functional CB1R one day after KA application. Thus, we
examined whether, 24 h after KA application, CB1R
activity was present by measuring changes in cAMP
levels, because the chief target of CB1R is inhibition of
adenylyl cyclase (Howlett et al., 2004). We used forskolin
(1 lM; 30 min) to largely stimulate cAMP synthesis
(Steﬀens et al., 2004) in the rat spinal cord
(Veeraraghavan and Nistri, 2015) and veriﬁed how
CB1R ligands could aﬀect it. Fig. 2A shows basal cAMP
concentration in samples treated with KA did not signiﬁ-
cantly deviate (within 10% variation) from sham ones. A
signiﬁcant (P< 0.05) reduction in cAMP levels was, how-
ever, observed after LY 2183240 applied alone or after
KA washout (KA/LY). Likewise, AEA, applied either alone
or after KA (KA/AEA), signiﬁcantly decreased cAMP
(Fig. 2A; n= 4 in each treatment). These data suggest
that residual CB1R activity (expressed as inhibition of
cAMP synthesis) after KA application could be enhanced
by either blocking endocannabinoid degradation or by
AEA: this observation led us to examine the expression
pattern and electrophysiological correlates of these
phenomena.
Eﬀect of KA and cannabinoid ligand treatment on
CB1R expression
Many studies have shown that there is a change in
cannabinoid receptor intensity after neuropathic pain or
any excitotoxic insult to brain and spinal regions
(Mitrirattanakul et al., 2006; Garcia-Ovejero et al., 2009;
Miller and Devi, 2011). To ﬁnd out if excitotoxicity could
alter CB1R expression in the present spinal cord model,
we studied the CB1R immunohistochemical changes after
KA, KA/LY, KA/AEA or KA/AM treatments. Fig 2B shows
examples of CB1R expression after KA and CB1R
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ligands’ application in cross sections of the spinal cord,
indicating scattered damage that also comprised
motoneurons. To quantify the changes in CB1R expres-
sion followed by these protocols, individual (surviving/
pyknotic) cells were analyzed (as discussed in the
methods section). In the ventral region that is critical for
locomotor activity (Kiehn, 2016), there was no marked
diﬀerence in CB1R immunosignal compared to sham
spinal cords regardless whether we examined
non-pyknotic or pyknotic cells for any tested treatment
(Fig 3A–C). Conversely, in the dorsal region, the cells sur-
vived after KA or KA/AM treatment showed lower intensity
of CB1R expression (n= 11 or 12 spinal cords, respec-
tively; Fig 3A, B). In the survived cells of the central
region, CB1R intensity was greatly reduced by KA/AM
treatment (n= 12) in comparison with KA only treated
preparations (Fig 3B). KA/LY spinal cords showed an
increase in the CB1 receptor expression around the
pyknotic cells in the dorsal region (n= 6; Fig 3A, C).
These data suggest that, within the ﬁrst 24 h following
excitotoxic stimulation, there was a region-related change
in the CB1R expression.
CB1R modulation on synaptic reﬂexes after KA
mediated excitotoxicity
Our recent report has examined the eﬀects of sustained
application of AEA, LY2183240, 2-AG or AM251 on
synaptic transmission of rat spinal networks
(Veeraraghavan and Nistri, 2015). In the present study
we conﬁrmed that monosynaptic reﬂexes recorded from
VRs 24 h after KA application (1 h) were signiﬁcantly
depressed in their amplitude and area (Fig. 4A–C;
Mazzone et al., 2010). When LY2183240 or AM251 were
applied after KA wash (KA/LY n= 6, or KA/AM n= 11,
respectively), monosynaptic responses were further
decreased in amplitude and area in comparison to
KA-only treated preparations (n= 17; Fig 4A–C). The
polysynaptic reﬂex depression induced by KA remained
unchanged in amplitude by LY2183240 or AM251 appli-
cation (Fig 4D, E), while the decrease in the response
area was intensiﬁed (Fig 4F). A modest improvement in
the monosynaptic reﬂex area with no apparent change
in peak amplitude was observed in spinal cords treated
with AEA after KA washout (KA/AEA), while depression
of polysynaptic responses persisted (n= 10; Fig 4A–F).
Fig. 1. Eﬀect of cannabinoid ligands on KA-induced VR depolarization. (A) Examples of KA (50 lM)-evoked depolarization following pre-application
of cannabinoid ligands as indicated by vertical arrows. (B) Histograms show that the amplitude of the KA-evoked response is unchanged by
LY2183240 (3 lM; n= 9), AEA (5 lM; n= 10), 2-AG (2 lM; n= 3), or AM251 (5 lM; n= 3) compared to KA only treated preparations (n= 17;
data here are shown as mean ± SEM).
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In analogy, reﬂex parameters were not improved by 24-h
administration of 2-AG after KA. Monosynaptic amplitude
and area were 0.03 ± 0.01 mV and 3.61 ± 0.50 mV.ms,
respectively (n= 8), thus largely depressed with respect
to sham data (see Fig. 4). Likewise, polysynaptic ampli-
tude and area values were 0.37 ± 0.08 mV and 366.93
± 61.31 mV.ms, respectively (n= 8), results that
showed no improvement vs. sham data (cf. Fig. 4).
Eﬀect of CB1R modulation on network rhythmicity
after KA treatment
DR train-evoked VR oscillations typical of FL were
abolished by KA and not restored by LY2183240, AEA,
AM251 or 2-AG application (Fig 5A, B). The depression
in cumulative depolarization (and its area) induced by
KA treatment was not changed by AEA (KA/AEA,
n= 10 vs. KA, n= 17, respectively; Fig 5A–D),
whereas LY2183240 (KA/LY, n= 6), AM251 (KA/AM,
n= 11) or 2-AG (KA/2AG, n= 8) further increased it
(Fig. 5A, C). In analogy with these data, chemically
(NMDA plus 5-HT)-induced FL was suppressed by KA
treatment and was not rescued by anyone of the CB1R
ligands used. Sporadic, irregular VR bursts were
observed in a few preparations treated with KA (8/17),
KA/LY (2/6) and KA/AEA (6/10) with rather low
amplitude and variable periodicity (Fig 6A–C): this
observation conﬁrms that rhythmic networks were not
completely destroyed by KA, yet no FL recovery could
be produced by CB1R modulation. None of the KA/AM
treated preparations showed any burst like activity in
NMDA/5HT application (n= 11, Fig 6A). Furthermore,
only two out of eight preparations treated with 2-AG
after KA displayed low amplitude, sporadic oscillations
(Fig. 6A–C).
The intrinsic rhythmicity of spinal networks emerging
from pharmacological inhibition of GABA and glycinergic
transmission is a reliable index of the basic excitability
of these simpliﬁed circuits (Bracci et al., 1996).
KA-mediated excitotoxicity strongly scaled down the burst
frequency, amplitude and intraburst occurrence without
changing single burst duration (Fig 7A). These eﬀects
were mainly unchanged by LY2183240 or AEA applica-
tion after KA washout. Only burst duration was prolonged
by AM251 together with even lower burst frequency
(Fig. 7B, D).
Histological changes induced by KA and
cannabinoid ligand treatment
Lack of neuroprotection by LY2183240 or AEA despite
persistence of functional CB1R activity could simply
Fig. 2. Eﬀect of KA and cannabinoid ligands on CB1R activity and its expression. (A) Box plots illustrating the distribution of changes in induced
cAMP levels (expressed as % of sham samples). Data are shown as median with 25th and 75th quartile distribution. *P< 0.05, #P< 0.001
(Kruskal–Wallis one-way analysis of variance on ranks). (B) Examples of CB1R immunostaining of sham, KA or KA/cannabinoid ligands treated
preparations at low magniﬁcation (for experimental protocols see Methods). Scale bar = 100 lm.
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indicate that CB1Rs were not neuroprotective in this
model because their expression was inadequate in
regions strategic for locomotor function. This possibility
prompted us to look more closely at the regional
topography of the excitotoxic damage following
application of CB1R ligands (Fig. 8A).
Fig. 8B shows the distribution of pyknosis within
dorsal, central and ventral ROI after KA application with
or without subsequent administration of CB1R ligands.
As expected, the dorsal ROI was the most intensely
lesioned one because it contains the largest number of
neurons (Cifra et al., 2012). LY2183240, AEA or 2-AG
did not signiﬁcantly alter the pyknosis data in any ROI
compared to KA. However, when AM251 was applied
after KA, a threefold increase (P< 0.001) in the percent
of pyknotic cells was observed in the central ROI
(Fig. 8B), suggestive of a certain role of CB1R intrinsic
tone in modulating excitotoxicity.
Characterization of neuronal damage evoked by KA
and its changes after cannabinoid ligand treatment
Fig 9C summarizes the changes in the number of NeuN-
positive cells followed by KA and CB1R ligand treatments
in the dorsal and central region. The dorsal region had a
higher loss of neurons after KA treatment (around 20%).
It is known from previous studies that KA receptors are
predominantly present in the dorsal horn of the rat
spinal cord (To¨lle et al., 1993) and that excitotoxicity is pri-
marily directed to nerve cells (Kuzhandaivel et al., 2011).
None of the cannabinoid ligand treatments changed the
number of dorsal horn neurons compared to KA treatment
(Fig. 9A, C). KA/LY- or KA/2-AG-treated cords showed no
change in the number of neurons compared to KA in the
central region. Conversely, after KA/AEA application only
a minimal neuronal loss was observed in the central
region compared to KA-only treated preparations
(P< 0.05; Fig. 9B, C). AM251 treatment signiﬁcantly
Fig. 3. Analysis of single-cell CB1R expression after KA or KA/cannabinoid ligands. (A) Examples of CB1R immunoreactivity in dorsal, central and
ventral regions of spinal cords treated with KA or KA followed by cannabinoid ligands (for experimental protocols see Methods). Cell nuclei are
stained with DAPI. Scale bar = 10 lm. (B) Bar graphs showing changes of CB1R immunostaining (in AU values; mean ± SEM) in non-pyknotic
cells after KA (n= 11), KA/LY (n= 6), KA/AEA (n= 8) or KA/AM (n= 12) treatments compared to sham (n= 9) for the three indicated ROIs. (C)
Histograms showing the mean (± SEM) of CB1R intensity in pyknotic cells after KA, KA/LY, KA/AEA or KA/AM treatments. Number of spinal cords
as in (B). *P< 0.05, **P< 0.01, #P< 0.001 (pyknotic cells are indicated in arrows; one-way analysis of variance with Tukey test for pairwise
multiple comparison procedures).
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(P< 0.05) reduced the NeuN-positive cells in the central
region in accordance with pyknosis data shown in Fig. 8B.
Large SMI-32-positive neurons were counted in the ven-
tral region to determine changes in motoneuronal survival
after treatments with the same protocols shown above
(Fig. 10A, B). The number of motoneurons was halved
after KA treatment compared to sham and it was left
unchanged with any of the CB1R ligand application.
DISCUSSION
The present study demonstrated two substantive
outcomes after an excitotoxic insult to the rat spinal
cord: (1) Even 24 h later and despite the associated
neuronal loss, CB1R activity was well preserved, (2)
CB1R activity was probably an intrinsic defense
mechanism, yet its role was insuﬃcient to bring about
structural and functional protection of locomotor
networks even when enhanced by AEA, LY2183240 or
2-AG.
Early eﬀect of cannabinoid ligands on KA evoked
damage
The endocannabinoid system has been shown as a
promising therapeutic target for a spectrum of spinal
neurological diseases including multiple sclerosis,
spasticity, neuropathic pain, and SCI (Pacher et al.,
2006; Koppel et al., 2014). Endocannabinoids are
retrogradely released by strongly excited neurons to
depress further transmitter release in a negative feedback
process (Piomelli, 2014). In principle, this mechanism
might be expected to contrast the spinal lesion caused
by KA excitotoxicity associated with a large release of
endogenous glutamate (Mazzone and Nistri, 2011). On
the other hand, in hippocampal slices endogenous
cannabinoids are rapidly mobilized to the neuronal mem-
brane after KA receptor activation resulting in a decline
of GABA release (Lourenc¸o et al., 2011) which could per-
haps intensify any excitation-related damage. In fact, our
former data show early depression of GABA-mediated
responses by AEA in the rat spinal cord (Veeraraghavan
and Nistri, 2015). Within this context, the impact of
CB1R activation on spinal network responsiveness to KA
could not be predicted a priori. Hence, we studied whether
early block or activation of CB1Rs (for 30 min) should
aﬀect KA-induced depolarization, and whether sustained
manipulation of CB1R activity at later times might deter-
mine the outcome after the excitotoxic paradigm.
The present report indicates that AEA was not a
functional antagonist of KA because it could not contrast
the KA-induced network depolarization. Analogous
results were obtained after applying 2-AG.
Delayed CB1R modulation in a SCI model
Using an in vivo rat model of contusion SCI, Arevalo-
Martin et al. (2010, 2012) have shown that injection of
Fig. 4. Eﬀect of KA and cannabinoid ligands on DR-stimulation-evoked synaptic transmission after 24 h in vitro. Representative traces of
monosynaptic (A) and polysynaptic (D) reﬂex responses in sham, KA or KA/cannabinoid ligand treated preparations (for experimental protocols see
Methods). (B, C) Histograms showing the peak amplitude (B) and area (C) of monosynaptic responses after KA (n= 17), KA/LY (n= 6), KA/AEA
(n= 10) or KA/AM (n= 11) treated cords vs. sham (n= 17). (E, F) Bar graphs showing the changes in polysynaptic reﬂex amplitude (E) and area
(F) after various treatments as above (same preparations as in B, C). *P< 0.05, **P< 0.01, #P< 0.001 (All data are expressed in mean ± SEM;
one-way analysis of variance with Tukey test for pairwise multiple comparison procedures).
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the endocannabinoid agonist 2-AG 30 min after the
mechanical lesion exerts beneﬁcial eﬀects (persisting for
a few weeks) on the white matter lesion. Although the
extent of functional recovery was not reported in those
experiments, the data indicate that administration of a
mixed agonist like 2-AG, that can activate CB1 and CB2
receptors (Di Marzo and De Petrocellis, 2012), may
improve recovery when the target is primarily the spinal
white matter. Because our excitotoxic model targets pre-
dominantly neurons rather than glia (see review by
Kuzhandaivel et al. (2011), we did not observe neuropro-
tection by 2-AG. Tissue degradation of 2-AG into poten-
tially toxic metabolites (Sang et al., 2007) might have
contributed to the intensiﬁcation of the KA evoked func-
tional deﬁcit.
The speciﬁc role of CB1Rs, that are mainly expressed
by the spinal gray matter (Sideris et al., 2012), has been
investigated by Hong et al. (2015) who also used an
in vivo model of mouse SCI. In their study, daily adminis-
tration of a selective CB1R agonist improved spinal tissue
preservation and functional recovery after one or more
weeks with respect to the normal degree of spontaneous
recovery. These studies support a positive role of endo-
cannabinoids during the late injury stages probably by
modulating the neuroinﬂammatory process associated
with the complex SCI pathophysiology (Piomelli, 2005).
It remained, however, to be clariﬁed the impact of endo-
cannabinoids on neuronal numbers and the activity of
the locomotor CPG shortly after the primary lesion. This
issue was explored in the present report that inquired
whether delayed CB1R activation was still possible after
an excitotoxic insult and could provide functional and his-
tological neuroprotection during the ﬁrst 24 h. This
approach also stemmed from in vivo SCI reports showing
an early phase (4–24 h) of increased endocannabinoid
levels (Garcia-Ovejero et al., 2009; Arevalo-Martin et al.,
2012).
An excitotoxic insult may cause not only cell death, but
also a compensatory mechanism in surviving cells whose
resistance may depend on their receptor expression
ability (Friedman et al., 1994). In this context we studied
the CB1R function in terms of cAMP inhibition (Howlett
et al., 2004) that was clearly observed with application
of AEA or LY2183240 one day after KA treatment. This
result was validated by the CB1R expression proﬁle in
both pyknotic and non-pyknotic cells. Although the
intensity of immunoﬂuorescence signal even at single-
cell level is not an absolute index of receptor expression
Fig. 5. Changes in DR train-evoked VR responses after 24 h in vitro. (A) Examples of ﬁctive locomotion evoked by DR train in sham (top left), KA
(top right), KA/LY (middle left), KA/AEA (middle right), KA/2-AG (bottom left) or KA/AM (bottom right). For experimental protocols see Methods. (B)
Histograms showing the very intense depression of oscillations in the same spinal cords shown in Fig. 4. (C) Bar graphs indicating the decline in the
amplitude of cumulative depolarization after KA and KA/cannabinoid ligand treatments. (D) Plots showing the fall in area of the FL after the same
treatments as in B, C. KA/LY, KA/2-AG (n= 8) and KA/AM treated cords showed large depression in area. *P< 0.05, #P< 0.001 (mean ± SEM;
one-way analysis of variance with Tukey test for pairwise multiple comparison procedures).
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strength, the present data did not indicate a large deﬁcit in
CB1Rs.
Impact of CB1Rs on cell survival in a model of SCI
Enhancing CB1R activity with AEA or LY2183240 had
diﬀerential consequences on cell survival depending on
the spinal ROI examined. Thus, in the dorsal ROI that
contains the largest number of neurons (Cifra et al.,
2012), the CB1R expression was the lowest and their acti-
vation had no or slight consequence for neuronal survival.
The central ROI expressed stronger CB1R immunoreac-
tivity, signiﬁcant (though not complete) neuroprotection
by AEA and larger damage when CB1Rs were pharmaco-
logically inhibited. The ventral ROI inclusive of motoneu-
rons showed large CB1R expression, poor
neuroprotection and particularly severe loss of motoneu-
rons that could not be altered by endocannabinoids.
These results suggest that there was no straightforward
relation between topography of CB1R expression and
neuronal resilience to insult. Immaturity of the CB1R sys-
tem was unlikely to account for this neuroprotective failure
because endocannabinoids are neuroprotective against
excitotoxicity by KA applied to neonatal rat brain
(Ferna´ndez-Lo´pez et al., 2010). Thus, the functional con-
sequences of the present data were explored with electro-
physiological recording 24 h after applying KA.
Electrophysiological characteristics of locomotor
networks after excitotoxic stimulation
Following application of KA, the rather modest
improvement in spinal reﬂexes evoked by AEA was not
translated into recovery of FL elicited by either DR
stimulus trains or NMDA plus 5-HT. Although previous
experiments have shown that AEA can partially depress
VR oscillations evoked by DR stimuli (Veeraraghavan
and Nistri, 2015), in the present study the modest depres-
sant action by AEA did not appear to be additive to the
strong depression by KA, perhaps suggesting that the
Fig. 6. Expression of ﬁctive locomotion evoked by NMDA plus 5-HT after 24 h in vitro. (A) Examples of onset and maintenance of ﬁctive locomotor
patterns in sham, KA or KA/cannabinoid ligands treated spinal cords (for experimental protocols see Methods). Note the VR alternating rhythmic
activity evoked by chemicals is disrupted by KA alone or followed by cannabinoid ligands treatment when compared to sham. Boxed sections show
at faster time speed the typical patterns of ﬁctive locomotion. (B) Bar graphs showing the signiﬁcant depression of peak amplitude of few bursts seen
after KA, KA/LY, KA/2-AG or KA/AEA treatments compared to sham. (C) Histograms indicating the periodicity of the sparse oscillatory cycles
detectable after KA and cannabinoids treatment. #P< 0.001 (mean ± SEM; one-way analysis of variance with Tukey test for pairwise multiple
comparison procedures). Full details are in Figs. 4 and 5 legends.
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Fig. 7. Intrinsic rhythmicity of spinal cords following KA and cannabinoid ligands’ treatment. (A) Examples of disinhibited bursts induced by inhibiting
GABA and glycinergic transmission with bicuculline and strychnine (for experimental protocols see Methods) after 24 h in vitro. (B) Bar graphs
showing signiﬁcant decrease in number of bursts (in 20 min observation time) after KA (n= 13), KA/LY (n= 5), KA/AEA (n= 9) or KA/AM
(n= 10) compared to sham (n= 15). (C) Histograms indicating the signiﬁcant reduction in peak amplitude after various treatments compared to
sham. (D) Bar graphs indicating changes in single burst duration after KA and cannabinoid ligand treatments compared to sham. (E) Histograms
showing signiﬁcant reduction in the number of fast oscillations within each burst after KA, KA/LY or KA/AEA treatments. **P< 0.01, #P< 0.001
(mean ± SEM; one-way analysis of variance with Tukey test for pairwise multiple comparison procedures).
Fig. 8. Histological changes induced by KA or KA/cannabinoid ligand treatments after 24 h in vitro. (A) Schematic representation of the dorsal,
central and ventral ROIs taken for analysis. (B) Box plots showing the percent of pyknotic nuclei after KA (n= 11), KA/LY (n= 6), KA/AEA
(n= 10), KA/2-AG (n= 5) or KA/AM (n= 12) treatments compared to sham (n= 8) in each region. A rather strong increment is observed as
signiﬁcant in the central ROI after KA/AM. *P< 0.05, **P< 0.01, #P< 0.001 (Median and quartile distribution of all the data sets are shown;
Kruskal–Wallis one-way analysis of variance on ranks).
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neuronal pathways depressed by AEA had been
destroyed by KA. While the mechanism responsible for
this occlusion remains unclear, the main implication is that
AEA could not ameliorate this neurotoxic eﬀect. In certain
protocols like the use of LY2183240 with the aim of boost-
ing the extracellular concentration of AEA, further deterio-
ration of electrophysiological responses became
apparent. This result was consistent with the depressed
network activity elicited by LY2183240 applied for 24 h
(Veeraraghavan and Nistri, 2015) and might be due to
alterations in the endogenous level of glutamate
(Gonzalez-Islas et al., 2012). FL elicited by DR trains
was more severely depressed than the one induced by
NMDA plus 5HT. In the latter, few sporadic cycles
appeared probably indicating that the severity of the exci-
totoxic damage was not very large, yet capable of sup-
pressing locomotor generation. Thus, bath-applied
neurochemicals that are expected to excite a broader
network that electrical pulses to a single DR can do,
could apparently stimulate fragmentary elements of the
locomotor program without reviving a full network output.
The 2-day limit of in vitro survival of our preparation did
not allow studying whether these primitive oscillatory
components could be reorganized into locomotor patterns
at later times.
The central region of the spinal cord is believed to
contain the principal neural elements critical for
generating locomotion (Kiehn, 2006). One might therefore
expect that even relatively small changes in neuronal
numbers can profoundly impact on the operation of these
networks (Kuzhandaivel et al., 2011). Although AEA
applied after KA almost restored neuronal numbers in this
ROI, FL did not return. It is also noteworthy that the intrin-
sic rhythmicity observed as disinhibited bursting was also
irreversibly depressed. We propose that one major con-
tributor to this functional deﬁcit was the strong damage
to motoneurons unmitigated by either AEA or
LY2183240. Because motoneurons are thought to be
not only the output elements of the locomotor networks
but also to actively contribute to rhythm generation
Fig. 9. Changes in neuronal numbers (identiﬁed with NeuN positivity) induced by KA or KA/cannabinoid ligand treatments after 24 h in vitro. (A, B)
show examples of neuronal distribution in dorsal or central ROIs, respectively. Data pertain to treatment with KA (n= 11), KA/LY (n= 3), KA/AEA
(n= 9), KA/2-AG (n= 5) or KA/AM (n= 12) and are compared to sham (n= 9). (C) Summarizes neuronal numbers after the treatments indicated
above. *P< 0.05, #P< 0.001 (mean ± SEM; one-way analysis of variance with Tukey test for pairwise multiple comparison procedures).
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(Tresch and Kiehn, 2000), our proposal is that loss of
motoneurons was a critical phenomenon underlying lack
of locomotor network activity. Thus, attempts to repair
the damaged networks become a desirable goal
(Bradbury and McMahon, 2006).
The mixed CB1R and CB2R agonist 2-AG applied
after the excitotoxic stimulation also proved to be
ineﬀective to neuroprotect locomotor network activity
and neuronal numbers in the rat spinal cord in vitro,
suggesting that even encompassing CB2R activation did
not confer additional amelioration. We propose that
activation of endocannabinoid systems might be
beneﬁcial with respect to the late phases evolving from
the primary lesion when neuroinﬂammatory processes
become important to determine the lesion outcome
(Park et al., 2004; Oyinbo, 2011).
Our current data do not exclude some mitigation of KA
neurotoxicity by local endocannabinoid release because
the functional and morphological damage was strongly
enhanced by applying the CB1R antagonist AM251.
Interestingly, damage intensiﬁcation was detected when
the antagonist was applied after KA washout,
suggesting that endocannabinoid release perhaps
continued after the ﬁrst stage of acute excitotoxicity,
although it was inadequate to arrest subsequent damage.
CONCLUSIONS
It seems likely that the CB1R activity developing in the
aftermath of the KA insult was partially neuroprotective.
Since CB1Rs were probably nearly saturated by
endogenous ligands in this pathological condition, any
further increase in CB1R activity with an exogenous
agonist would be ineﬀective. On the other hand,
inhibiting CB1Rs with AM251 could result in the loss of
a naturally occurring protective mechanism as
demonstrated by the present experiments.
This scenario indicates that, despite reports that in the
rat brain CB1R agonists reduce short-term mitochondrial
dysfunction and oxidative stress after excitotoxicity
Fig. 10. Eﬀect of KA and cannabinoid ligand treatment on motoneurons after 24 h in vitro. (A) Examples of large ventral horn neurons stained with
SMI-32 and identiﬁed as motoneurons following the experimental protocols indicated in Methods. (B) Histograms quantify the number of
motoneurons in the ventral ROI following various treatments. Sham (n= 4), KA (n= 7), KA/LY (n= 3), KA/AEA (n= 3), KA/2-AG (n= 5) and KA/
AM (n= 7) spinal cords. Cannabinoid ligands do not change the large fall in motoneuron number evoked by KA. #P< 0.001 (mean ± SEM; one-
way analysis of variance with Tukey test for pairwise multiple comparison procedures).
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(Rangel-Lo´pez et al., 2015) and minimized matrix metallo-
proteinase (MMP) activity with consequently minimal cell
loss after SCI (Hong et al., 2015), spinal networks rely
only partially on their endocannabinoid system to contain
early excitotoxic damage. Even the observed small neu-
ronal losses in the central region, that is important for
rhythm generation, may bring the locomotor network
below the threshold value for network membership ade-
quate to support such a coordinated and complex function
(Kuzhandaivel et al., 2011). This situation is likely to be
aggravated by the motoneuron loss.
The beneﬁcial eﬀects of CB1R activity may be better
expressed at later times when a complex series of
cellular events including activation of microglia and
gliosis are called upon to transform the acute lesion into
a chronic condition (Are´valo-Martı´n et al., 2003; Pacher
et al., 2006). During such a phase, spasticity and chronic
pain may also beneﬁt from cannabinoids (Boadas-Vaello
et al., 2016) as supported by recently issued clinical
guidelines (Koppel et al., 2014) and by experimental stud-
ies indicating that hypoactivity of the spinal cannabinoid
system results in NMDA-dependent hyperalgesia
(Richardson et al., 1998).
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Highlights 
 
 ASIC channels are nonselective pores activated by mild acidification and modulating 
neuronal function 
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 Expression of ASIC channels by mouse spinal cord was increased after a borderline 
excitotoxic stimulation 
 ASIC pharmacological blockers or the ASIC1a knockout phenotype intensified 
excitotoxicity 
 Electrophysiological network oscillations were suppressed by mild excitotoxic stimuli 
followed with ASIC block 
 ASIC activity was an unexpected controller of neurotoxicity to restrain spinal network 
damage  
 
 
 
 
 
 
 
 
Abstract 
In the spinal cord high extracellular glutamate evokes excitotoxic damage with neuronal loss and 
severe locomotor impairment. During the cell dysfunction process, extracellular pH becomes 
acid and may activate acid-sensing ion channels (ASICs) thought to be important contributors to 
neurodegenerative pathologies. Our previous studies have shown that transient application of the 
glutamate analogue kainate (KA) evokes delayed excitotoxic death of spinal neurons, while 
white matter is mainly spared. The present goal was to enquire if ASIC channels modulated KA 
damage in relation to locomotor network function and cell death. Mouse spinal cord slices were 
treated with KA (0.01 or 0.1 mM) for 1 h, and then washed out for 24 h prior to analysis. RT-
PCR results showed that KA (at 0.01 mM concentration that is near-threshold for damage) 
increased mRNA expression of ASIC1a, ASIC1b, ASIC2 and ASIC3, an effect reversed by the 
ASIC inhibitor 4',6-diamidino-2-phenylindole (DAPI). A KA neurotoxic dose (0.1 mM) reduced 
ASIC1a and ASIC2 expression. Cell viability assays demonstrated KA-induced large damage in 
spinal slices from mice with ASIC1a gene ablation. Likewise, immunohistochemistry indicated 
significant neuronal loss when KA was followed by the ASIC inhibitors DAPI or amiloride. 
Electrophysiological recording from ventral roots of isolated spinal cords showed that alternating 
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oscillatory cycles were slowed down by 0.01 mM KA, and intensely inhibited by subsequently 
applied DAPI or amiloride. Our data suggest that early rise in ASIC expression and function 
counteracted deleterious effects on spinal networks by raising the excitotoxicity threshold, a 
result with potential implications for improving neuroprotection. 
 
Keywords: pH; acid sensing ion channels (ASICs); neuroprotection; kainic acid; spinal cord 
injury; fictive locomotion. 
 
Abbreviations 
ANOVA, analysis of variance; ASICs, Acid-sensing ion channels; AU, arbitrary unit; DAPI, 
4’,6-diamidino-2-phenylindole; DIV, days in vitro; DME/HIGH, Dulbecco’s modified Eagle’s 
medium high glucose; DR, dorsal root; FCS, fetal calf serum; KA, kainate; NGF, nerve growth 
factor; NeuN, neuronal specific nuclear protein; PBS, phosphate-buffered saline; PI, propidium 
iodide; S100β, astroglial calcium-binding protein S100 β; SCI, spinal cord injury; SEM, standard 
error of the mean; VR, ventral root. 
 
 
Introduction 
Spinal cord injury (SCI) is a devastating event marked by a series of cellular and molecular 
mechanisms that promote or contrast neuronal death and loss of locomotor activity in a process 
slowly developing after the primary lesion (Borgens and Liu-Snyder, 2012; Anwar et al., 2016). 
During this dynamic disturbance it is likely that neuronal acid homeostasis needs tight control to 
avoid aggravating the pathophysiological outcome (Ruffin et al., 2014). Acid pH fluctuations at 
synaptic (and perisynaptic) level may originate, at least in part, from the high proton content of 
synaptic vesicles (Sinning and Hübner, 2013) during exaggerated synaptic transmission as well 
as lesion-evoked neuronal disruption. Acidosis has been recently demonstrated to be a Janus-like 
process that may lead, on the one hand, to hyperexcitability due to dysregulation of cortical 
GABAergic neurons and alterations in glutamate re-uptake by astrocytes (Huang et al., 2015a), 
or to inhibition of glutamate receptors to curtail excessive excitation (Giffard et al., 1990; Tang 
et al., 1990). Furthermore, several types of voltage or ligand gated channels are modulated by pH 
with complex impact on neuronal excitability (Holzer, 2009), for instance activation of certain 
background K
+
 conductances by acid pH can stabilize the resting membrane potential and 
depress excitability (Ma et al., 2012). 
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In addition to classical modulation of synaptic transmission by pH, more recent targets of 
protons have been identified as a subpopulation of membrane channels termed ASICs (Gründer 
and Pusch, 2015; Boscardin et al., 2016). ASIC channels are proton-gated, non-selective cationic 
channels belonging to the degenerin epithelial sodium channel superfamily (Osmakov et al., 
2014). ASIC channels are activated when pH falls below 7 and generate a transient inward 
current that rapidly fades to a shallow, persistent current potentially suitable to induce longterm 
effects on neurons (Alexander et al., 2011; Osmakov et al., 2014). Recent studies have proposed 
that activation of ASICs, particularly the ASIC1a subtype that mediates Na
+
, K
+
 and Ca
2+
 
transmembrane flow (Yang and Palmer, 2014), plays a critical role in neuronal injury associated 
with neurological disorders such as brain ischemia (Krishtal, 2003), multiple sclerosis (Arun et 
al., 2013), and spinal cord lesion (Hu et al., 2011). Furthermore, ASIC1a channels are important 
mediators of aberrant plasticity of AMPA receptor-mediated synapses in the hippocampus 
following transient anoxia (Quintana et al., 2015). The elucidation of the acidosis mechanism 
involvement in acute SCI remains, however, to be clarified. Our previous studies were focused 
on exploiting a lesion model based on transient excitotoxic stress as the trigger mechanism for 
delayed damage of the spinal cord (Taccola et al., 2008; Mazzone et al., 2010; Mazzone and 
Nistri, 2011a). This approach stems from the notion that excitotoxicity (due to temporary, large 
release of glutamate) is critical for lesion amplification and severity (Oyinbo, 2011; Borgens and 
Liu-Snyder, 2012), and that, in a clinical setting, the associated metabolic impairment is 
promptly corrected with intensive care treatment (Park et al., 2004; Dietz, 2010). This model, 
based on the neonatal rodent isolated spinal cord and organotypic spinal slices, offers an 
advantageous device to test preclinical approaches to neuroprotection because excitotoxicity 
(evoked by the glutamate analogue kainate, KA) destroys neurons with only modest white matter 
damage (Taccola et al., 2008; Mazzone et al., 2010; Mazzone and Nistri, 2011a). The damage is 
produced without intervening changes in blood pressure or general metabolism, thus providing a 
platform for testing proof of principle of direct neuroprotection at central level. The aim of the 
present study was to understand whether ASIC channel activity might have a beneficial or 
negative effect on the outcome of excitotoxicity studied 24 h after the primary insult and 
investigated with histological and electrophysiological methods. In particular, we wished to 
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explore if modulation by ASIC channels might transform a near-threshold neurotoxic action of 
KA into a more damaging one in terms of histology and function.  
Experiments were carried out with mouse spinal cord preparations, using wild type or ASIC1a 
knockout mice (Price et al., 2001; Wemmie et al., 2002), and were also performed with ASIC 
channel inhibitors like DAPI (Chen et al., 2010) and amiloride (Alexander et al., 2011; Leng et 
al., 2016) even if such drugs may exert additional effects on the nervous system. 
 
Materials and Methods 
 
Choice of spinal preparation 
The present study used mouse spinal cord tissue for three preparations in vitro: organotypic 
slices, acute spinal cord slices and the isolated spinal cord. Because of the ease of accessibility 
and positioning of the electrochemical biosensor, the organotypic slices were used for measuring 
glutamate release and pH changes plus correlated tests of neuronal survival and gene expression 
(Mazzone and Nistri, 2011b). Acute spinal slices were employed for evaluating the local 
distribution of neurotoxicity assessed with fluorescence changes due to intracellular 
accumulation of propidium iodide (PI) in topographically-intact sub-regions and laminae to 
which PI could be readily distributed via bath-application. For monitoring delayed changes in 
neuronal survival and network activity, we used the isolated spinal cord preparation that requires 
several intact segments to express coordinated alternating rhythmic discharges (Kjaerulff and 
Kiehn, 1996) investigated electrophysiologically (Taccola et al., 2008). This approach enabled us 
to examine the issue of neurotoxicity from various research angles converging onto the same 
spinal networks (Mazzone et al., 2010; Cifra et al., 2012). 
Thoracolumbar spinal cord preparations were isolated from neonatal C57BL/6J mouse (3 days 
old). The experiments were conducted  with the approval from the Scuola Internazionale 
Superiore di Studi Avanzati (Trieste) Ethical Committee, in accordance with the National 
Institutes of Health (NIH) guidelines and the Italian act D.Lgs. 27/1/92 n. 116 (implementing the 
European Community directives n. 86/609 and 93/88). The experiments performed in Argentina 
were carried out according to National guidelines and approved by local Ethical Committees, 
Comisión Institucional para el Cuidado y Uso de Animales de Laboratorio (CICUAL, FCEN-
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UBA, act C.D. Nº 3141/11, protocol Nº 42). A total of 103 animals were used for the 
immunohistochemistry and functional analysis. Details of animal numbers in each group are as 
follows: sham = 19; KA = 22; KA/DAPI = 13; KA/amiloride = 27; DAPI = 9; amiloride = 13. 
All efforts were aimed at minimizing animal use and suffering. Spinal cords were continuously 
superfused in a recording chamber with Krebs’ solution of the following composition (in mM): 
NaCl, 113; KCl, 4.5; MgCl2.7H2O, 1; CaCl2, 2; NaH2PO4, 1; NaHCO3, 25; glucose, 11; gassed 
with 95% O2 5% CO2; pH 7.4 at room temperature. All details about laboratory procedures have 
been previously published and the experimental setup has been fully reported (Taccola et al., 
2008). Drugs were dissolved in Krebs solution and bath applied at the concentrations indicated in 
the text. 
Spinal cord organotypic slice cultures were prepared from pregnant C57BL/6J mouse, at 13 days 
of gestation, in accordance with our standard procedure as previously reported (Mazzone et al., 
2010; Cifra et al., 2012). This study comprised 6 series of different cultures, each one yielding, 
on average, 40 slices for immunohistochemistry, gene expression and electrochemical release.
 
Briefly, culture slices were grown in a medium containing 82 % Dulbecco’s Modified Eagle 
medium (DME/HIGH; osmolarity 300 mOsm, pH 7.35, “complete medium”), 8 % sterile water 
for tissue culture, 10 % foetal bovine serum (FBS Invitrogen, Carlsbad, CA, USA), 5 ng/ml 
nerve growth factor (NGF; Alomone Laboratories; Jerusalem, Israel), and maintained in culture 
for 22 days in vitro (DIV) in accordance with standard procedures (Gahwiler, 1981; Mazzone et 
al., 2010). DME/HIGH, penicillin and streptomycin were purchased from Euroclone 
(Paignton,UK), chicken plasma was from Rockland Immunochemicals (Gilbertsville, PA, USA), 
thrombin was from Merck KGaA (Darmstadt, Germany). KA was purchased from Ascent 
Scientific (Weston-Supermare, UK). Unless otherwise indicated, other reagents were purchased 
from Sigma-Aldrich (Milan, Italy and Buenos Aires, Argentina).  
 
Protocol for spinal cord excitotoxic injury 
Excitototoxicity was induced by applying KA for 1 h (10 µM or 100 µM) dissolved in Krebs’ 
solution for isolated in vitro spinal preparations, or complete culture medium for organotypic 
cultures, and then washed out to induce a minimal to moderate injury (Mazzone et al., 2010). 4', 
6-Diamidino-2-phenylindole (DAPI, Sigma-Aldrich, 3.5 µM) (Chen et al., 2010) or amiloride 
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(Sigma-Aldrich, 100 µM) (Chen et al., 2010) was administered for 24 h after KA washout. 
Following KA washout, cultures were used for mRNA RT-PCR analysis, electrophysiological 
recordings and/or immunohistochemistry studies. Each experiment contained untreated 
preparations (sham) that were maintained for the same time and subjected to the same 
experimental procedures. 
 
Electrochemical Release  
Electrochemical biosensors (Sarissa Biomedical Ltd, Coventry, UK) were used in accordance 
with our previous reports (Mazzone and Nistri, 2011b; Mazzone et al., 2013). On-line records 
were integrated with a potentiostat (Pinnacle Technology Inc., Lawrence, KS, USA) and 
analysed off-line with PAL software (V1.6.7; Pinnacle Technology Inc.). Thus, we employed 
glutamate and null biosensors placed at each side of the ventral fissure (Fig. 1 A). The current 
generated by released glutamate was monitored with the glutamate-sensing electrode, while the 
null electrode was used for recording the background current known to be directly proportional 
to the extracellular pH change (Llaudet et al., 2005; Robinson et al., 2008). Hence, as previously 
demonstrated (Llaudet et al., 2005), in control solution the null electrode current linearly grew in 
relation to test acidification of the medium within the 5.8-7.4 pH range (see linear plot in Fig. 1 
B with data fitted by the equation y = -0.06626x + 0.486, R² = 0.9933, n=6, p≤ 0.05, t-test from 
7.4 pH). Thus, a calibration curve for the null sensor was obtained by using different basal 
solutions adjusted within the 5.8-7.4 pH range. The level of acidification detected by the null 
sensor was estimated as a mean current change expressed in nA. Because the experimental data 
were obtained from organotypic cultures whose structure normally comprises two cell layers 
only and, thus, they are comparatively small with respect to the extracellular volume, it seems 
unlikely that the calculated values reflected changes in the extracellular space. At the beginning 
of each experiment the specificity of the glutamate sensor was validated by using a glutamate 
calibration curve (0.5-50 µM) and a single point calibration (with 25 µM) was repeated at the 
end of each experimental day. The change of glutamate and null electrode signals were recorded 
simultaneously by using a basal solution (containing in mM: NaCl, 152; KCl, 5; CaCl2, 2; 
MgCl2, 1; HEPES, 10; glucose, 10, pH 7.4; 300–320 mOsm; Sigma-Aldrich, Milan, Italy).  
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Real-time PCR expression levels 
The expression levels of ASIC1a, ASIC1b, ASIC2 and ASIC3 were evaluated in spinal cord 
organotypic slice cultures by real-time PCR using specific primers (Table 1). The design of 
primers and/or their specificity check was performed using Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The total RNA was isolated using Tri Reagent 
solution according to the manufacture’s protocol (Invitrogen). RNA samples were quantified in a 
spectrophotometer at 260 nm. Retrotranscription using 1 µg of total RNA was performed with an 
iScript cDNA Synthesis Kit (BIORAD Cat. No 170-8891) according to the manufacture’s 
suggestions. The reaction was run in a thermocycler at 25°C for 5 min, 42°C for 45 min, 85°C 
for 5 min. The reaction was performed in the iQ Real Time PCR Thermal Cycler (BIO RAD) 
using the fluorescent dye SYBR Green (SYBR Green Supermix kit IQTM; BIORAD). The 
analysis of the results was performed using iCycle iQ Real Time PCR Detection System 
(BIORAD) program. mRNA samples were calibrated to obtain similar amplification of the 18S 
and β-actin as housekeeping mRNA. Cycling parameters were determined, and calculations for 
relative mRNA transcript levels were performed using the comparative CT method (ΔΔCT; 
Pfaffl, 2001)) between cycle thresholds of different reactions, normalized to the housekeeping 
gene. Melting curve analysis was performed to assess product specificity. 
 
Immunostaining and cell counting 
Immunohistochemistry experiments were performed in accordance with previous reports 
(Mazzone et al., 2010; Cifra et al., 2012). Spinal cord preparations were fixed in 4 % 
paraformaldehyde for 60 min at room temperature and stored in phosphate buffer saline (PBS) 
until use or in 30 % sucrose PBS for cryoprotection (24 h at 4°C). Cryoprotective slices were 
cryostat-sectioned and collected sequentially on histology slides. Organotypic slices were 
blocked with 3 % fetal calf serum (FCS), 3 % bovine serum albumin (BSA), 0.3 % Triton in PBS 
(blocking solution) for 1 h at room temperature, followed by overnight incubation at 4°C in a 
blocking solution containing the previously-validated primary antibodies using the following 
dilutions: NeuN (1:250; Millipore, Billerica, MA, USA) and S100β (1:1000; Dako, Glostrup, 
Denmark). For neonatal spinal cord preparations, sections were pre-incubated in blocking 
solution containing with 5 % FCS, 5 % BSA, 0.3 % Triton in PBS for 1 h at room temperature. 
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Slices were incubated overnight at 4°C in a solution containing 1 % FCS, 1 % BSA, 0.1 % Triton 
in PBS, with primary antibodies using the following dilutions: NeuN (1:200; Millipore) and 
S100β (1:500; Dako). Primary antibodies were visualized using a secondary fluorescent antibody 
(Alexa Fluor 488 or 594 at 1:500 dilution, Invitrogen, Carlsbad, CA, USA) after mounting the 
sections with Vectastashield medium (Vector Laboratories, Burlingame, CA, USA). 
For each slice culture, the number of NeuN and S100β positive cells was obtained by counting 
images with a Zeiss Axioskop2 microscope (Zeiss Axioskop2, Carl Zeiss MicroImaging, 
Thornwood, NY, USA) or FV300 confocal microscope (Olympus Optical, Tokyo, Japan), as 
previously reported (Cifra et al., 2012). The counting was performed with “eCELLence” 
software (Glance Vision Tech, Trieste, Italy) or by counting manually with using Image J 
software (version 1.49v, Wayne Rasband, National Institutes of Health, Bethesda, MD). NeuN 
positive cells were counted in three regions of interest (ROIs, namely: dorsal, central and 
ventral). When biomarker staining was diffuse, like in the case of S100β, signals were collected 
as mean fluorescence intensity, expressed in arbitrary units (AU) with densitometry analysis 
using a Zeiss Axioskop2 microscope with MetaVue imaging software (Molecular Devices, 
Sunnyvale, CA) in fields of 500x500 µm area. For neonatal spinal cord preparations NeuN and 
S100β positive cells were counted in four different ROIs: dorsal grey matter, ventral grey matter, 
and central grey matter (110 x110 µm), using FV300 confocal microscope by counting stacks of 
4 images (60x magnification, pinhole was airy 1 corresponding to 102 μm) in an area of 52,900 
µm
2
. The total number of neurons, NeuN positive cells, and the mean fluorescence intensity for 
S100β astrocytes, were normalized by the ROI size (µm2) to obtain cell density. 
 
Propidium iodide staining 
Thoracolumbar spinal cord preparations isolated from neonatal C57BL/6J mouse (3 days old), 
were embedded in 1.5% Agarose (Sigma)/Krebs’ solution at 35°C and allowed to solidify on ice 
for 5 min (Mitra and Brownstone, 2012). For these experiments, a total of 10 mice were used, 5 
of them belonged to the C57BL/6J strain and 5 ASIC1a
-/-
 genotype: 67 slices were obtained in 
total. Slice numbers used for each experimental group are as follows: C57BL/6J control = 9; 
KA = 13; ASIC1a
-/-
 control = 9; KA = 15. Slices (300 µm) were obtained by using a vibrating 
tissue slicer (Integraslice 7550PSDS, Campden Instruments Limited, UK). Slices were then 
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incubated in PEG solution (30% v/v, PEG pure in distillated water) for 60 s, and washed twice in 
Krebs’ solution. Slices were kept in Krebs’ solution (at 35°C) gassed with 95% O2 5% CO2 for 1 
h. After this incubation time, slices were maintained at RT for spinal cord excitotoxic injury 
protocol as previously described. Slices were incubated with propidium iodide staining solution 
(PI, P3566 - Molecular Probes, Invitrogen, Buenos Aires, Argentina, 0.2 µL/1 mL in Krebs’ 
solution) at room temperature for 5 min in the dark. Slices were observed under a BX51WI 
upright microscope with a 10X objective lens (LUMPlane FI, Olympus) and an EMCCD camera 
(AndoriXon, Oxford Instruments), together with cell-M System Coordinator/ cell-R Real Time 
controller software. PI quantification was done with Image J software. Fig. 1 C, D shows an 
example of enhanced PI signal when the same spinal cord slice was treated (for 5 min) with 100 
µM HCl that induced strong dye accumulation. For the present study we also used a batch of 
ASIC1a
−/−
 mice (Wemmie et al., 2002) kindly donated by Dr. J.A. Wemmie, University of Iowa, 
USA. PCR tests confirmed that these mice were knockout for the ASIC1a
-/-
 gene (Fig. 1 E) in 
accordance with previous data (Price et al., 2001; Wemmie et al., 2002).  
 
Electrophysiological recordings 
Using tight-fitting Ag/Ag-Cl monopolar suction electrodes, DC-coupled records were obtained 
from lumbar (L2 and L5) ventral roots (VRs) that contain the motor axons of flexor-extensor 
motor pools of hind limbs (Taccola et al., 2008). Electrical square pulses (0.1 ms) were delivered 
to a single lumbar dorsal root (DR) through a bipolar suction electrode and the responses from 
VRs were simultaneously recorded at 10 KHz with a DP-304 Differential amplifier (Warner 
Instruments LLC, Hamden, CT, USA). Response threshold was determined for each preparation 
by applying graded electrical stimuli and detecting a minimal response in ipsi-lateral and ipsi-
segmental VRs. Two to three times threshold stimulus intensity at frequency of 2 Hz for 15 s was 
given to induce DR evoked fictive locomotion (Marchetti et al., 2001). Chemically-induced 
fictive locomotion was obtained by bath-applying N-methyl-D-aspartate (NMDA) (1.5-6 µM) 
plus 5-hydroxytryptamine (Kiehn and Kjaerulff, 1998) (5-HT; 10 µM). Signals were acquired 
and processed with pClamp software (version 9.2; Molecular Devices, Sunnyvale, CA, USA). 
Measurements concerning locomotor rhythm were in accordance with Taccola et al. (Taccola et 
al., 2008). 
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Statistics 
Results were expressed as means ± SEM unless otherwise indicated; n refers to the number of 
sections (acute spinal cord slices), organotypic cultures, or isolated spinal cords. Statistical 
calculations were done using SigmaStat 3.11 (Systat Software, Chicago, IL, USA). To 
distinguish between parametric or non-parametric data, the normality test equal variance criteria 
were routinely used in accordance with the software directed choice. For multiple comparisons 
the ANOVA test for parametric data followed by the Tukey-Kramer post-hoc test or Fisher’s 
least significant difference test were used. Non-parametric values were analyzed with the 
Kruskal-Wallis test followed by Dunn's Method for multiple comparisons. When two groups 
were compared, the Student’s t-test for parametric data or the Mann-Whitney Rank Sum Test for 
non-parametric data was applied. Two groups of data were considered statistically different if p 
≤ 0.05. 
 
Results 
Excitotoxic cell death is modulated by H
+
 release  
In our previous study concerned with an vitro model of SCI, we have shown that KA induces 
delayed excitotoxic cell death (Taccola et al., 2008) and evokes release of endogenous glutamate 
(Mazzone and Nistri, 2011b) with insult-related proliferation of endogenous spinal 
neuroprogenitors over a relatively brief time course (Mazzone et al., 2013). The early factors 
controlling this process and determining the functional outcome remain incompletely 
understood. Our previous experiments have also indicated that the release of endogenous 
glutamate can be quantified with a real-time electrochemical assay as a useful, simple index of 
spinal network activity in culture (Mazzone and Nistri, 2011b).
 
A
 
useful adjunct of this method is 
that the null electrode can be successfully employed for monitoring pH changes alongside 
glutamate concentrations (Llaudet et al., 2005; see Methods), thus enabling concurrent 
estimation of extracellular glutamate and pH. Fig. 2A, B shows average time course and extent 
of glutamate release induced by 10 (left) or 100 (right) µM KA from a mouse organotypic slice 
culture. As indicated by the different vertical scales in Fig. 2 A, B, the peak amplitude of the 
glutamate sensor response was significantly higher with 100 than 10 µM KA (4.39±1.08 vs 
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0.061±0.004 nA, respectively, n=6, * p≤ 0.05, t-test): the higher gain of the latter response is 
accompanied by larger basal noise. For either KA concentration the signal peaked within 10 min 
from the start of KA application and then gradually waned to reach baseline by 30 min in 
analogy with former data with rat spinal slice cultures (Mazzone and Nistri, 2011b). Fig. 2 C, D 
illustrates the concomitant changes in current recorded by the glutamate-insensitive null 
electrode and representing extracellular acidification. Although the response size of the null 
electrode was similar to the glutamate one when 10 µM KA was applied (Fig. 2 C), in the 
presence of 100 µM KA the null electrode response peak was ten times smaller than the 
glutamate current signal (Fig. 2 D). On the basis of the calibration plot (see Methods and Fig. 1 
B), it was estimated that the average pH attained during 10 µM KA application was 6.10±0.09 
(n=6). Thus, even with a KA concentration (10 µM) that was just at threshold value to evoke 
excitotoxicity (Mazzone et al., 2010), the pH fall and the glutamate release peaked at the same 
time (2.7±0.7 or 2.7±0.6 min for pH or glutamate, respectively (n=5, p=0.926, t-test) with a 
similar rate of rise (τ value = 0.8±0.4 or 0.5±0.4 min, respectively; n=5, p=0.166, t-test). These 
observations suggested that these two parameters were likely interconnected, a notion compatible 
with the  view that protons perhaps released by spinal cells might act as neuromodulators (Ruffin 
et al., 2014).  
To further evaluate how pH changes might impact on the extent and topography of early cell 
damage induced by KA, we studied the topographical distribution of the fluorescent probe PI 
that, being a large molecule, readily accumulates inside cells with damaged plasma membrane 
(Brana et al., 2002). Fig. 3A shows examples of PI fluorescence signals in spinal cord slices 
treated with KA (10 µM; 1 h) (Fig. 3B) that, at this concentration, yielded minimal cell death 
(Fig. 3B) in accordance with the modest release of glutamate (Fig. 2A). Further observations 
suggested that this phenomenon was related to extracellular pH and the ability to activate ASIC 
channels. In fact, Fig. 3C, E, F compares the PI signals from WT and ASIC1a
-/-
 spinal slices, 
indicating that, in this genotype, the toxic effect of KA was intensified (n=9-15 slices, * p≤ 0.05, 
t-test, vs. control). These data unexpectedly suggested that extracellular protons could exert some 
damage-limiting action against excitotoxicity. 
 
ASIC channel mRNA modulation induced by KA 
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We next investigated whether KA mediated excitotoxicity might impact on the expression of 
ASIC1a, 1b, 2 and 3 by spinal cord organotypic cultures evaluated by RT-PCR. ASIC1a and 
ASIC2 are specific for spinal cord tissue, while ASIC1b and 3 are expressed by other structures 
like DRGs and non-neuronal cells (Deval and Lingueglia, 2015). In preliminary experiments we 
validated (by quantitative RT-PCR) the ASIC gene expression in spinal cord organotypic 
cultures. As described in previous studies (Baron et al., 2008), ASIC1a and ASIC2 were the 
predominant mRNAs in these preparations (1.26±0.01 and 1.10±0.06 change over the house 
keeping gene products β-actin and 18S, n=3 experiments), whereas ASIC3 and ASIC1b 
expression was relatively low (0.89±0.15 and 0.63±0.08, n=3) consistent with their specific 
location to sensory neurons (Deval and Lingueglia, 2015) and ciliated neurons of the spinal cord 
central canal (Jalalvand et al., 2016b).  
In the current experiments on organotypic slices treated with  KA (1 h) and analyzed 24 h later, 
the mRNA level of all four ASIC genes was significantly upregulated by 10 µM KA, while, on 
the contrary, only ASIC1a and ASIC2 were significantly reduced by KA (100 µM; Fig. 4, n=15 
slices for each experimental condition from 3 independent experiments; **p≤0.01,*p≤0.05  vs 
control; Kruskal-Wallis, Dunn's Method) in line with the large toxicity evoked by such a high 
KA concentration (Mazzone et al., 2010). Unexpectedly, when slices were incubated with DAPI, 
a previously reported ASIC inhibitor (Chen et al., 2010; Alexander et al., 2011), for 24 h during 
KA washout, the upregulation of ASIC1a, ASIC1b and ASIC 3 was prevented (Fig. 4, n=15 
slices for each experimental condition from 3 independent experiments; #p≤0.05, ##p≤0.01 vs 
KA 10 µM, Kruskal-Wallis, Dunn's Method). DAPI alone had no effect on any ASIC gene 
expression.  
 
Cell loss mediated by ASIC inhibitors 
Representative images of NeuN (neuron) and S100β (glial) positive cells in spinal cord 
organotypic culture treated with KA (10 µM) followed by 24 h DAPI application are shown in 
Fig. 5A. This data indicates that no toxic effect was apparent 24 h after washout of KA (Fig. 5A, 
B, C). Conversely, histograms show that the number of neurons and glial cells fell 24 h after KA 
application plus DAPI (Fig. 4A, B and C, respectively). While neuron numbers were unaffected 
by DAPI alone for 24 h, the average fluorescence signal from glia was significantly lowered after 
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DAPI (n=11-22 slices, *p≤0.05 vs control, #p≤0.05 vs KA, Kruskal-Wallis, Dunn's Method) in 
accordance with the report of its potentially toxic effect on proliferative cells via inhibition of 
RNA and DNA polymerase (Baraldi et al., 2004).  
We next compared two ASIC inhibitors, namely DAPI and amiloride (AM, 100 µM), for their 
effect on KA neurotoxicity in the isolated mouse spinal cord 24 h later (Fig. 6). Fig. 6A shows 
representative images of regions of interest (ROIs) in spinal cord sections under control 
condition, after KA treatment only, or after KA application followed by DAPI or amiloride. Fig. 
6A shows that, in the three ROIs examined 24 h after KA (10 µM; 1 h application), neuronal 
survival was excellent to confirm the lack of neurotoxicity of this low concentration of the 
glutamate agonist (Table 2). When DAPI or amiloride were administered for 24 h after KA 
washout, neuronal numbers were significantly decreased (Fig. 6 C, D and Fig. 6 B, respectively) 
as exemplified by quantification for the central ROI (Fig. 6E, n=9-29, *p≤0.05 vs control, # p≤ 
0.05 vs AM alone, Kruskal-Wallis, Dunn's Method,  $ p≤ 0.005 vs DAPI alone,  Mann-Whitney 
Rank Sum Test) which is the one believed to contain the central pattern generator for locomotion 
(Kiehn, 2006, 2016). The insets to Fig. 6D indicate that DAPI administration after KA was 
associated with pyknosis shown as condensed chromatin appearance (Taccola et al., 2008; 
Mazzone et al., 2010). No change in S100 positive astrocytes was observed (Fig. 6 A-D). It is 
noteworthy that neither amiloride nor DAPI applied alone induced significant neuronal loss (Fig. 
6 C-E).  
It should be noted that there was an apparent discrepancy in the strength of the effects of 10 µM 
KA followed by DAPI on cell survival (Fig. 5B for organotypic slices and Fig. 6E for isolated 
spinal cords): we propose that the simpler bilayered structure of the organotypic slice (Cifra et. 
al, 2012) with comparatively fewer glial cells might have been less efficiently equipped to 
handle glutamate release and pH changes. Our data, thus, suggested that, regardless the type of 
ASIC inhibitor used, their application converted a near-threshold excitotoxic stimulus to a 
neurotoxic one. 
 
ASIC inhibitors enhanced functional disruption by excitotoxicity 
We next evaluated the effect of 10 µM KA, DAPI or amiloride (either applied alone or in 
combination) on synaptic transmission in the isolated spinal cord. Amiloride alone depressed the 
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polysynaptic peak amplitude and made significant decrease on mono and polysynaptic 
transmission following KA application (Table 3). In addition to testing synaptic activity evoked 
by single pulses applied to one DR, we also investigated the coherent expression of rhythmic 
network discharges expressed as fictive locomotion evoked by DR stimulus trains (Marchetti et 
al., 2001) and emerging as regular bouts of oscillations alternating amongst ventral roots (VRs; 
Fig. 7). This phenomenon comprises a slowly developing cumulative depolarization caused by 
non-linear summation of synaptic inputs (Sivilotti et al., 1993; Baranauskas and Nistri, 1996; 
Barbieri and Nistri, 2001) with superimposed spiking and oscillatory cycles, none of which was 
affected by subthreshold concentration of KA (10 µM; Fig. 7 A-D). Nevertheless, KA treatment 
followed by DAPI or amiloride for 24 h elicited significant decrease in the number of 
oscillations (Fig. 7B). Significant depression of cumulative depolarization by amiloride applied 
after KA was also observed (Fig. 7 C, D).  
Alternating rhythmic oscillations recorded from lumbar VRs are thought to indicate the 
functional output of the locomotor central pattern generator (Kiehn, 2006, 2016). In the present 
experiments, NMDA (1.5-6 µM) plus 5HT (10 µM; see Methods) were used to generate such 
oscillations (Beato et al., 1997). Despite using a range of NMDA doses, oscillations expressed by 
mouse preparations are less stable and persistent than in other mammalian species (Zhong et al., 
2012) as confirmed in our tests: this characteristic was present even after 24 h in vitro in the 
present experiments. In fact, only 3/11 spinal cords generated 20 consecutive cycles rhythmically 
alternating amongst flexor and extensor motor pools used a standard index of fictive locomotion 
(Kjaerulff and Kiehn, 1996) and exemplified in Fig. 8. These cycles were all expressed at low 
periodicity (10.3±3.6 s; n=6). The remaining preparations generated variable bouts of alternating 
rhythmic discharges (4 to 12). After exposure to KA (10 µM), the probability of observing 20 
cycles remained similarly low (2/12 preparations), and the number of cycles in a bout varied 
from 4 to 12 (in 4/12 preparations) with average period of 14.6±2.3 s (n=6) and lacking 
alternation. DAPI or amiloride did not significantly change these patterns when they were 
applied after KA (2/5 or 8/12 spinal cords for DAPI or amiloride, respectively) while cycle 
periodicity remained slow (14.0±1.6 or 17.8±2.1 s, respectively). Cycle alternation was 
preserved with DAPI or amiloride per se, yet absent when these drugs followed KA.  
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These results could not be simply attributed to inefficient network depolarization by NMDA and 
5HT because the average VR depolarization evoked by 3 µM NMDA and 10 µM 5-HT was 
similar in sham (0.72±0.08 mV, n=11), after KA (0.64±0.07 mV, n=12), DAPI (0.95±0.19 mV, 
n=7) or amiloride (0.55±0.14 mV, n=5) protocols, even when applied after KA (0.47±0.06 or 
0.49±0.08 mV, n=5 or n=12, respectively).  
 
Discussion 
The present report shows that, in mouse spinal cord networks, the histological and functional 
outcome of excitotoxicity could depend on extracellular pH changes that likely involved 
activation of ASIC channels, and were important for the operation of locomotor circuitry. It was 
unexpected that inhibitors of ASIC channels or ASIC1a genetic ablation actually intensified the 
damage evoked by a borderline excitotoxic stimulus.  
 
Protons modulate neurotoxicity 
Notwithstanding the multifarious effects of acidification on neuronal receptors and channels 
(Holzer, 2009), the role of ASICs in the central nervous system is complex and subjected to 
intense regulation to modulate and transmit network signals (Krishtal, 2003) related to 
pathological and physiological conditions (Duan et al., 2007; Baron et al., 2008). For instance, 
during brain ischemia affecting mouse cortical neurons, the activation of homomeric ASIC1a 
channels (highly permeant to Ca
2+
) may play a key role in acidosis-induced neuronal death 
(Xiong et al., 2004). Decreases in extracellular pH to 6.5 (or below) occur in several pathologies 
such as cerebral ischaemia, hypoxia or epilepsy due to increased lactate production by 
glycolysis, and, moreover, even sustained neuronal activity can lower pH (Chu and Xiong, 
2012). In physiological conditions transient acidosis is normally compensated by proton uptake, 
for instance during glutamate release (Hnasko and Edwards, 2012). Buffering H
+
 to keep the 
intracellular neuronal pH around 7.1 is effected by membrane located acid-base transporters 
(Chesler, 2003).  
While the extracellular pH value is normally 7.4, intense, sustained transmitter release (when 
synaptic vesicles with internal pH of ~5.5 discharge their content) can significantly acidify the 
synaptic cleft (Hnasko and Edwards, 2012). It follows that using KA to persistently stimulate 
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release of glutamate stored in synaptic vesicles is likely to provide, within spinal networks, a 
microenvironment with acid pH to which glia might have also contributed. In fact, stimulation of 
astrocytes from neonate mouse brain cortex acidifies the extracellular space leading to activation 
of neuronal ASIC1a channels and firing of action potentials (Li et al., 2014). This finding implies 
a functional interaction between neurons and astrocytes for proton regulation, a process that 
perhaps was operative in spinal networks as well. 
In the present study extracellular acidification by KA was evaluated with simultaneous recording 
via the glutamate biosensor and the null electrode as recently demonstrated (Llaudet et al., 2005). 
Although the background current attributed to pH changes faded away during KA application, 
we first suspected that the early fall in extracellular pH might have triggered the activation of 
deleterious processes that were then translated into neuronal cell death (Shabbir et al., 2015a). To 
our surprise, we observed that, while no significant increase in cell death was evoked by 10 µM 
KA as previously reported (Mazzone et al., 2010), the borderline between survival and death was 
readily surpassed in the presence of two different ASIC inhibitors, namely DAPI or amiloride, or 
with genetic ablation of the ASIC1a gene. Finally, upregulation of ASIC mRNA was observed 
after KA application. Altogether, these data unexpectedly indicated that a fall in extracellular pH 
induced by KA was somehow protecting from cell death.  
 
ASIC expression in spinal networks 
Functional ASICs are homo or heterotrimers of different subunit assembly. To date, six subunits 
of ASICs have been identified, namely 1a, 1b, 2a, 2b, 3, and 4 (Krishtal, 2003). Our data suggest 
a predominant role for the ASIC1a and ASIC2a subunits in response to KA in mouse spinal 
networks in analogy with previous studies (Deval and Lingueglia, 2015). A former investigation 
has shown that ASIC1 and 2 subtypes are expressed by the majority of small as well as large 
neurons in all laminae of the spinal cord (Baron et al., 2008).When 100 µM KA induced 
extensive neuronal cell death without large glial loss (Mazzone et al., 2010), significant 
reduction in ASIC1a and ASIC2 occurred attributable to cell loss. On the contrary, when 10 µM 
KA was applied, significant mRNA increase was observed for all subunits. To further investigate 
the contribution by ASICs to excitotoxicity following KA administration, DAPI, a potent ASIC 
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inhibitor (Chen et al., 2010), was applied during the KA washout and observed to decrease 
mRNA expression of all subunits. 
 
Involvement of ASIC channels in the effect evoked by KA 
In standard recording conditions DAPI had no effect on synaptic transmission or locomotor 
network rhythms while amiloride depressed polysynaptic activity. The latter phenomenon might 
be attributed to other actions by amiloride like inhibition of Cl
-
 transport, and of certain subtypes 
of Na
+
 and K
+
 channels (Leng et al., 2016). Although amiloride and its chemical derivatives are 
currently proposed as tools to develop ASIC channel blockers (Leng et al., 2016), it seems 
probable that the effects of amiloride on excitotoxicity could not be simply due to ASIC block. 
Nevertheless, in analogy to the effect of DAPI, one may posit that ASIC inhibition by DAPI or 
amiloride favoured excitotoxicity. Because the relatively modest acidification evoked by 10 µM 
KA had rather small effects on network function, it seems likely that the fall in extracellular pH 
evoked by KA was probably followed by reactive changes in intracellular pH as has been 
demonstrated in brain trauma and SCI (Huang et al., 2015b). Furthermore, early (and often 
overlooked) experiments had shown that moderate acidification can protect cortical or cerebellar 
neurons from excitotoxicity via block of NMDA receptor-mediated currents (Giffard et al., 1990; 
Andreeva et al., 1992) because H
+
 is a strong modulator of the NMDA channel activity (Tang et 
al., 1990). In the present investigation ASIC inhibitors applied after KA substantially depressed 
network activities, especially those that required coherent oscillatory patterns. Indeed, when the 
ASIC inhibitors were applied after KA, the orderly recruitment of circuit elements was disrupted 
so that locomotor-network oscillations evoked by DR stimuli were significantly decreased. 
Conversely, there was much less disruption of locomotor rhythm when NMDA and 5-HT were 
bath applied to induce fictive locomotion. This discrepancy was due to the fact that, in the 
mammalian spinal cord, the ventral part of lumbar region itself can generate alternated rhythmic 
pattern even after ablating the dorsal horns (Kiehn and Kjaerulff , 1998; Ballerini et al., 1999) 
which are the areas where the strongest lesion by kainate is observed (Mazzone et al., 2010).   
 
Mechanisms of delayed neurotoxicity by ASICs inhibitors 
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On the assumption that the operation of ASIC channels somehow raised the threshold for KA 
neurotoxicity, the question then arises how that would have been possible. Recent studies have 
indicated a physiological role of ASICs expressed by the central region of the lamprey spinal 
cord for detecting pH changes with a negative feedback to motor circuits resulting in suppression 
of locomotor activity (Jalalvand et al., 2016a,b). This implies that the spinal cord, at least of 
lower vertebrates, has a precise control system for sensing pH changes. In the mouse spinal cord 
an analogous system might rely on pH changes to deploy several effectors to contrast 
excitotoxicity at different times after the initial insult. While considering the relatively short time 
frame from the start of KA application, we would like to propose that ASIC activation might 
depress spike activity and, therefore, restrict the network excitation induced by KA (Vukicevic 
and Kellenberger, 2004), or that acidification may relieve the inhibitory interaction of ASIC 
channels with membrane K
+
 channels, thereby favouring membrane potential repolarization 
(Petroff et al., 2008) . At later times, KA-evoked stimulation and proliferation of neuroprecursors 
in the central region (Mazzone et al., 2013) might be mediated by upregulation of ASIC gene 
activity as observed in the present study. Furthermore, ASIC1a-mediated Ca
2+
 influx with 
consequent ERK 1/2 and Akt activity (Su et al., 2014) may upregulate Homer1 proteins that play 
an important role in synaptic plasticity of the spinal cord (Miletic et al., 2009) and are 
neuroprotective in traumatic brain injury (Luo et al., 2014). These possibilities should be 
investigated in future studies. 
 
Conclusions 
Our work proposes that moderate extracellular acidification might contribute to ASIC activation 
in turn likely to trigger cell processes to diminish excitability and neuronal loss with a relatively 
short delay. One might envisage a scenario where this process perhaps operates in concert with 
another mechanism, namely pH-mediated opening of leak K
+
 channels that can also be activated 
pharmacologically by a neuroprotective volatile anesthetic (Shabbir et al., 2015b).  
Our earlier results indicate that contrasting an intense excitotoxic insult may require intracellular 
processes like HSP70-dependent inhibition of non-apoptotic cell death (Shabbir et al., 2015a). 
Combinatorial strategies adopted by endogenous neuroprotective processes might be the reason 
why excitotoxic neuronal death in the rodent and human spinal cord is often limited to the 
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minority of neurons (Mazzone et al., 2010) although the functional impact is suppression of 
locomotor-like output (Taccola et al., 2008).   
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Figure legends 
  
Fig. 1 pH calibration of electrochemical experiments, pH action on cell viability and gene 
expression by ASIC1a knockout tissue (A) Example of organotypic mouse spinal cord culture 
after 22 DIV showing the ventral fissure where null and glutamate sensors were placed for 
detection of glutamate and pH as shown in Fig. 2. (B) Calibration curve done with Krebs 
solution at different pH (5.8, 6.5 and 7.4) showing the mean current change for null biosensor, 
expressed in nA, n=6, *p≤ 0.05, t-test. (C, D) Examples of spinal slices stained with propidium 
iodide in control condition or after 5 min HCl (100 µM) application. Slices show intense 
propidium iodide uptake after HCl application (pseudocolor scale in D). (E) Representative 
experiment to demonstrate gene expression profile of wildtype or ASIC1a
-/-
 spinal cord samples 
to validate gene ablation.  
 
Fig. 2 Analysis of proton and glutamate release by organotypic slices with electrochemical 
biosensors. Average glutamate current (n=6 slices) observed from slices exposed to KA 10 µM 
(A) or 100 µM (B; black traces). (C, D) the average current continuously monitored throughout 
the experiment with the null biosensor indicates pH changes detected with KA (10 and 100 µM). 
For sake of clarity, SEM values were omitted; SEM values are given for mean peak currents in 
the text. 
 
Fig. 3 Analysis of cell death induced by KA using propidium iodide staining of spinal slices. 
Cross sections of spinal slices (A-D) in control condition or after 1 h KA (10 µM) application for 
WT animals or ASIC1a
-/-
. Signals are coded by pseudocolors. (E, F) Histograms comparing the 
effect of KA on WT and ASIC1a
-/-
 slices: data are expressed as fractional change in average 
propidium iodide fluorescence intensity over control; n=9-15 slices from 8 independent 
experiments, * p≤ 0.05, t-test, vs. control. 
 
Fig. 4 ASIC mRNA expression in organotypic spinal cord cultures by RT-PCR. Ordinate: 
fractional change with respect to control condition. Cultures treated with KA (10 µM and 100 
µM) demonstrated changes in the levels of mRNA transcripts of ASIC1a (A), ASIC1b (B), 
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ASIC2a (C), ASIC3 (D). mRNA increase was significant reduced by addition of DAPI (3.5 µM) 
during KA (10 µM) washout. For each ASIC gene product, amplification values were 
normalized with β-actin and 18S mRNA levels. Control level was set at 1 for each gene product;  
medians (black horizontal line) and individual data (filled circles) are shown in each panel, n=15. 
Different slices for each experimental condition from 3 independent experiments. For each ASIC 
gene, *p≤0.05, **p≤0.01, vs control; #p≤0.05, ##p≤0.01, vs KA10 µM, Kruskal-Wallis, Dunn's 
Method). 
 
Fig. 5 Quantification of neuronal and glial staining in organotypic spinal cord cultures. (A) 
Example of neuronal and glial staining in control condition (NeuN red, S100β green, DAPI blue) 
in spinal cord organotypic cultures. (B) Plots show the median of NeuN positive cells (black 
horizontal line) calculated 24 h after the application of KA (10 µM; 1 h) in control or DAPI (3.5 
µM) solution, and the distribution of individual data (filled circles), n=4-7 slices, *p≤0.05 vs 
control, #p≤0.05 vs KA, Kruskal-Wallis, Dunn's Method. (C) Plots show the median of  
fluorescent intensity data (arbitrary units, black horizontal line) together with the distribution of 
single measurements for S100β antibody signal detected at  24 h, n=11-22 slices, *p≤0.05 vs 
control, #p≤0.05 vs KA, Kruskal-Wallis, Dunn's Method. 
 
Fig. 6 Neuronal and glial staining of mouse isolated spinal cord. (A) The upper left panel shows 
an example of neuronal and glial staining (NeuN green, S100β red) in mouse isolated spinal cord 
in control condition (left) or 24 h after the application of KA (10 µM) for 1 h (right). Three 
different gray matter ROIs, namely dorsal, central and ventral, are delimited by yellow boxes. 
(B) Example of neuronal and glial staining in control condition or 24 h after the application of 
KA (10 µM) followed by amiloride (AM, 100 µM) or amiloride only. (C-D) Examples of NeuN 
and S100β staining (low or high magnification, respectively) after the application of KA (10 µM) 
followed by DAPI (3.5 µM) or DAPI per se. Insets in panels D shows the condensed chromatin 
nucleus as marker for pyknosis.  (E) Plots show the median of NeuN positive cells (black 
horizontal line) in the central area for control condition and 24 h after the application of KA (10 
µM, 1 h) alone or followed by amiloride (AM, 100 µM) or DAPI (3.5 µM), and the distribution 
of individual data points (filled circles); n= 9-29 slices, 6 independent experiments were done to 
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include in each case 2-8 spinal cords, *p≤0.05 vs control, # p≤ 0.05 vs AM alone, Kruskal-
Wallis, Dunn's Method; $ p≤ 0.005 vs DAPI alone, Mann-Whitney Rank Sum Test.                                                                                                                                                                                                                                                                                                
 
Fig. 7 Functional effect of ASIC inhibitors on mouse isolated spinal cord. (A) Examples of 
electrically evoked oscillatory patterns recorded from lumbar VRs 24 h after application of KA 
alone or followed by DAPI or amiloride. (B) Bar chart indicating the number of oscillations 
detected with sham, KA, KA/DAPI., DAPI, KA/amiloride or amiloride protocols. Note 
significant reduction in KA/DAPI and KA/amiloride responses (n=11-16 spinal cords 
preparations; *p≤0.05; ***p≤0.001, ANOVA, Tukey-Kramer). (C) Histograms showing 
cumulative depolarization amplitude for the above protocols; *p≤0.05; **p≤0.005, ANOVA, 
Fisher LSD. (D) Bar graph summarizing the area of DR evoked cumulative depolarization; 
*p≤0.05, ANOVA, Tukey-Kramer. 
 
Fig. 8 NMDA and 5-HT evoked VR oscillations of mouse spinal cord. (A) Representative traces 
of oscillatory patterns evoked by excitatory chemicals applied with the protocols mentioned in 
Fig. 6. Traces are shown on a slow time scale on the left and records within boxed sections are 
also depicted on a faster time base on the right (B). (C) Histograms showing peak amplitude of 
the observed rhythms. Pooled data shown here are from spinal cords which produced at least 4 
oscillations. Note there is no significant difference in the amplitude (p=0.14, ANOVA) (D) Bar 
graphs indicating the rhythm periodicity. There is no significant change in between groups 
(p=0.49, ANOVA, n=5-12 spinal cords preparations). 
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Table 1: List of primer sequences used for the quantification of specific mRNAs by real time 
RT-PCR in organotypic spinal cord cultures. The primer sequence was based on reliable 
amplification as previously reported (Baron et al., 2008; Mazzone et al., 2009; Swain et al., 
2012). 
 
 
Gene Primer Forward Primer Reverse 
-Actin1 CCTTCTTGGGTATGGAATCCTGTG CAGCACTGTGTTGGCATAGAGG 
18S 
2
 GCCGCTAGAGGTGAAATTCT CATTCTTGGCAAATGCTTTCG 
ASIC1a
2
 GGCCAACTTCCGTAGCTTCA ATGCCCTGCTCTGTCGTAGAA 
ASIC1b
3
 AGAATCGGAAGAAGAAGAAGAGAAG GTAGAGCAAGTCAGGGTAGCTGAG 
ASIC2a GAGGCGCTCAATTACGAGAC ATCATGGCTCCCTTCCTCTT 
ASIC3 TGAGAGCCACCAGCTTACCT ATGTCAAAAGTCGGACTGGG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Quantification of NeuN-positive neurons in three ROIs  
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Table 3. Effects of KA, amiloride or DAPI on synaptic transmission 
 
 
 
* P<0.05 vs sham data 
ROIs Sham 24 h after KA 
Dorsal 312.5±26.1 373.9±46.8 
Central 324.4±18.5 222.2±47.9 
Ventral 280.2±32.5 245.3±32.7 
Reflex 
Parameters 
Sham 
(n=11) 
KA(10 
µM; 1h; 
n=14) 
KA(1h)/ 
DAPI(3.5 
µM; 24h; 
n=11) 
DAPI (3.5 
µM; 24h; 
n=7) 
KA(1h)/A
MILORID
E (100 µM; 
24h; n=16) 
AMILOR
IDE (100 
µM; 24h; 
n=7) 
Monosynaptic 
amplitude (mV) 
0.04±0.01 0.04±0.02 0.04±0.01 0.05±0.01 0.04±0.01 0.03±0.01 
Monosynaptic 
Area (mV.ms) 
7.47±1.98 6.39±1.46 6.19±2.01 8.48±1.11 3.23±0.33* 5.90±1.51 
Polysynaptic 
amplitude (mV) 
0.41±0.09 0.40±0.06 0.32±0.08 0.32±0.10 0.20±0.03* 0.18±0.02* 
Polysynaptic area 
(mV.ms) 
1892.90±8
03.39 
1888.57±5
07.25 
1109.58±2
00.91 
1357.94±39
8.65 
1323.21±204
.94 
2145.08±35
0.69 
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10. DISCUSSION & CONCLUSION 
 
In summary, the following ones are the principal findings with respect to the objectives 
of the current study:  
 CB1Rs of rat spinal cord remained functionally active after 24 h in vitro  
 Chronic block of CB1Rs completely inhibited the spinal locomotor activity and 
changed its cell expression  
 CB1Rs remained functional after SCI 
 CB1R block further exacerbated SCI 
 Only a limited functional and histological recovery of SCI was observed after 
treatment with endocannabinoids 
 A low concentration of kainate (KA) could change pH in the spinal cord 
 ASIC expression was modulated by KA evoked excitotoxicity 
 Activity of ASICs was functionally important for the outcome after SCI 
 
10.1. Changes in synaptic transmission by CB1Rs  
Locomotor networks receive rhythmic inhibitory and excitatory inputs during the 
appropriate phases of each locomotor cycle. As mentioned before, various studies on 
hippocampus and cerebellum slices have shown that endocannabinoids are synthesized 
and released by membrane depolarization (caused by any ongoing network activity) and 
they act as retrograde messengers to depress synaptic transmission by inhibiting voltage-
activated Ca2+ channels in presynaptic terminals (Brown et al., 2003; Chevaleyre and 
Castillo, 2003; Freund and Hájos, 2003; Kreitzer and Regehr, 2001 a, b; Wilson and 
Nicoll, 2001; Wilson et al., 2001). This effect gives the possibility to test if the 
endocannabinoid system is contributing to generation and regulation of locomotor 
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network activity when motoneurons and interneurons are cyclically active to maintain the 
rhythm. To support the locomotor rhythm, group I metabotropic glutamate receptors 
(mGluR1) are one of the factors that enhances the excitability of the neurons (El Manira 
et al., 2002; Nistri et al., 2006).    
In the isolated lamprey spinal preparation, Kettunen et al. have shown that mGluR1 
activation during ongoing locomotion induces the release of endocannabinoids from 
neurons which further increase the frequency of rhythmicity. This study has also shown 
that the increase in locomotor activity is due to the depressant effect of endocannabinoids 
on inhibitory synaptic transmission onto motoneurons and crossing inhibitory 
interneurons (leading to a decreased left-right alternation; Kettunen et al., 2005). 
However, studies on in vivo animal models have shown a reduction in locomotor activity 
after CB1R activation, although the precise mechanism and the site of action remain 
unclear (Bosier et al., 2010; Lee et al., 2006). Supporting this evidence, Di Marzo et al. 
have demonstrated that even a single dose of a CB1R agonist can reduce locomotion (Di 
Marzo et al., 2000). 
Since many years cannabinoid ligands have been used to treat chronic pain, spasticity and 
obesity for an extended treatment (Clifford, 1983; Greenberg et al., 1994; Malfitano et 
al., 2008; Pagotto et al., 2005; Russo, 2008). Nevertheless, the report issued by National 
Institute of Drug Abuse (NIDA) has mentioned many short and long-term drug effects by 
cannabinoids starting from psychological disturbance to impaired body movement 
(NIDA website 
:https://www.drugabuse.gov/publications/drugfacts/marijuana#references). Hence, it is 
important to study the effect of cannabinoid ligands on mammalian locomotor network at 
various time points.  
It is evident from earlier studies that CB1Rs are widely expressed in the rat spinal cord 
(Farquhar-Smith et al., 2000; Herkenham et al., 1991). In our study, it is shown that the 
CB1Rs are distributed throughout the lumbar dorsal, central and ventral region of 
neonatal (P0-P2) rat spinal cord. Their activity after 24 h in vitro is well preserved. This 
was confirmed by checking the levels of cAMP (which are lowered when CB1Rs are 
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active by inhibiting adenylyl cyclase; Howlett et al., 2004) in both basal and induced (by 
forskolin) conditions. Our novel result was the significant depression of the CB1R 
expression at the central region of spinal cord after prolonged treatment with the 
antagonist AM251. However, it was important to examine the functional effect of 
cannabinoid ligands on synaptic transmission to understand any change in complex 
network activity. Hence, the present study aimed to detail changes in synaptic 
transmission after cannabinoid ligand treatment.  
Results from previous studies have shown a decline in GABAA mediated synaptic 
transmission (Azad et al., 2003; Jennings et al., 2001; Pernía-Andrade et al., 2009). In 
accordance with these results, the current study confirmed GABA depression (30%) after 
30 mins of AEA application. This effect was not seen after 24 h AEA treatment even if 
the CB1Rs were found active. In addition, our study has also shown that there was no 
change in glycinergic or glutamergic synaptic transmission after short and long term 
treatment with the agonist AEA. Either AEA or AM251 applied up to 6 h could not 
produce any marked effect on monosynaptic and polysynaptic reflexes. Conversely, there 
was a significant decline in the polysynaptic reflex area 24 h after treatment with AM251 
or rimonabant, effect not reversed even after washout. This could be due to primary 
afferent depression since the CB1R staining is found in all cells of the dorsal region 
(Herkenham et al., 1991). However, dorsal root-dorsal root potentials (DR-DRPs) after 
AM251 treatment were unchanged showing no alteration in primary afferent 
depolarization.  
10.2. Modulation in network properties after CB1R ligands treatment 
Short application (<3h) of AEA or AM251 showed much less modulation of network 
properties unlike in the lamprey spinal cord where 30-60 min application modulated the 
frequency of ongoing fictive locomotion (El Manira et al., 2008). In addition, prolonged 
treatment (12-24 h) with the agonists (AEA or 2AG) or with the uptake inhibitors (FAAH 
or MAGL inhibitors to increase endogenous cannabinoids (Mulvihill and Nomura, 2014; 
Otrubova et al., 2011) led to mild to severe modulation of spinal motor rhythm without 
changing reflex activities. This depression was usually observed with DR evoked fictive 
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locomotion, while NMDA plus 5HT induced rhythmic activity was unimpaired. 
Interestingly, a strong depression of network activity was observed in AM251 or 
rimonabant treated preparations starting from 6 h (mild effect) to 24 h (strong effect). 
There was a complete abolition of electrically and chemically evoked fictive locomotion 
after prolonged application. This finding is in line with results by Kettunen et al., as they 
have shown a gradual depression of locomotor activity in the lamprey spinal cord 
(Kettunen et al., 2005). Nonetheless, the mechanism of this depression is yet to be 
established. The inability to generate fictive locomotion and the depression in its 
components could be due to less excitation of neurons in the network.  
To check for the excitatory drive (which is the initiator of locomotor rhythm) disinhibited 
bursts (Bracci et al., 1996a) were recorded after chronic CB1R block. In analogy with the 
previous data, a strong decline in the burst periodicity was observed. In the present study 
it is evident that there was no change in cell survival after CB1R blockers treatment 
confirming that any changes in synaptic transmission was due to some synaptic strength 
change. 
Earlier studies have shown that, in CNS, CB1Rs are important during the developmental 
stages to ensure the correct axon guidance (Berghuis et al., 2007; Harkany et al., 2007). 
Thus, to avoid the possibility of development-related effects of CB1R blockers, the 
outcome of AM251 treatment was also studied on P4 rats that are already in the early 
stages of maturation (Cifra et al., 2012). The same depressive effect was observed after 
treating the cords with AM251 for more than 3 h. Hence, the present study clearly 
provides evidence that there was no maturation related change.  
To summarize, the function of CB1R in the rat spinal cord in vitro was explored. The 
severe depression of locomotor activity after prolonged CB1R block could be due to 
decreased expression of CB1R in the central region where the CPG generators are present 
(Grillner, 2006; Kiehn, 2011). Hence, from these results it is hypothesized that CB1Rs 
stabilized the operational activity of the locomotor central pattern generator in the rat 
spinal cord in a time-dependant fashion. However, the exact molecular pathway 
controlling the locomotor CPG is yet to be determined.   
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10.3. Expression and activity of CB1R after SCI 
Endocannabinoids are used to treat inflammation, oxidative stress, spasticity, neuropathic 
pain, neuronal injury and several neurodegenerative diseases (Koppel et al., 2014; Di 
Marzo and Petrosino, 2007; Scotter et al., 2010). In a study conducted by Donat et al. it is 
shown that there is an increase in cannabinoid receptors 6 h after traumatic brain injury 
(TBI; Donat et al., 2014). In neuropathic pain and multiple sclerosis, increase in 
cannabinoid receptor expression reduces the disease progression (Pertwee, 2009) 
whereas, in other diseases, alterations in receptor expression are maladaptive (Teixeira-
Clerc et al., 2006; Wang et al., 2008). Hence, the regulation of cannabinoid receptor 
expression is of interest from a therapeutics perspective. Apart from the cannabinoid 
receptors, modulation in the endogenous cannabinoids also plays a major role in 
determining the injury or disease progression (Garcia-Ovejero et al., 2009; Lourenço et 
al., 2011; Piomelli, 2014). Studies of in vivo locomotion have shown that the 
endocannabinoid system (increases in 2-AG and CB2, decreases in CB1) in the lesioned 
spinal cord changes in parallel with any spontaneous recovery (Garcia-Ovejero et al., 
2009). However, the exact functional recovery (whether it is from pattern generation or 
pattern formation region) after the first few hours of injury has to be determined. To 
pursue this issue, the current study focused on in vitro neonatal rat spinal cord model 
Fig 15: Graphical summary of CB1R activity in the normal locomotor function (A). Alterations 
in the rhythm after agonists (B) and inverse agonists/antagonists (C).  CB1R,  
Endogenous/Exogenous CB1R agonists,  CB1R inverse agonists,  Gi subunit, 
cAMP 
A B C 
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(kainate induced injury) of SCI where the secondary injury and its effects can be recorded 
during the first 24 h (Kuzhandaivel et al., 2011; Taccola et al., 2008).  
After KA injury, a strong decline of CB1R expression in the dorsal region was observed. 
This depression was severely extended to the central region of AM251 treated cords after 
KA mediated experimental injury. This shows an injury related change of CB1R 
expression in the current experimental model. However, the activity of CB1R was well 
preserved even after 24 h of injury which was measured through examining the levels of 
cAMP. This data provides an anticipation that the conserved CB1R activity could 
respond to KA induced SCI and protect the neurons.  
10.4. Limited recovery by endocannabinoids after SCI  
A modest recovery in the spinal synaptic transmission and network activity was only 
observed after AEA treatment. This mild functional recovery corresponded to a border-
line protection of central region neurons, while the FAAH inhibitor depressed the 
functional activity further. This could be apparently due to the fact that the inhibitor can 
increase the levels of endogenous glutamate (Gonzalez-Islas et al., 2012) which could 
expand the injury. The other non specific CB1R agonist, 2AG gave no improvement in 
reflex and network parameters. These results contradict earlier studies where the 
cannabinoids lowered the injury progression and improved the motor scores in vivo 
(Garcia-Ovejero et al., 2009). It is to be noted that, in the current study, the injury model 
is kept for 24 h (maximum time to preserve functional elements) when only a partial 
recovery phase can be studied.      
10.5. Exaggeration of SCI after CB1R block 
CB1R activation mobilizes a large number of signal transduction pathways including 
neurotoxic and protective ones. Because CB1Rs are largely presynaptic (Maejima et al., 
2001; Wilson et al., 2001) and can inhibit Ca2+ influx (Mackie and Hille, 1992), their 
reversal of excitotoxic effects might be partly originate from reducing Ca2+-dependent 
release of excitatory neurotransmitters, such as glutamate. Therefore, it is important to 
study the role of innate CB1R activity in the spinal cord after injury for any therapeutic 
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approach. Our current functional and histological (in the grey matter) data have shown 
that the SCI expanded after blocking CB1Rs with antagonist-inverse agonists. There was 
severe loss in dorsal and central region neurons after KA treatment followed by AM251 
application. This provides evidence that basal CB1R activity is important after the injury. 
The improvement in spinal cord injury shown by other studies (Arévalo-Martín et al., 
2003; Pacher et al., 2006) might be the result of complex later events like gliosis which 
occurs after a chronic time period. Nonetheless, the importance of CB1R immediately 
after SCI could help clinical research to provide a time dependant pharmacological 
intervention. Data from the current work provide basic information about the potential 
therapeutic application CB1R on SCI. Yet the accurate cellular mechanism and types of 
cells that can be manipulated by the endocannabinoid system need to be further 
investigated in detail. 
 
 
 
10.6. Modulation of protons and ASICs after KA mediated excitotoxicity 
Excitotoxic neuronal injury is known to be associated with increases in cytosolic Ca2+ 
concentrations which trigger a sequence of downstream pathways related to cell death 
(Arundine and Tymianski, 2003; Zhang and Bhavnani, 2006). However, it is only during 
the last decades that perturbations by protons associated with glutamate induced neuronal 
death have been studied (Hartley and Dubinsky, 1993). Studies have shown that in a few 
Fig 16: Graphical summary of CB1R activity in the KA induced SCI. Partial recovery of 
locomotor network after CB1R agonist (A). Complete depression of the activity after CB1R 
block (B).  CB1R,  Endogenous/Exogenous CB1R agonists,  CB1R inverse 
agonists,  Kainate. 
A B 
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minutes of glutamate exposure there is cumulative increase in intracellular hydrogen ions 
(Hartley and Dubinsky, 1993). Intracellular protons are constantly buffered by ASIC 
activity resulting in homeostasis to avoid an environment stressful to neurons. ASICs 
play an important role in physiological/pathological conditions, from sensory 
transmission (such as touch, taste, and nociception) to memory, retinal function, seizure, 
and ischemia (Wu et al., 2004). Growing evidence suggests that modulating ASICs can 
protect neurons from ischemia related injury (Huang et al., 2015; Xiong and Xu, 2012). 
Hence, in the present study the importance of ASICs on SCI was studied.  
The present study has shown that even a borderline KA concentration could change the 
extracellular pH (from pH 7.4 to 6.1), trigger glutamate release and increase ASIC 
mRNA in the spinal cord.  
10.7. Impact of ASIC blockade on SCI 
Previous studies on cultured neurons have shown neuronal death prevention by a modest 
intracellular acidification induced by either lowered medium pH or inhibiting Na+/H+ 
exchange through a coupling mechanism between NMDA receptor activation and 
superoxide production (Lam et al., 2013). In contrast, glial alkalization through 
optogenetic activation of a proton pump leads to cessation of glutamate release and to 
relief of ischemic brain damage in vivo (Beppu et al., 2014). These studies suggest that 
modulation of protons in the cellular environment results in protection or magnification 
of injury depending upon the type of cells. Thus, the current study focused on the role of 
ASICs in the neonatal moderate SCI to investigate the proton flux and its impact during 
spinal locomotor impairment.  
 
In physiological conditions, ASIC blockers (DAPI or amiloride) had no significant effect 
on the locomotor network except a mild depression of polysynaptic activity by amiloride. 
This depressive effect by amiloride could be due to the fact that it also inhibits Cl-, Na+, 
and K+ channels (Leng et al., 2016). Conversely, after a moderate SCI, ASIC blockers  
expanded the injury by depressing the network rhythms evoked via stimulating dorsal 
sensory inputs. These results implied that a slight proton increase after injury was 
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beneficial for the recovery from the secondary phase of neuronal injury. In addition, these 
results were confirmed by propidium iodide (PI) fluorescence distribution based on 
uptake of this dye by the disrupted cell membrane. In fact, ASIC1A-/- spinal slices 
showed increased uptake of this probe after KA treatment when compared to wild type, 
indicating that the toxicity of KA was aggravated by ASIC deletion. Furthermore, 
histological results also indicated the expansion of neuronal injury (not astrocytes) after 
mild KA treatment followed by ASIC block. Altogether the current study shows the 
protective role of modulated proton levels after borderline excitotoxicity in neurons.  
The present study in analogy with earlier ones (Jalalvand et al., 2016) has indicated that 
the spinal cord could sense even a minor change in extracellular pH.  Although the 
precise mechanism of how ASIC block exacerbates the injury is unknown in the current 
experimental model, this injury expansion could be due to the fact that mild acidification 
can reduce NMDA receptor mediated currents (Andreeva et al., 1992; Giffard et al., 
1990). Further detailed studies are needed to clarify the downstream changes after proton 
modulation in the present study model.   
 
 
 
 
Fig 17: ASIC block on KA mediated SCI. Reduction of locomotor activity after amiloride or 
DAPI application following KA. ASICs,  Amiloride,  DAPI,  Kainate. 
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11. FUTURE PERSPECTIVES    
Based on the above findings, it is evident that ASIC ion channels and CB1Rs can 
modulate the spinal locomotor rhythms in both physiological and pathological conditions. 
On the other hand, the detailed molecular mechanisms of this modulation need to be 
further studied. The current observations on CB1Rs clearly depict the fact that their long 
term block greatly reduces in vitro locomotor activity. This depression extensively 
affected both cellular and functional aspects after injury. A similar depression was seen 
when ASICs were blocked.  
Current legalization of cannabis in countries like Australia and USA has further raised 
the importance of studying such compounds in network systems. Before the extensive use 
of these compounds as therapeutics (for pain or neurodegenerative disease), there are 
many crucial concepts that need to be investigated. For example, Luongo et al. 2010 has 
reported crosstalk between glia and neurons after modulation of endocannabinoid system. 
Such interaction might alter the locomotor drive as well. Hence, in the present SCI model 
it is important to see such interaction of neurons and glia during CB1R modulation. 
Recent evidence on cannabinoids has shown that there is a differential effect dependent 
on gender (Fattore and Fratta, 2010). Thus, the importance of  male and female hormones  
in regulating CBR function should be taken into account when considering prescribing 
cannabinoid drugs. The current study showed the importance of the ASIC function after 
SCI, even though the range of extracellular acidification beneficial for recovery of SCI 
remains to be explored. Overall, the present study might provide us with useful 
information for improving the treatment of SCI at least at preclinical level.  
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13. SUPPLEMENTARY DATA 
We studied the changes in motoneuronal properties after CB1R inverse agonist (AM251) 
treatment to demonstrate its severe depressive effect on fictive locomotion parameters. 
These experiments followed the same methods from our previous study, Ostroumov et 
al., 2011.  
 
 
Fig 1: Changes in neurochemicals induced depolarization after AM251 (5 µM) treatment 
for 30 mins (A) and 24 h (B). Note the significant depression of NMDA and AMPA 
mediated depolarization after prolonged application of AM251 (*p<0.05). 
A 
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Fig 2: Field potential recorded from motoneuronal pool. (A) Representative recording of 
motoneuronal field in sham and AM251 (24 h) treated conditions (B) Bar graph showing 
peak amplitude of recorded potential.  
 
Fig 3: Antidromic action potential recorded from individual motoneurons through ventral 
root stimulation in sham and AM251 treated cords.  
A B 
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Table 1: Motoneuronal properties after AM251 (24 h) application compared to sham 
preparations 
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Fig 4: Spontaneous synaptic activity of individual motoneuron recorded by sharp 
electrodes at resting membrane potential. (A) Sample recordings from sham and AM251 
treated motoneurons. (B) Plot showing the significant decline in spontaneous activity 
after AM251 application for 24 h (*p<0.05).   
 
These preliminary results show that the motoneuron survival is not affected by 
continuous CB1R block. However, their excitation is slightly impaired. Further detailed 
studies are required to dissect out the mechanism. 
 
 
 
 
 Resting membrane 
potential (mV) 
Spike amplitude (mV) 
Sham (n=22) -68.50±3.25 72.10±3.15 
AM251 24h (n=19) -67.35±6.35 70.25±7.45 
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